# CITATION REPORT List of articles citing

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

DOI: 10.1183/09031936.04.00014304 European Respiratory Journal, 2004, 23, 932-46.

Source: https://exaly.com/paper-pdf/37542563/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
2344	Does Aerobic Exercise Training Improve Inspiratory Muscle Function in Individuals with Chronic Obstructive Pulmonary Disease? A Systematic Review. <b>2004</b> , 18, 3-13	
2343	Simply the best: the 2004 ERS/ATS web guidelines for management of COPD. <b>2004</b> , 1, 11-12	
2342	Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. <b>2004</b> , 5, 1815-26	9
2341	Gene expression profiling of human lung tissue from smokers with severe emphysema. <b>2004</b> , 31, 601-10	136
2340	COPD in Japan: the Nippon COPD Epidemiology study. <b>2004</b> , 9, 458-65	399
2339	Alphabet soup: assessment of dyspnea. <b>2004</b> , 1, 151-2	2
2338	Outcome measures in COPD. 2004, 13, 177-8	1
2337	Antisis de las publicaciones sobre la EPOC en ARCHIVOS DE BRONCONEUMOLOGA 2 a^os despus de la designacia del A^o EPOC. <b>2004</b> , 40, 575-579	2
2336	A favor del timino EPOC. <b>2004</b> , 40, 480-482	O
2335	In Support of the Term Chronic Obstructive Pulmonary Disease (COPD). <b>2004</b> , 40, 480-482	
2334	Analysis of Publications on COPD in ARCHIVOS DE BRONCONEUMOLOGA 2 Years After the Designated COPD Year. <b>2004</b> , 40, 575-579	
2333	New anti-inflammatory approaches in COPD. <b>2004</b> , 1, 335-343	4
2332	Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma. <b>2004</b> , 114, 715-24; quiz 725	13
2331	Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections. <b>2004</b> , 2, 831-43	12
2330	Burden and clinical features of chronic obstructive pulmonary disease (COPD). <b>2004</b> , 364, 613-20	738
2329	Treatment of stable chronic obstructive pulmonary disease. <b>2004</b> , 364, 791-802	68
2328	Oxygen therapy for exercise training or rehabilitation in chronic obstructive pulmonary disease. <b>2005</b> ,	

#### (2005-2005)

Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease: is it a real or statistical phenomenon?. 2005, 171, 1317; author reply 1317-8 Reduced intracellular oxygen radical production in whole blood leukocytes from COPD patients 2326 9 and asymptomatic smokers. 2005, 128, 2051-8 Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. 2005, 89 2325 128, 62-9 Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in 265 2324 patients with COPD. 2005, 128, 1168-78 The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease. 2005, 2323 3 329, 181-9 Current Management of Chronic Obstructive Pulmonary Disease. 2005, 12, S2-S6 Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. 2005, 37, 529-35 12 2320 Bibliography Current World Literature. 2005, 11, 174-185 2319 Cardiovascular risks associated with beta-agonist therapy. 2005, 127, 2283-5 3 New treatment strategies for COPD. Pairing the new with the tried and true. 2005, 117, 27-34 A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. 2005, 166 2317 128, 3810-6 Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive 2316 pulmonary disease?. 2005, 11, 121-8 Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive 2315 pulmonary disease?. 2005, 4, 303-310 Rehabilitation for the home care patient with COPD. 2005, 23, 578-84; quiz 585-6 6 Urinary Incontinence in Japanese Women with Chronic Obstructive Pulmonary Disease: Review. 7 2313 2005, 17, 119-124 Evidence supporting a new rate threshold for multifocal atrial tachycardia. 2005, 28, 561-3 11 Reducing airways inflammation to prevent exacerbations in chronic obstructive pulmonary disease. 2311 5 2005, 60, 1350-6 2310 Perspectives for cytokine antagonist therapy in COPD. **2005**, 10, 93-106 34

2309 Farmacoeconomâ en el asma y en la EPOC. <b>2005</b> , 41, 239-241	5
2308 Broncodilatadores de acciñ corta: ¿qu'lugar les reservamos?. <b>2005</b> , 41, 8-14	1
2307 ¿Agonistas adrenfgicos 🏿 de acciñ prolongada como primera elecciñ?. <b>2005</b> , 41, 15-20	1
Controversias farmacolĝicas reflejadas en las gu <b>â</b> s y normativas nacionales e internacionales. <b>23</b> 06 <b>2005</b> , 41, 32-37	
2305 Importancia del atrapamiento afeo en la EPOC. <b>2005</b> , 41, 1-8	1
2304 Valoraci <del>n</del> funcional del paciente con EPOC. <b>2005</b> , 41, 18-23	5
2303 La disnea en la EPOC. <b>2005</b> , 41, 24-32	10
2302 Tiotropio: anësis crtico. <b>2005</b> , 41, 39-47	1
¿Cuèes el papel del entrenamiento de los m <sup>®</sup> sculos inspiratorios en el tratamiento de la EPOC?. <b>2005</b> , 41, 593-595	3
2300 <b>Respuesta. 2005, 41, 641</b>	
[Bronchodilators in chronic obstructive pulmonary disease (COPD)]. <b>2005</b> , 100, 246-54	О
Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. <b>2005</b> , 330, 640-4	37
Population-based data as an important contribution to better investigate chronic respiratory diseases. <b>2005</b> , 63, 69-71	
2296 An update on chronic obstructive pulmonary disease. <b>2005</b> , 20, 965-75	
Analysis of the current care model of the COPD patient: a health outcomes assessment and economic evaluation. <b>2005</b> , 11, S3-7; quiz S20-2	15
Contemporary issues in the care of patients with chronic obstructive pulmonary disease. <b>2005</b> , 11, S2-13; quiz S14-6	6
O desafio de diagnosticar tromboembolia pulmonar aguda em pacientes com doen <b>à</b> pulmonar obstrutiva cr <b>û</b> ica. <b>2005</b> , 31, 528-539	
Respiratory medicine in general practice: what is the role of the pulmonary specialist?. <b>2005</b> , 63, 3-5	3

### (2005-2005)

2291	Factors affecting survival of hospitalised patients with COPD. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 234-41	13.6	173
2290	Evidence for a genetic susceptibility to lung carcinoma. <b>2005</b> , 60, 287-287		78
2289	Induced sputum for the diagnosis of paediatric pulmonary TB. 2005, 60, 300-300		78
2288	Does leptin play a cytokine-like role within the airways of COPD patients?. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 398-405	13.6	85
2287	Randomised trial of ambulatory oxygen in oxygen-dependent COPD. <i>European Respiratory Journal</i> , <b>2005</b> , 25, 1032-8	13.6	81
2286	Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 214-22	13.6	273
2285	Guidelines for the diagnoses and treatment of adult lower respiratory tract infections: a true "European cooperative effort". <i>European Respiratory Journal</i> , <b>2005</b> , 26, 979-81	13.6	10
2284	Skeletal muscle inflammation and nitric oxide in patients with COPD. <i>European Respiratory Journal</i> , 13.6 89		89
2283	Pathogenesis of chronic obstructive pulmonary disease. <b>2005</b> , 2, 258-66; discussion 290-1		242
2282	2282 Cystic lesions of the lung: a forgotten menace. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 748-9 13.6 1		1
2281	Convergence of the epidemiology and pathology of COPD. <b>2006</b> , 61, 86-8		57
2280	Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. <b>2005</b> , 60, 842-7		115
2279	Bronchodilator response in the lung health study over 11 yrs. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 45-51	13.6	79
2278	Randomised trial of ambulatory oxygen in oxygen-dependent COPD. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 747-8; author reply 748	13.6	
2277	The precision of longitudinal lung function measurements: monitoring and interpretation. <b>2005</b> , 62, 695	-701	25
2276	[Bronchial asthma versus chronic obstructive lung disease (COPD). From pathogenesis to differential diagnosis and differential therapy]. <b>2005</b> , 130, 812-8		3
2275	Surgical therapy for chronic obstructive pulmonary disease. <b>2005</b> , 26, 167-91		39
2274	A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. <b>2005</b> , 172, 573-80		42

2273	Combination therapy for chronic obstructive pulmonary disease: clinical aspects. <b>2005</b> , 2, 272-81; discussion 290-1	24
2272	Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. <b>2005</b> , 172, 1510-6	129
2271	Epidemiology and global impact of chronic obstructive pulmonary disease. <b>2005</b> , 26, 204-10	50
2270	The role of corticosteroids in chronic obstructive pulmonary disease. <b>2005</b> , 26, 235-45	18
2269	Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. <b>2005</b> , 172, 460-4	64
2268	Inhaled corticosteroids and chronic obstructive pulmonary disease: new and improved evidence?. <b>2005</b> , 172, 407-8	4
2267	Systemic effects of chronic obstructive pulmonary disease. <b>2005</b> , 2, 367-70; discussion 371-2	184
2266	Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment. <b>2005</b> , 5, 423-35	4
2265	Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Pulmonary Disease. <b>2005</b> , 171, 1317-1317	
2264	Prescription of oxygen: still problems after all these years. <b>2005</b> , 172, 517-8	6
2263	Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. <b>2005</b> , 49, 3382-6	229
2262	The Airway Pathophysiology of COPD: Implications for Treatment. <b>2005</b> , 2, 253-262	17
2261	Diaphragm dysfunction in chronic obstructive pulmonary disease. <b>2005</b> , 172, 200-5	168
2260	Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. <b>2005</b> , 14, 775-83	84
2259	Liquid oxygen, is it the gold standard?. <b>2005</b> , 2, 181-2	5
2258	Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease. <b>2005</b> , 6, 2525-34	4
2257	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. 2005, 2, 277-283	191
2256	Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. <b>2005</b> , 22, 604-7	57

#### (2005-2005)

2255	Long-acting inhaled bronchodilators in COPD: how many drugs do we need?. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 190-1	13.6	5
2254	From the authors. European Respiratory Journal, 2005, 26, 748-748	13.6	2
2253	Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. <b>2005</b> , 60, 282-7		198
2252	Oxidative stress and airway inflammation in severe exacerbations of COPD. <b>2005</b> , 60, 293-300		243
2251	Acute electrophysiologic effects of inhaled salbutamol in humans. <b>2005</b> , 127, 2057-63		41
2250	Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. <b>2005</b> , 366, 1875-81		626
2249	Pulmonary rehabilitation and the BODE index in COPD. European Respiratory Journal, 2005, 26, 630-6	13.6	229
2248	[Improving diagnosis of chronic obstructive pulmonary disease in the general population]. <b>2005</b> , 34, 16	12-4	Ο
2247	[General practice patients at risk of chronic obstructive pulmonary disease: epidemiologic survey of 3 411 patients]. <b>2005</b> , 34, 1617-22		6
2246	[Inhaled steroids in the treatment of COPD]. 2005, 205, 24-6		
2245	Guidelines for the management of adult lower respiratory tract infections. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 1138-80	13.6	501
2244	Progressive breathlessness in COPD - the role of hyperinflation and its pharmacological management. <b>2005</b> , 14, 285-93		4
2243	Pulmonary function testing and extreme environments. <b>2005</b> , 26, 485-507, vii		6
2242	NICE versus nGMS: what the evidence tells us. <b>2005</b> , 14, 8-10		1
2241	[Understanding clinical trials in COPD]. <b>2005</b> , 22, 561-5		1
2240	Question 4-9. Prise en charge nutritionnelle, place des anabolisants. <b>2005</b> , 22, 88-99		0
2239	LâInterniste face aux muscles respiratoires : quand faut-il explorer les muscles respiratoires ?. <b>2005</b> , 22, 62-67		1
2238	Question 2. Indications de la rhabilitation respiratoire chez le BPCO. <b>2005</b> , 22, 17-18		1

2237	Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach. <b>2005</b> , 6, 13-25		2
2236	Interpretative strategies for lung function tests. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 948-68	13.6	3735
2235	The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. <b>2005</b> , 27, 531-42		22
2234	Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis. <b>2005</b> , 27, 926-39		6
2233	Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. <b>2005</b> , 18, 397-404		76
2232	COPD, a multicomponent disease: implications for management. <b>2005</b> , 99, 670-82		135
2231	Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. <b>2005</b> , 99, 663-9		7
2230	Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. <b>2005</b> , 99, 1115-24		18
2229	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. <b>2005</b> , 99, 1546-54		49
2228	Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. <b>2005</b> , 99, 1418-24		28
2227	Measuring the effects of COPD on the patient. <b>2005</b> , 99 Suppl B, S11-8		50
2226	Treatments for COPD. <b>2005</b> , 99 Suppl B, S28-40		21
2225	COPD: Challenges and opportunities for primary care. <b>2005</b> , 1, 43-52		1
2224	Domiciliary oxygen therapy in COPD. <b>2005</b> , 1, 53-58		2
2223	Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. <b>2005</b> , 118 Suppl 7A, 39S-44S		23
2222	Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. <b>2005</b> , 118, 1415		113
2221	Validation of the Clinical COPD questionnaire in Italian language. <b>2005</b> , 3, 9		28
2220	Inhaler treatment options in COPD. <b>2005</b> , 14, 102-108		56

2219	Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. 2005, 65, 695-724		15
2218	Ipratropium Bromide HFA. <b>2005</b> , 4, 221-222		
2217	Acute exacerbation of chronic bronchitis: expanding short-course therapy. <b>2005</b> , 26 Suppl 3, S156-63		6
2216	[Health care costs of asthma and chronic obstructive pulmonary disease]. 2005, 41, 239-41		3
	[What is the role of inspiratory muscle training in the treatment of chronic obstructive pulmonary disease?]. <b>2005</b> , 41, 593-5		
	[Corticosteroids in exacerbations of chronic obstructive pulmonary disease: yes, but less]. <b>2005</b> , 41, 641; author reply 641		
	Authors' Reply to âllorticosteroids in Exacerbations of Chronic Obstructive Pulmonary Disease: Yes, but Lessâll <b>2005</b> , 41, 641		
2212	Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. European Respiratory Journal, <b>2005</b> , 26, 835-45	13.6	229
2211	Using the Internet in Asthma Management. <b>2005</b> , 13, 287-293		3
	Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol. <b>2005</b> , 4, 447-55		19
	The role of tiotropium bromide, a long-acting anticholinergic bronchodilator, in the management of COPD. <b>2005</b> , 4, 275-81		10
2208	Minimal clinically important differences in COPD lung function. 2005, 2, 111-24		332
	Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. <b>2006</b> , 3, 58-65		39
2206	Pulmonary rehabilitation for chronic obstructive pulmonary disease. <b>2006</b> , CD003793		428
	Effective management of COPD in primary care - the role of long-acting beta agonist/inhaled corticosteroid combination therapy. <b>2006</b> , 15, 143-51		3
2204	Qualit <sup>e</sup> des soins dans le domaine de la BPCO. <b>2006</b> , 23, 44-56		O
	Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. <b>2006</b> , CD001387		18
2202	Recommendations for the management of cough in adults. <b>2006</b> , 61 Suppl 1, i1-24		334

2201	Long-term oxygen therapy in chronic obstructive pulmonary disease: the use of concentrators and liquid oxygen systems in north-western Greece. <b>2006</b> , 73, 777-82		12
2200	Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. <b>2006</b> , <i>4</i> , 101-24		29
2199	Do health-status measures play a role in improving treatment in chronic obstructive pulmonary disease?. <b>2006</b> , 7, 57-61		6
2198	Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. <b>2006</b> , 43, 75-80		198
2197	Case definitions for chronic obstructive pulmonary disease. <b>2006</b> , 3, 95-100		73
2196	The "oil well analogy" as a comprehensive interpretation of factors leading to muscle injury and wasting. <b>2006</b> , 30, 247-52		3
2195	Mortality in COPD: Role of comorbidities. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 1245-57	.6	689
2194	N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. <b>2006</b> , 3, 195-202		37
2193	Algoritmo terap?utico de la EPOC estable. <b>2006</b> , 9, 4124-4125		
2192	Rehabilitaciñ respiratoria. <b>2006</b> , 13, 469-477		2
2191	Tratamiento antimicrobiano de la enfermedad pulmonar obstructiva cr <del>â</del> ica en el anciano. <b>2006</b> , 41, 362-377		0
2190	Enfermedad pulmonar obstructiva crâica (1). <b>2006</b> , 9, 4077-4079		
2189	Enfermedad pulmonar obstructiva cr?nica (2). <b>2006</b> , 9, 4080-4087		
2188	Farmacolog?a de la enfermedad pulmonar obstructiva. <b>2006</b> , 9, 4097-4104		
2188 2187	Farmacolog?a de la enfermedad pulmonar obstructiva. <b>2006</b> , 9, 4097-4104  Protocolo diagnŝtico y teraplutico de la agudizaciñ de la enfermedad pulmonar obstructiva crñica. <b>2006</b> , 9, 4120-4123		
2187	Protocolo diagnâtico y terapûtico de la agudizaciñ de la enfermedad pulmonar obstructiva		
2187	Protocolo diagnŝtico y teraplitico de la agudizaciñ de la enfermedad pulmonar obstructiva crñica. <b>2006</b> , 9, 4120-4123		

2183 l	Place de la corticothfapie dans l'arsenal thfapeutique aux urgences: mise au point. <b>2006</b> , 15, 533-539	0
	Synthŝe : association de bronchodilatateurs de longue durè dâ⊞ction –́ corticostfoĝes inhalŝ : existe-t-il un effet additif ?. <b>2006</b> , 23, 46-47	O
	Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. <b>2006</b> , 15, 346-53	50
	[Effectiveness and efficiency of a specialized unit in the care of patients with chronic obstructive pulmonary disease and respiratory insufficiency]. <b>2006</b> , 42, 104-12	5
	[Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease]. <b>2006</b> , 42, 332-7	17
2178	[Chronic obstructive pulmonary disease in life and death]. <b>2006</b> , 42, 421-2	
	[Functional status and survival in patients with chronic obstructive pulmonary disease following pulmonary rehabilitation]. <b>2006</b> , 42, 434-9	6
	[Arterial blood gases study in patients with stable chronic obstructive pulmonary disease in accordance with spirometric values]. <b>2006</b> , 127, 90-2	4
2175	The genetics of chronic obstructive pulmonary disease. <b>2006</b> , 7, 130	49
2174	Airway inflammation contributes to health status in COPD: a cross-sectional study. <b>2006</b> , 7, 140	17
	Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. <b>2006</b> , 7, 62	167
2172 (	Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. <b>2006</b> , 7, 64	59
2171	Markers of exacerbation severity in chronic obstructive pulmonary disease. 2006, 7, 74	39
	Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations. <b>2006</b> , 7, 80	16
	Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. <b>2006</b> , 4, 31	112
2168 I	Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. <b>2006</b> , CD001104	54
2167	Antibiotics for exacerbations of chronic obstructive pulmonary disease. <b>2006</b> , CD004403	86
2166	The effective treatment of COPD: Anticholinergics and what else?. <b>2006</b> , 3, 277-286	12

2165	Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted patients with chronic obstructive pulmonary disease. <b>2006</b> , 173, 1122-9	
2164	Epidemiology and costs of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , <b>2006</b> , 27, 188-207	504
2163	Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. <b>2006</b> , 61, 1043-7	208
2162	The role of patient-centered outcomes in defining the clinical course of chronic obstructive pulmonary disease. Introduction. <b>2006</b> , 119, 1-3	130
2161	Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. <b>2006</b> , 119, 46-53	20
2160	Video-assisted thoracic surgery pulmonary resection for lung cancer in patients with poor lung function. <b>2006</b> , 81, 1996-2003	63
2159	Laboratory markers for COPD in "susceptible" smokers. <b>2006</b> , 364, 124-38	19
2158	[Antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD)]. 2006, 36, 706-17	3
2157	[Contribution of microbiological investigations to the diagnosis of lower respiratory tract infections]. <b>2006</b> , 36, 570-98	1
2156	Prise en charge des infections des voies respiratoires basses de l'adulte immunocompetent. Texte long. <b>2006</b> , 36, S231-S261	1
2155	[Follow-up criteria for community acquired pneumonias and acute exacerbations of chronic obstructive pulmonary disease]. <b>2006</b> , 36, 636-49	1
2154	Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?. <b>2006</b> , 35, 58-65	35
2153	Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. <b>2006</b> , 19, 112-9	10
2152	Markers of disease severity in chronic obstructive pulmonary disease. <b>2006</b> , 19, 189-99	112
2151	Acute exacerbation of chronic bronchitis: need for an evidence-based approach. 2006, 19 Suppl 1, 4-10	4
2150	Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. <b>2006</b> , 100, 264-72	202
2149	Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. <b>2006</b> , 100, 595-609	34
2148	Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. <b>2006</b> , 100, 846-54	76

### (2006-2006)

2147	Therapy Adherence (MISOTA). <b>2006</b> , 100, 795-806	41
2146	Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. <b>2006</b> , 100, 996-1005	26
2145	Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD. <b>2006</b> , 100, 965-71	28
2144	Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. <b>2006</b> , 100, 1277-81	29
2143	Self-care approaches to managing chronic obstructive pulmonary disease: a provincial survey. <b>2006</b> , 100, 1540-6	29
2142	A critical evaluation of the guidelines of obstructive lung disease and their implementation. <b>2006</b> , 100, S22-S30	2
2141	Tiotropium in COPD patients not previously receiving maintenance respiratory medications. <b>2006</b> , 100, 1495-503	19
2140	Epidemiology and global impact of chronic obstructive pulmonary disease. <b>2006</b> , 1, 114-120	6
2139	Commentary on: âThe relationship between effort intolerance, spirometry and blood gas analysis in patients with chronic obstructive airways diseaseâ[]2006, 1, 122-134	
2138	Evaluating physical capacity in patients with chronic obstructive pulmonary disease: comparing the shuttle walk test with the encouraged 6-minute walk test. <b>2006</b> , 32, 106-13	15
2137	Terapia nutricional na doen <b>à</b> pulmonar obstrutiva cr <b>û</b> ica e suas complica <b>à</b> s nutricionais. <b>2006</b> , 32, 461-471	8
2136	Clinical History and Diagnosis of Chronic Obstructive Pulmonary Disease. <b>2006</b> , 49, 313	
2135	The global burden of chronic respiratory diseases. <b>2006</b> , 3, 20-29	5
2134	Functionality of patients with chronic obstructive pulmonary disease: energy conservation techniques. <b>2006</b> , 32, 580-6	23
2133	Chronic disease in the elderly: back to the future of internal medicine. <b>2006</b> , 3, 40-49	11
2132	Limitaciñ crñica al flujo afeo en pacientes con secuelas de tuberculosis pulmonar: Caracterizaciñ y comparaciñ con EPOC. <b>2006</b> , 22, 98	1
2131	New treatments for chronic obstructive pulmonary disease using ergogenic aids. <b>2006</b> , 32, 66-74	5
2130	Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. <b>2006</b> , 13 Suppl A, 5-47	38

The role of serum leptin and tumor necrosis pulmonary disease patients. <b>2006</b> , 119, 628	s factor-⊞ in malnutrition of male chronic obstructive -633	18
Improving Health Status through Physical A <b>2006</b> , 23, 111-128	activity for Individuals with Chronic Pulmonary Diseases.	2
COPD, inflammation and its modulation by FEV1. <b>2006</b> , 129, 5-6	phosphodiesterase 4 inhibitors: time to look beyond the	16
2126 BRONCHODILATORS   Anticholinergic Agen	nts. <b>2006</b> , 285-288	
Nurse-conducted smoking cessation in patie behavioral support. <b>2006</b> , 130, 334-42	ents with COPD using nicotine sublingual tablets and	106
2124 Lower Respiratory Tract Infections Introduc	ction. <b>2006</b> , 18, 25-51	
2123 Evidence of lower oxidative stress in the air	spaces of patients with reversible COPD. <b>2006</b> , 19, 617-28	5
2122 Up-regulated membrane and nuclear leukol	triene B4 receptors in COPD. <b>2006</b> , 129, 1523-30	32
2121 GOLD Stage 0 COPD. <b>2006</b> , 130, 309-310		13
2120 Airway inflammation and cellular stress in n	oneosinophilic atopic asthma. <b>2006</b> , 129, 1194-202	14
Effect of fluticasone propionate/salmetero COPD. <b>2006</b> , 130, 647-56	l on lung hyperinflation and exercise endurance in	171
2118 The Search for the Genetic Component of C	COPD: Role of the Clinical Phenotype. <b>2006</b> , 2, 299-304	
2117 Exercise-induced systemic effects in muscle	e-wasted patients with COPD. <b>2006</b> , 38, 1543-52	90
2116 Spirometry use in clinical practice following	diagnosis of COPD. <b>2006</b> , 129, 1509-15	96
2115 FEV1/FVC ratio of 70% misclassifies patient	ts with obstruction at the extremes of age. <b>2006</b> , 130, 200-6	98
2114 Conference Summary. <b>2006</b> , 3, 539-542		O
Oxygen supplementation for chronic obstru , 12, 140-4	uctive pulmonary disease patients during air travel. 2006	25
Multiple-drug-resistant bacteria in patients pulmonary disease: Prevalence, risk factors,	with severe acute exacerbation of chronic obstructive , and outcome. <b>2006</b> , 34, 2959-66	69

Patterns of inflammation and the use of reversibility testing in smokers with airway complaints.  2006, 6, 11  2109 Patterns of inflammation and the use of reversibility testing in smokers with airway complaints.  2006, 6, 11  2107 Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. 2006, 6, 27  2106 Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. 2006, 60, 514-7 16  2105 Epidemiology of chronic obstructive pulmonary diseases: health effects of air pollution. 2006, 11, 523-32 90  2104 Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease. 12  2105 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. 12  2100 Meta-analysic anticholinergics and inhaled corticostructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronic que obstructive. 2006, 20, 196-201  2009 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der COPD. 2006, 3, 198-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2097 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary  2096 Exazerbation der COPD. 2006, 263, 1-8  2097 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary  309 The physiological rationale of reverse critical power estimation in patients with COPD. 2006, 96, 59-65  180 The physiological rationale of reverse critical power estimation in patients with COPD. 2006, 96, 59-65	2111	Role of Macrolides as Immunomodular Agents. <b>2006</b> , 13, 274-281	О
2006, 6, 11  2108 Dyspnea assessment and adverse events during sputum induction in COPD. 2006, 6, 17  2107 Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. 2006, 6, 27  2106 Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. 2006, 60, 514-7  2105 Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. 2006, 11, 523-32  200 Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease.  210 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. 2006, 36, 506-12  2102 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Chronique obstructive. 2006, 20, 196-201  2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 119-128  2095 Exazerbation der COPD. 2006, 3, 119-128  The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2110		84
Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. 2006, 6, 27  2106 Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. 2006, 60, 514-7  2107 Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. 2006, 11, 523-32  2108 Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease.  2109 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease.  2100 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2096 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 119-128  2095 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2109		3
chronic obstructive pulmonary disease requiring admission to intensive care unit. 2006, 6, 27  2106 Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. 2006, 60, 514-7  2105 Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. 2006, 11, 523-32  200 2104 Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease.  210 2105 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease.  210 2106 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et'prise en'charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2009 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  200 2008 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2007 Therapie der stabilen COPD. 2006, 3, 119-128  2008 Exazerbation der COPD. 2006, 3, 119-128  2009 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2108	Dyspnea assessment and adverse events during sputum induction in COPD. <b>2006</b> , 6, 17	9
Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. 2006, 11, 523-32 90  2104 Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease. 12  2103 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. 2006, 36, 506-12 5  2102 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9 87  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6 8  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201 2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30 20  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 119-128  2096 Exazerbation der COPD. 2006, 3, 119-128  2097 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2107		34
Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease. 2006, 11, 741-7  2103 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. 2006, 36, 506-12  2102 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2106	Frequency of Hoover's sign in stable patients with chronic obstructive pulmonary disease. <b>2006</b> , 60, 514-7	16
2006, 11, 741-7  2103 Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. 2006, 36, 506-12  2102 Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2009 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2105	Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. 2006, 11, 523-32	90
pulmonary disease. 2006, 36, 506-12  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. 2006, 21, 1011-9  Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 19-128  2096 Exazerbation der COPD. 2006, 3, 119-128  2097 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2104		12
mortality in COPD. 2006, 21, 1011-9  2101 Energy expenditure in underweight chronic obstructive pulmonary disease patients before and during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et prise en charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2103		5
during a physiotherapy programme. 2006, 60, 870-6  2100 Rhabilitation respiratoire et 'prise en 'charge nutritionnelle dans la bronchopneumopathie chronique obstructive. 2006, 20, 196-201  2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2102		87
2099 Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  2095 The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2101		8
compared with anticholinergics and inhaled corticosteroids. 2006, 31, 219-30  2098 Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. 2006, 3, 28-36  2097 Therapie der stabilen COPD. 2006, 3, 98-109  2096 Exazerbation der COPD. 2006, 3, 119-128  The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8	2100		
The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8  The physiological rationale of heat and moisture and moisture exchangers in post-laryngectomy pulmonary 39	2099		20
2096 Exazerbation der COPD. 2006, 3, 119-128  The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. 2006, 263, 1-8  39	2098	Akute Exazerbation der chronisch-obstruktiven Lungenerkrankung. <b>2006</b> , 3, 28-36	
The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. <b>2006</b> , 263, 1-8	2097	Therapie der stabilen COPD. <b>2006</b> , 3, 98-109	
<sup>2095</sup> rehabilitation: a review. <b>2006</b> , 263, 1-8	2096	Exazerbation der COPD. <b>2006</b> , 3, 119-128	
2094 Alternative strategies for exercise critical power estimation in patients with COPD. <b>2006</b> , 96, 59-65	2095		39
	2094	Alternative strategies for exercise critical power estimation in patients with COPD. <b>2006</b> , 96, 59-65	18

	Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. <b>2006</b> , 32, 1022-9	70
2092 [	[Therapeutic goals and outcome measurements in COPD patients]. <b>2006</b> , 101, 279-82	2
2091 [	[Pharmacological treatment of COPD and future of anti-inflammatory therapy]. 2006, 101, 283-92	2
2090 [	[Chronic obstructive lung disease (COPD)]. <b>2006</b> , 101, 559-70; quiz 571-2	O
2089 [	[Pathomechanisms in chronic obstructive pulmonary disease (COPD)]. <b>2006</b> , 101, 951-6	1
2088 [	[Comorbidities of COPD]. <b>2006</b> , 47, 895-6, 898-900	14
2087 [	[Pathogenesis of chronic obstructive pulmonary disease]. <b>2006</b> , 47, 885-6, 888-90, 892-4	4
	Modification of gene expression of the small airway epithelium in response to cigarette smoking. <b>2007</b> , 85, 39-53	151
2085 [	[Acute exacerbation in COPD]. <b>2006</b> , 118, 85-90; quiz 91	
2084	Stoppen van onderhoudsbehandeling met inhalatiesteroŷlen bij COPD. <b>2006</b> , 49, 777-784	
,	scoppen van ondernodassenandering mee innatatiester ogen bij eor b. <b>2000</b> , 12, 111 101	
<u>'</u>	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. <b>2006</b> , 6, 21-36	6
2083 E		6
2083 E	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. <b>2006</b> , 6, 21-36	
2083 E 2082 A 2081 L	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. <b>2006</b> , 6, 21-36  Anticholinergic agents in asthma and COPD. <b>2006</b> , 533, 36-9	106
2083 E	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. <b>2006</b> , 6, 21-36  Anticholinergic agents in asthma and COPD. <b>2006</b> , 533, 36-9  Leukocyte navigation mechanisms as targets in airway diseases. <b>2006</b> , 11, 866-79  Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic	106
2083 E 2082 A 2081 L 2080 C	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. 2006, 6, 21-36  Anticholinergic agents in asthma and COPD. 2006, 533, 36-9  Leukocyte navigation mechanisms as targets in airway diseases. 2006, 11, 866-79  Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease?. 2006, 26, 522-32  Efectividad y eficiencia de una consulta monográca hospitalaria para pacientes con EPOC e	106 17 10
2083 E 2082 F 2081 L 2080 C	Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. 2006, 6, 21-36  Anticholinergic agents in asthma and COPD. 2006, 533, 36-9  Leukocyte navigation mechanisms as targets in airway diseases. 2006, 11, 866-79  Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease?. 2006, 26, 522-32  Efectividad y eficiencia de una consulta monográca hospitalaria para pacientes con EPOC e insuficiencia respiratoria. 2006, 42, 104-112	106 17 10

2075 Tratamiento endosc<sup>a</sup>pico del enfisema. 2006, 42, 32-37 1 2074 Corticoides inhalados y supervivencia en la EPOC. 2006, 42, 38-46 Tratamiento antimicrobiano de la enfermedad pulmonar obstructiva crâica en el anciano. 2006, 2073 42, 5-19 Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor 92 of phosphodiesterase 4. 2006, 129, 56-66 2071 An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. 2006, 129, 1693-708 26 2070 Pooled clinical trial analysis of tiotropium safety. 2006, 130, 1695-703 135 The quality of obstructive lung disease care for adults in the United States as measured by 91 adherence to recommended processes. 2006, 130, 1844-50 2068 Update in chronic obstructive pulmonary disease 2005. 2006, 173, 1056-65 27 2067 ABC of chronic obstructive pulmonary disease. Diagnosis. 2006, 332, 1261-3 8 2066 Pharmacological management--inhaled treatment. 2006, 332, 1439-41 6 Post-bronchodilator spirometry reference values in adults and implications for disease 2065 131 management. 2006, 173, 1316-25 Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary 2064 disease. 2006, 10, 329-32 2063 Titin and diaphragm dysfunction in chronic obstructive pulmonary disease. 2006, 173, 527-34 66 Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation. 2062 18 2006, 3, 641-4 Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: 2061 1 Misconstrued Immortal Time Bias. 2006, 173, 464a-465 2060 Predicting mortality in chronic obstructive pulmonary disease: chasing the "Holy Grail". 2006, 173, 1298-9 2059 Pathophysiology of exacerbations of chronic obstructive pulmonary disease. 2006, 3, 245-51 125 2058 Overview of lung transplantation and criteria for selection of candidates. 2006, 27, 441-69 30

	e effect of helium and oxygen on exercise performance in chronic obstructive pulmonary sease: a randomized crossover trial. <b>2006</b> , 173, 865-70		84
2056 Pro	edictors of mortality in patients with emphysema and severe airflow obstruction. <b>2006</b> , 173, 1326-34		310
2055 Th	omas a. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. <b>2006</b> , 3, 478-81		37
2054	ithromycin in bronchiolitis obliterans: is the evidence strong enough?. <b>2006</b> , 173, 465-6; author oly 466		5
2053 Lu	ng function decline and outcomes in an adult population. <b>2006</b> , 173, 985-90		88
	noking history effect on peripheral lung inflammation and gene transcription in chronic structive pulmonary disease. <b>2006</b> , 174, 2-3		1
	nical assessment, staging, and epidemiology of chronic obstructive pulmonary disease acerbations. <b>2006</b> , 3, 252-6		18
2050 Pu	lmonary safety of inhaled insulins: a review of the current data. <b>2006</b> , 22, S21-S28		10
	ronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. <b>06</b> , 3, 276-80		28
	e natural history of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , <b>2006</b> , , 627-43	13.6	174
	piratory flow limitation detected by forced oscillation and negative expiratory pressure.  Tropean Respiratory Journal, <b>2007</b> , 29, 363-74	13.6	78
	mbined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in rmoxic COPD. <b>2006</b> , 61, 559-67		74
2045 Lie	es, damned lies and mortality statistics?. <b>2006</b> , 61, 923-4		6
	able COPD: predicting benefit from high-dose inhaled corticosteroid treatment. <i>European</i> spiratory Journal, <b>2006</b> , 27, 964-71	13.6	190
2043 Dy	namic hyperinflation: is it worth measuring?. <b>2006</b> , 3, 239-44		40
	fferences in microsatellite DNA level between asthma and chronic obstructive pulmonary sease. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 472-8	13.6	24
2041 Em	nphysema in COPD: consequences and causes. <b>2006</b> , 61, 1031-2		3
2040 <b>D</b> y	rnamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?. <b>2006</b> , 15, 68-71	I	9

#### (2006-2006)

2039	Overnight prescription of oxygen in long term oxygen therapy: time to reconsider the guidelines?. <b>2006</b> , 61, 779-82		16
2038	Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease. <b>2006</b> , 63, 645-52		7
2037	The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients. <b>2006</b> , 3, 3-9		59
2036	Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. <b>2006</b> , 126, 725-35		108
2035	"Susceptible" smokers?. <b>2006</b> , 61, 924-5		3
2034	Caring for the burden of COPD. <b>2006</b> , 61, 831-2		5
2033	Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. <i>European Respiratory Journal</i> , <b>2006</b> , 27, 972-9	13.6	72
2032	Genetic variability of the beta2 adrenergic receptor and asthma exacerbations. <b>2006</b> , 61, 925-7		12
2031	Flawed interpretative strategies for lung function tests harm patients. <i>European Respiratory Journal</i> , <b>2006</b> , 27, 1322-3; author reply 1323-4	13.6	19
2030	Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. <b>2006</b> , 3, 461-5		41
2029	Gender and chronic obstructive pulmonary disease in high-risk smokers. <b>2006</b> , 73, 306-10		35
2028	Telomere shortening in smokers with and without COPD. European Respiratory Journal, 2006, 27, 525-8	13.6	243
2027	ERRATA. European Respiratory Journal, <b>2006</b> , 27, 242-242	13.6	2
2026	From the authors. European Respiratory Journal, 2006, 27, 241-242	13.6	
2025	Ventilation inhomogeneity in alpha1-antitrypsin-deficient emphysema. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 323-9	13.6	9
2024	ERRATA. European Respiratory Journal, <b>2006</b> , 27, 242-242	13.6	3
2023	Repeated pulmonary rehabilitation in severe and disabled COPD patients. 2006, 73, 769-76		27
2022	Should the choice of a long-acting bronchodilator in the long-term therapy of chronic obstructive pulmonary disease depend entirely on the onset of action?. <b>2006</b> , 73, 410-1		2

2021 Developing COPD: a 25 year follow up study of the general population. <b>2006</b> , 61, 935-9	377	
2020 Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. <b>2006</b> , 61, 854-62	149	
2019 COPD exacerbations.5: management. <b>2006</b> , 61, 535-44	72	
2018 Infrequent Infections in COPD. <b>2006</b> , 2, 357-371	1	
Systemic immunological response to exercise in patients with chronic obstructive pulmonary disease: what does it mean?. <b>2006</b> , 73, 255-64	14	
Measurement of combined oximetry and cutaneous capnography during flexible bronchoscopy.  European Respiratory Journal, <b>2006</b> , 28, 386-90	6 24	
2015 Potential misclassification of causes of death from COPD. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 781-5 13.	6 103	
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.  European Respiratory Journal, <b>2006</b> , 27, 902-7	6 190	
2013 Outcomes of adult domiciliary oxygen therapy in pulmonary diseases. <b>2006</b> , 6, 59-66		
2012 Eligibility testing for long-term domiciliary oxygen therapy: more often, more effective?. <b>2006</b> , 6, 33-5		
Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?. <b>2006</b> , 3, 233-42	33	
2010 OXYGEN THERAPY. <b>2006</b> , 278-282		
Global burden of COPD: systematic review and meta-analysis. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 523-32	6 946	
The potential impact of anaemia of chronic disease in COPD. European Respiratory Journal, 2006,	6 102	
<sup>2008</sup> 27, 390-6		
	20	
<sup>2008</sup> 27, 390-6 <sup>13.</sup>	20	
2008 27, 390-6  2007 Development of a COPD severity score. <b>2006</b> , 22, 1679-87  2006 Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. <i>European</i>	20	

## (2007-2006)

Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. <b>2006</b> , 173, 393-7		161
2002 Treatment of chronic obstructive pulmonary disease in older adults. <b>2006</b> , 2, 277-293		2
Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. <b>2007</b> , 62, 932-7		171
2000 Assessing the prognosis of patients with chronic obstructive pulmonary disease. <b>2007</b> , 3, 250-254		1
Prospective study of dietary patterns and chronic obstructive pulmonary disease among US men. <b>2007</b> , 62, 786-91		101
COPD prevalence in a random population survey: a matter of definition. <i>European Respiratory Journal</i> , <b>2007</b> , 30, 232-9	13.6	85
Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. <b>2007</b> , 1, 25-33		25
1996 Advances in the management of chronic obstructive pulmonary disease. <b>2007</b> , 8, 23-37		6
Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. <b>2007</b> , 11, 1273-86		22
1994 Inflammation in COPD: a link to systemic comorbidities. <b>2007</b> , 16, 91-97		12
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. <b>2007</b> , 175, 144-9		261
1992 What's new in COPD?. <b>2007</b> , 52, 36-41; quiz 42, 57		
Diaphragm dysfunction in chronic obstructive pulmonary disease: a role for heparan sulphate?.  European Respiratory Journal, <b>2007</b> , 30, 80-9	13.6	14
The role of nebulised budesonide in the treatment of exacerbations of COPD. <i>European Respiratory</i> Journal, <b>2007</b> , 29, 660-7	13.6	63
1989 Palliative care in chronic obstructive pulmonary disease: a review for clinicians. <b>2007</b> , 100, 225-33		54
COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. <b>2007</b> , 131, 29-36		98
1987 Inhaled corticosteroids for stable chronic obstructive pulmonary disease. <b>2007</b> , CD002991		90
1986 Diagnostic labeling of COPD in five Latin American cities. <b>2007</b> , 131, 60-7		93

1985	Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. <b>2007</b> , 131, 4S-42S	881
1984	Spirometry utilization for COPD: how do we measure up?. <b>2007</b> , 132, 403-9	144
1983	Acute exacerbations of COPD in subjects completing pulmonary rehabilitation. 2007, 132, 127-34	32
1982	Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. <b>2007</b> , 132, 477-82	38
1981	Differences in cardiopulmonary exercise test results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease stage categories and gender. <b>2007</b> , 132, 1204-11	41
1980	Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. <b>2007</b> , 176, 1200-7	182
1979	Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. <b>2007</b> , 175, 458-63	331
1978	Gas exchange response to short-acting beta2-agonists in chronic obstructive pulmonary disease severe exacerbations. <b>2007</b> , 176, 350-5	17
1977	"In the Beginning" of COPD: is evolution important?. <b>2007</b> , 175, 423-4	12
1976	Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. <b>2007</b> , 20, 753-63	46
1975	Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. <b>2007</b> , 176, 343-9	93
1974	The interaction of host and pathogen factors in chronic obstructive pulmonary disease exacerbations and their role in tissue damage. <b>2007</b> , 4, 611-7	4
1973	Gender and the diagnosis, management, and surveillance of chronic obstructive pulmonary disease. <b>2007</b> , 4, 686-91	40
1972	Ethical issues confronted in pulmonary clinical trials. <b>2007</b> , 4, 200-5; discussion 205	4
1971	Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. <b>2007</b> , 176, 498-504	119
1970	Chronic obstructive pulmonary disease and premature aging. <b>2007</b> , 175, 1217-8	27
1969	Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. <b>2007</b> , 175, 998-1005	186
1968	Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. <b>2007</b> , 175, 32-9	208

1967	Exacerbations of chronic obstructive pulmonary disease. <b>2007</b> , 4, 554-64	114
1966	Update in chronic obstructive pulmonary disease 2006. <b>2007</b> , 175, 1222-32	69
1965	Are beta2-agonists safe in patients with acute exacerbations of COPD?. <b>2007</b> , 176, 322-3	2
1964	Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. <b>2007</b> , 4, 647-58	12
1963	[Rehabilitation of patients with chronic obstructive pulmonary disease (COPD). S2 guideline of the German Society for Pneumology and Respiratory Medicine and the German Society for Rehabilitation Science (RGRW)]. <b>2007</b> , 61, 233-48	14
1962	[Mechanical ventilation in acute ventilatory insufficiency]. 2007, 61, 531-5	1
1961	[Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft f\u00d8Pneumologie und Beatmungsmedizin]. <b>2007</b> , 61, e1-40	137
1960	Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. <b>2007</b> , 8, 633-48	16
1959	Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis. <b>2007</b> , 23, 459-66	9
1958	Systemic effects of chronic obstructive pulmonary disease. <b>2007</b> , 1, 75-84	9
1957	COPDthe primary care perspective: addressing epidemiology, pathology, diagnosis, treatment of smoking's multiple morbidities and the patient's perspective. <b>2007</b> , 4, 67-83	10
1956	Raising awareness of COPD: a call to action by the readers of COPD. <b>2007</b> , 4, 1-2	0
1955	Maintaining the benefits of pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: where are we now?. <b>2007</b> , 4, 131-3	
1954	Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. <b>2007</b> , 4, 145-68	220
1953	Exacerbations of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 1224-383.6	284
1952	Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. <b>2007</b> , 62, 237-41	156
1951	Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. <b>2007</b> , 4, 597-601	21
1950	Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis. <b>2007</b> , 62, 638-49	22

1949	Intermediate careHospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline. <b>2007</b> , 62, 200-10	42
1948	Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. <b>2007</b> , 62, 29-35	82
1947	The epidemiology and economics of chronic obstructive pulmonary disease. 2007, 4, 502-6	179
1946	The 6-min walking distance: long-term follow up in patients with COPD. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 535-40	130
1945	Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. <b>2007</b> , 175, 1259-65	291
1944	Series on comprehensive management of end-stage COPD. European Respiratory Journal, 2007, 30, 828-39.6	6
1943	The Nature of Immunological Reaction in the Peripheral Airways of Cigarette Smokers. <b>2007</b> , 3, 117-127	1
1942	Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. <b>2007</b> , 62, 109-14	38
1941	Eppur si muove, or COPD treatment success and inflammation. <i>European Respiratory Journal</i> , <b>2007</b> , 30, 409-10	1
1940	Mitochondrial dysfunction in COPD patients with low body mass index. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 643-50	109
		109
1939	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. <b>2007</b> , 45, 2064-7	56
1939 1938	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive	
	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. <b>2007</b> , 45, 2064-7  Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease	56
1938	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. <b>2007</b> , 45, 2064-7  Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. <b>2007</b> , 46, 1373-9	56 7
1938	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. 2007, 45, 2064-7  Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. 2007, 46, 1373-9  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. 2007,	56 7
1938 1937 1936	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. 2007, 45, 2064-7  Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. 2007, 46, 1373-9  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. 2007,  COPD screening efforts in primary care: what is the yield?. 2007, 16, 41-8	56 7 1 74
1938 1937 1936 1935	Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease. 2007, 45, 2064-7  Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. 2007, 46, 1373-9  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. 2007,  COPD screening efforts in primary care: what is the yield?. 2007, 16, 41-8  COPD screening in primary care: who is sick?. 2007, 16, 49-53  Optimal treatment of chronic obstructive pulmonary disease: the search for the magic combination	56 7 1 74 26

1931	Palliative care in chronic obstructive pulmonary disease: a review for clinicians. <b>2007</b> , 100, 225-233	55
1930	Current world literature. Skin and soft tissue infections. <b>2007</b> , 20, 204-16	
1929	Bibliography. Current world literature. Obstructive, occupational and environmental diseases. <b>2007</b> , 13, 142-55	
1928	Chronic obstructive pulmonary disease: "learn more, breathe better". <b>2007</b> , 27, 311-3	2
1927	Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. <b>2007</b> , 131, 37-43	89
1926	Six-minute walking-induced systemic inflammation and oxidative stress in muscle-wasted COPD patients. <b>2007</b> , 131, 439-45	42
1925	Conflicting definitions of airways obstruction: Drawing the line between normal and abnormal. <b>2007</b> , 131, 335-6	20
1924	Retrospective Study of Pulmonary Function Tests in Patients Presenting With Isolated Reduction in Single-Breath Diffusion Capacity: Implications for the Diagnosis of Combined Obstructive and Restrictive Lung Disease. <b>2007</b> , 82, 48-54	31
1923	Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not 2007, 131, 349-55	181
1922	Effects of short-acting bronchodilators added to maintenance tiotropium therapy. <b>2007</b> , 132, 1493-9	20
1921	A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. <b>2007</b> , 49, 22-30	28
1920	Efficacy of pursed-lips breathing: a breathing pattern retraining strategy for dyspnea reduction. <b>2007</b> , 27, 237-44	74
1919	A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. <b>2007</b> , 131, 682-689	99
1918	Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. <b>2007</b> , 132, 1283-90	41
1917	[Exercise training in chronic pulmonary disease]. <b>2007</b> , 13, 101-28	6
1916	Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. <b>2007</b> , 56, 15-22	11
1915	Insuffisance respiratoire chronique´: place du mdecin ghfaliste pour la prise en charge (traitement au long cours). <b>2007</b> , 2, 1-9	
1914	Exhaled carbon monoxide as a biomarker of inflammatory lung disease. <b>2007</b> , 1, 026004	12

1913	Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. <b>2007</b> , 132, 1733-40	58
1912	Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. <b>2007</b> , 20, 9-22	227
1911	Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. <b>2007</b> , 20, 258-64	16
1910	Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. <b>2007</b> , 20, 495-502	44
1909	Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. <b>2007</b> , 20, 462-72	31
1908	Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. <b>2007</b> , 20, 701-7	7
1907	Longitudinal deteriorations in patient reported outcomes in patients with COPD. 2007, 101, 146-53	91
1906	Red cell macrocytosis in COPD patients without respiratory insufficiency: a brief report. <b>2007</b> , 101, 349-52	3
1905	Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. <b>2007</b> , 101, 833-8	34
1904	Patient's perception of exacerbations of COPDthe PERCEIVE study. <b>2007</b> , 101, 453-60	104
1904 1903	Patient's perception of exacerbations of COPDthe PERCEIVE study. 2007, 101, 453-60  The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. 2007, 101, 746-53	104
	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise	<u> </u>
1903	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. <b>2007</b> , 101, 746-53  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD:	20
1903 1902	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. <b>2007</b> , 101, 746-53  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. <b>2007</b> , 101, 957-62  Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. <b>2007</b> ,	20
1903 1902 1901	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. 2007, 101, 746-53  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. 2007, 101, 957-62  Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. 2007, 101, 1338-43  Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult	20 24 30
1903 1902 1901	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. 2007, 101, 746-53  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. 2007, 101, 957-62  Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. 2007, 101, 1338-43  Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. 2007, 101, 1183-90	20 24 30
1903 1902 1901 1900	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. 2007, 101, 746-53  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. 2007, 101, 957-62  Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. 2007, 101, 1338-43  Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. 2007, 101, 1183-90  Content comparison of health-related quality of life instruments for COPD. 2007, 101, 1113-22  Survival and future need of long-term oxygen therapy for chronic obstructive pulmonary	20 24 30 10

#### (2007-2007)

1895	Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists. <b>2007</b> , 101, 1798-803	14
1894	The clinical management in extremely severe COPD. <b>2007</b> , 101, 1613-24	52
1893	Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. <b>2007</b> , 101, 1670-6	44
1892	Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. <b>2007</b> , 101, 1961-70	64
1891	Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). <b>2007</b> , 101, 1954-60	101
1890	Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. <b>2007</b> , 101, 2139-44	57
1889	Efficacy of pulmonary rehabilitation in chronic respiratory failure (CRF) due to chronic obstructive pulmonary disease (COPD): The Maugeri Study. <b>2007</b> , 101, 2447-53	49
1888	Systematic review of the effects of chronic disease management on quality-of-life in people with chronic obstructive pulmonary disease. <b>2007</b> , 101, 2233-9	46
1887	Making COPD a treatable diseaseâAn integrated care perspective. <b>2007</b> , 3, 49-56	2
1886	Pulmonary rehabilitation in chronic obstructive pulmonary disease. <b>2007</b> , 3, 57-64	1
1885	Influenza and pneumococcal vaccination in chronic obstructive pulmonary disease (COPD). 2007, 3, 95-101	
1884	Inflammation in COPD. <b>2007</b> , 3, 119-120	О
1883	Treating systemic effects of COPD. <b>2007</b> , 28, 544-50	25
1882	Definition, epidemiology and natural history of COPD. <i>European Respiratory Journal</i> , <b>2007</b> , 30, 993-1013 <sub>13.6</sub>	264
1881	Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. <b>2007</b> , 25, 335-9	28
1880	Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. <b>2007</b> , 120, 435-41	26
1879	Introduction. <b>2007</b> , 120, S1-S3	1
1878	Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. <b>2007</b> , 120, S4-13	16

1877	Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient?. <b>2007</b> , 120, S14-22	17
1876	Rĥabilitation du malade atteint de bronchopneumopathie chronique obstructive. <b>2007</b> , 50, 602-614	1
1875	Pulmonary rehabilitation in chronic obstructive pulmonary disease. <b>2007</b> , 50, 615-26, 602-14	16
1874	Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. <b>2007</b> , 57, 31S-38S	12
1873	Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. <b>2007</b> , 60, 634-42	87
1872	Reliability and validity of the Exercise Self-Regulatory Efficacy Scale for individuals with chronic obstructive pulmonary disease. <b>2007</b> , 36, 205-16	32
1871	International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <b>2007</b> , 370, 741-50	1498
1870	Global burden of COPD: risk factors, prevalence, and future trends. <b>2007</b> , 370, 765-73	1370
1869	What have we learned from large drug treatment trials in COPD?. 2007, 370, 774-85	47
1868	Avances en el tratamiento de la enfermedad pulmonar obstructiva cr <del>î</del> tica. Estrategias de aplicaci <del>î</del> n clâtica. <b>2007</b> , 9, 5942-5949	
1867	Lessons from the national emphysema treatment trial. <b>2007</b> , 19, 172-80	2
1866	Phenotypes of chronic obstructive pulmonary disease. <b>2007</b> , 4, 355-84	93
1865	Tratamiento antimicrobiano de la enfermedad pulmonar obstructiva crâica en el anciano. <b>2007</b> , 33, 65-79	
1864	Treino de exercĉio na doen <b>a</b> pulmonar cr <b>ĥ</b> ica. <b>2007</b> , 13, 101-128	1
1863	Critical illness neuromyopathy: from risk factors to prevention. <b>2007</b> , 175, 424-5	22
1862	Infections in chronic lung diseases. <b>2007</b> , 21, 673-95, viii	8
1861	Predictors of mortality in chronic obstructive pulmonary disease. <b>2007</b> , 28, 515-24, v	20
1860	Oxygen therapy during exercise training in chronic obstructive pulmonary disease. <b>2007</b> , CD005372	39

#### (2007-2007)

1859	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <b>2007</b> , 176, 532-55	5242
1858	Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. <b>2007</b> , 6, 4615-23	50
1857	Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. <b>2007</b> , 24, 555-72	12
1856	Update in surgical therapy for chronic obstructive pulmonary disease. <b>2007</b> , 28, 639-53, vii	11
1855	[Which definition to use when defining airflow obstruction?]. 2007, 24, 323-30	5
1854	Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. <b>2007</b> , 4, 526-34	53
1853	[Sensory-nerves and airway inflammation: interaction with beta-2-adrenoceptor agonists]. 2007, 65, 220-7	
1852	New approaches in pulmonary rehabilitation. <b>2007</b> , 28, 629-38, vii	8
1851	Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. <b>2007</b> , 82, 48-54	34
1850	Primary Care Sleep Medicine. <b>2007</b> ,	2
1849	Decline in FEV1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms. <b>2007</b> , 4, 5-13	31
1848	Impact of bronchodilator use on the prevalence of COPD in population-based samples. <b>2007</b> , 4, 113-20	61
1847	Spirometric determination of chronic obstructive pulmonary disease. <b>2007</b> , 3, 221-223	2
1846	A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. <b>2007</b> , 25, 695-711	28
1845	Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. <b>2007</b> , 4, 127-34	17
1844	Circadian-rhythm differences among emergency department patients with chronic obstructive pulmonary disease exacerbation. <b>2007</b> , 24, 699-713	33
1843	Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy. <b>2007</b> , 16, 1069-78	29
- O 10	Multidisciplinaire samenwerking COPD-management. <b>2007</b> , 2, 47-49	

1841	Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. <b>2007</b> , 9, 2157-73	95
1840	Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). <b>2007</b> , 4, 522-5	164
1839	Update on the pharmacologic therapy for chronic obstructive pulmonary disease. <b>2007</b> , 28, 589-607, vi-vii	7
1838	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. <b>2007</b> , 62, 595-601	140
1837	Self-management strategies in chronic obstructive pulmonary disease. <b>2007</b> , 28, 617-28, vii	42
1836	Insuficiencia respiratoria cr <del>ĥ</del> ica: papel del mdico general en el tratamiento a largo plazo. <b>2007</b> , 11, 1-9	
1835	Chronic obstructive pulmonary disease in the older patient. <b>2007</b> , 28, 703-15, vi	7
1834	[Which definition to use when defining reversibility of airway obstruction?]. 2007, 24, 1107-15	7
1833	Stratgies dâlhterprtation des explorations fonctionnelles respiratoires. 2007, 24, 83-108	3
1832	Disease modification in chronic obstructive pulmonary disease. <b>2007</b> , 28, 609-16,vii	3
1831	Chronic obstructive pulmonary disease in patients who have HIV infection. 2007, 28, 575-87, vi	48
1830	¿Debemos tener en cuenta la capacidad inspiratoria?. <b>2007</b> , 43, 245-247	2
1829	[Daily living activity in COPD: a new parameter to be evaluated?]. 2007, 129, 337-8	1
1828	[Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population]. <b>2007</b> , 39, 547-55	3
1827	A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. <b>2007</b> , 8, 25	106
1826	Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. <b>2007</b> , 8, 30	47
1825	Bronchial epithelial spheroids: an alternative culture model to investigate epithelium inflammation-mediated COPD. <b>2007</b> , 8, 86	19
1824	Rising to the challenge of resistance: a case study-based discussion. <b>2007</b> , 29 Suppl 1, S11-6	2

1823	[Reduced expression of the sarcoplasmic calcium pump SERCA2 in skeletal muscle from patients with chronic obstructive pulmonary disease and low body weight]. <b>2007</b> , 43, 4-8	8
1822	[The role played by exacerbations in the natural history of chronic obstructive pulmonary disease]. <b>2007</b> , 43, 55-8	
1821	[Drug prescription for chronic obstructive pulmonary disease and asthma by primary care physicians in the Spanish autonomous community of Madrid, 1996-2002]. <b>2007</b> , 43, 73-80	0
1820	[Air travel and respiratory diseases]. 2007, 43, 101-25	5
1819	Should We Be Paying Attention to Inspiratory Capacity?. <b>2007</b> , 43, 245-247	
1818	[Spirometry reference values after inhalation of 200 microg of salbutamol]. 2007, 43, 530-4	15
1817	[Benefits of a home-based pulmonary rehabilitation program for patients with severe chronic obstructive pulmonary disease]. <b>2007</b> , 43, 599-604	18
1816	[Prognostic factors in chronic obstructive pulmonary disease]. <b>2007</b> , 43, 680-91	2
1815	Pathogenesis of chronic obstructive pulmonary disease. <b>2007</b> , 28, 479-513, v	95
1814	Postoperative outcome after coronary artery bypass grafting in chronic obstructive pulmonary disease. <b>2007</b> , 14, 19-24	50
1813	Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. <b>2007</b> , 14 Suppl B, 5B-32B	263
1812	Nocturnal oxygen therapy in patients with chronic obstructive pulmonary disease: a survey of Canadian respirologists. <b>2007</b> , 14, 343-8	10
1811	Chronic productive cough in young adults is very often due to chronic rhino-sinusitis. 2007, 67, 90-4	3
1810	The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. <b>2007</b> , 22, 839-45	20
1809	Chronic obstructive pulmonary disease is underdiagnosed and undertreated in Sa Paulo (Brazil): results of the PLATINO study. <b>2007</b> , 40, 887-95	26
1808	Efficacy of the FEV1/FEV6 ratio compared to the FEV1/FVC ratio for the diagnosis of airway obstruction in subjects aged 40 years or over. <b>2007</b> , 40, 1615-21	30
1807	Symptom Questionnaire and Laboratory Findings in Subjects with Airflow Limitation: a Nation-wide Survey. <b>2007</b> , 63, 480	1
1806	[Severity of COPDa broader prognostic assessment is necessary]. <b>2007</b> , 96, 1901-5	1

1805 Assessing the impact of health policies on COPD. 2007, 12, 253-4, 256-9

1804	Does Aerobic Exercise Training Improve Inspiratory Muscle Function in Individuals with Chronic Obstructive Pulmonary Disease? A Systematic Review. <b>2007</b> , 18, 3-13	O
1803	Smoking cessation program as a tool for the early diagnosis of chronic obstructive pulmonary disease. <b>2007</b> , 33, 282-6	7
1802	Current opinion on the importance of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. <b>2007</b> , 120, 1539-1543	2
1801	Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design. <b>2007</b> , 34, 1029-36	8
1800	Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. <b>2007</b> , 12, 81-7	49
1799	It's time for an aetiology-based definition of chronic obstructive pulmonary disease. <b>2007</b> , 12, 317-9	10
1798	Severe chronic obstructive pulmonary disease in a family's everyday life in Finland: perceptions of people with chronic obstructive pulmonary disease and their spouses. <b>2007</b> , 9, 40-7	46
1797	Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. <b>2007</b> , 121, 448-61	63
1796	Aspects on pathophysiological mechanisms in COPD. <b>2007</b> , 262, 311-40	57
1795	Can hypertonic saline inhalation influence preformed chemokine and mediator release in induced sputum of chronic obstructive pulmonary disease patients? Comparison with isotonic saline. <b>2007</b> , 37, 1819-26	9
1794	Pharmacokinetics of a novel agent, R667, in patients with emphysema. <b>2007</b> , 63, 527-33	6
1793	The degree of exercise hypoxemia reflects pulmonary artery pressure during early exercise in chronic obstructive pulmonary disease patients. <b>2008</b> , 28, 64-9	3
1792	Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. <b>2007</b> , 61, 1516-22	42
1791	Role of primary care in early diagnosis and effective management of COPD. 2007, 61, 1380-9	25
1790	Use of dry powder inhalers in COPD. <b>2007</b> , 61, 2005-8	17
1789	Disminuciñ de la expresiñ de la bomba de calcio sarcoplâmica (SERCA2) en el m <sup>8</sup> culo esqueltico de pacientes con EPOC y bajo peso corporal. <b>2007</b> , 43, 4-8	5
1788	Utilizaciñ de medicamentos para la EPOC y el asma en atenciñ primaria en la Comunidad de Madrid (1996-2002). <b>2007</b> , 43, 73-80	4

#### (2007-2007)

1787	Valores de referencia para la espirometrâ despuŝ de la inhalaciâ de 200 <b>B</b> de salbutamol. <b>2007</b> , 43, 530-534	11
1786	Beneficios de un programa de rehabilitaci <del>n</del> respiratoria domiciliaria en pacientes con EPOC grave. <b>2007</b> , 43, 599-604	16
1785	Factores pron <del>ŝ</del> ticos en la EPOC. <b>2007</b> , 43, 680-691	6
1784	The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. <b>2007</b> , 29, 147-55	608
1783	Changing COPD definition. <b>2007</b> , 3, 195	
1782	Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. <b>2007</b> , 133, 1434-8	26
1781	El papel de las exacerbaciones en la historia natural de la EPOC. <b>2007</b> , 43, 55-58	2
1780	Patologâ respiratoria y vuelos en aviñ. <b>2007</b> , 43, 101-125	28
1779	Herencia y ambiente en la EPOC. <b>2007</b> , 43, 10-17	4
1778	Evaluaciñ funcional respiratoria (obstrucciñ y atrapamiento). <b>2007</b> , 43, 8-14	4
1777	Aspectos sistímicos y factores pron <del>â</del> ticos. <b>2007</b> , 43, 25-34	3
1776	Exercise adherence in patients with chronic obstructive pulmonary disease: an exploration of motivation and goals. <b>2007</b> , 32, 104-10	13
1775	Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. <b>2007</b> , 47, 131-48	32
1774	Opsporen van COPD in de huisartsenpraktijk: wie is er eigenlijk ziek?. <b>2007</b> , 50, 593-597	2
1773	Impulse oscillometry: an alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. <b>2007</b> , 7, 56-64	48
1772	Oxidative stress in patients with COPD and pulmonary hypertension. <b>2007</b> , 119, 428-34	35
1771	[The prevalence of COPD in Austriathe expected change over the next decade]. 2007, 119, 513-8	11
1770	Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. <b>2007</b> , 185, 21-4	33

1769	Respiratory sound analysis in healthy and pathological subjects: A wavelet approach. 2008, 3, 181-191	21
1768	Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. <b>2008</b> , 186, 403-9	78
1767	Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD. <b>2008</b> , 120, 749-55	32
1766	Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease. <b>2008</b> , 22, 412-28	24
1765	Structure of YraM, a protein essential for growth of Haemophilus influenzae. 2008, 73, 204-17	10
1764	Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor. <b>2008</b> , 97, 3321-34	15
1763	The role of gene polymorphisms in the pathogenesis of chronic obstructive pulmonary disease. <b>2008</b> , 63, 20-33	
1762	Differentiating chronic obstructive pulmonary disease from asthma. <b>2008</b> , 20, 445-54	13
1761	National study of emergency department visits for acute exacerbation of chronic obstructive pulmonary disease, 1993-2005. <b>2008</b> , 15, 1275-83	21
1760	Atomization inhalation of terbutaline and budesonide efficiently improved immunity and lung function of AECOPD patients. <b>2008</b> , 5, 287-91	12
1759	Novel long-acting bronchodilators for COPD and asthma. <b>2008</b> , 155, 291-9	105
1758	Smoke particulates stress lung cells. <b>2008</b> , 14, 1024-5	17
1757	Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers. <b>2008</b> , 2, 17-25	20
1756	Is CT a new research tool for COPD?. <b>2008</b> , 2 Suppl 1, 76-83	5
1755	Mineral status of COPD patients under long-term inhaled corticosteroid therapy. <b>2008</b> , 17, 462-7	7
1754	Enhanced exercise-induced plasma cytokine response and oxidative stress in COPD patients depend on blood oxygenation. <b>2008</b> , 28, 182-8	19
1753	Continuous positive airway pressure increases inspiratory capacity of COPD patients. <b>2008</b> , 13, 387-93	12
1752	Association between angiotensin-converting enzyme gene polymorphisms and exercise performance in patients with COPD. <b>2008</b> , 13, 683-8	29

1751	Tratamiento de la EPOC en 5 ciudades de Amfica Latina: estudio PLATINO. <b>2008</b> , 44, 58-64	12
1750	EPOC y acontecimientos cardiovasculares. <b>2008</b> , 44, 152-159	1
1749	[Impact of new therapeutic products for the treatment of chronic obstructive pulmonary disease and asthma in primary care in Madrid between 1996 and 2005]. <b>2008</b> , 22, 105-14	4
1748	Activaciñ de clulas satlite en el m <sup>8</sup> culo intercostal de pacientes con EPOC. <b>2008</b> , 44, 239-244	4
1747	La investigaciñ bêica en neumologâ. <b>2008</b> , 44, 621-628	4
1746	Advances in therapy for adult asthma. <b>2008</b> , 8, 62-75	1
1745	Actualizaciñ en los mecanismos de disfunciñ muscular en la EPOC. <b>2008</b> , 44, 328-337	16
1744	The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease. <b>2008</b> , 159-191	4
1743	Increased activation of p38 MAPK in COPD. European Respiratory Journal, 2008, 31, 62-9 13.6	198
1742	Autoantibodies in patients with chronic obstructive pulmonary disease. 2008, 177, 156-63	202
1741	[Critical evaluation of clinical practice guidelines]. 2008, 130, 376-9	4
1740	[Treatment of mild chronic obstructive pulmonary disease]. 2008, 130, 661-5	
1739	Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. <b>2008</b> , 9, 62	82
1738	Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. <b>2008</b> , 2, 329-35	20
1737	[Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study]. <b>2008</b> , 44, 58-64	12
1736	Chronic Obstructive Pulmonary Disease and Cardiovascular Events. <b>2008</b> , 44, 152-159	2
1735	Activation of Satellite Cells in the Intercostal Muscles of Patients With Chronic Obstructive Pulmonary Disease. <b>2008</b> , 44, 239-244	8

1733	Optimizing bronchodilator therapy in emphysema. <b>2008</b> , 5, 501-5	2
1732	A review of the role of FEV1 in the COPD paradigm. <b>2008</b> , 5, 310-8	13
1731	Chronic obstructive pulmonary disease: an evidence-based approach to treatment with a focus on anticholinergic bronchodilation. <b>2008</b> , 83, 1241-50	3
1730	[Cardiovascular manifestations in patients with COPD]. 2008, 25, 663-73	8
1729	What defines abnormal lung function in older adults with chronic obstructive pulmonary disease?. <b>2008</b> , 25, 717-28	18
1728	Chronic Obstructive Pulmonary Disease. <b>2008</b> , 16, 273-274	1
1727	The Emerging Chronic Obstructive Pulmonary Disease Epidemic. 2008, 16, 275-284	4
1726	Integrated Chronic Obstructive Pulmonary Disease Management in Primary Care. 2008, 16, 315-318	5
1725	Patients with Alpha-1 Antitrypsin Deficiency. <b>2008</b> , 16, 345-351	1
1724	Patients with Chronic Obstructive Pulmonary Disease. <b>2008</b> , 16, 353-358	2
1724 1723	Patients with Chronic Obstructive Pulmonary Disease. 2008, 16, 353-358  Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11	2 23
1723	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the	
1723	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11  [Lung function tests in refractory asthma]. 2008, 37, 143-54  The short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive	
1723 1722	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11  [Lung function tests in refractory asthma]. 2008, 37, 143-54  The short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary disease. 2008,	23
1723 1722 1721	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11  [Lung function tests in refractory asthma]. 2008, 37, 143-54  The short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary disease. 2008, 61, 489-97  Muscle stretching technique increases vital capacity and range of motion in patients with chronic	23 35
1723 1722 1721 1720	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11  [Lung function tests in refractory asthma]. 2008, 37, 143-54  The short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary disease. 2008, 61, 489-97  Muscle stretching technique increases vital capacity and range of motion in patients with chronic obstructive pulmonary disease. 2008, 89, 1103-7  Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review	23 35 32
1723 1722 1721 1720 1719	Quality of life in patients with chronic obstructive pulmonary disease: the predictive validity of the BODE index. 2008, 5, 7-11  [Lung function tests in refractory asthma]. 2008, 37, 143-54  The short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary disease. 2008, 61, 489-97  Muscle stretching technique increases vital capacity and range of motion in patients with chronic obstructive pulmonary disease. 2008, 89, 1103-7  Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review and meta-analysis. 2008, 121, 433-443.e4  Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention	23 35 32 111

### (2008-2008)

1715	Primary care of the patient with chronic obstructive pulmonary disease-part 4: understanding the clinical manifestations of a progressive disease. <b>2008</b> , 121, S33-45	29
1714	Time-dependent confounding in the study of the effects of regular physical activity in chronic obstructive pulmonary disease: an application of the marginal structural model. <b>2008</b> , 18, 775-83	45
1713	Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. <b>2008</b> , 21, 20-5	23
1712	Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. <b>2008</b> , 21, 160-5	4
1711	Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. <b>2008</b> , 21, 682-8	44
1710	The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. <b>2008</b> , 21, 767-73	22
1709	Use of respiratory medication in five Latin American cities: The PLATINO study. <b>2008</b> , 21, 788-93	13
1708	Improvements with tiotropium in COPD patients with concomitant asthma. 2008, 102, 50-6	95
1707	Chronic obstructive pulmonary disease and body mass index in five Latin America cities: the PLATINO study. <b>2008</b> , 102, 642-50	59
1706	Sleep, hypnotics and chronic obstructive pulmonary disease. <b>2008</b> , 102, 801-14	36
1705	What community measurements can be used to predict bone disease in patients with COPD?. <b>2008</b> , 102, 651-7	23
1704	One-year non-invasive ventilation in chronic hypercapnic COPD: effect on quality of life. <b>2008</b> , 102, 904-11	40
1703	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg. <b>2008</b> , 102, 1026-32	26
1702	Comparing supplementary oxygen benefits from a portable oxygen concentrator and a liquid oxygen portable device during a walk test in COPD patients on long-term oxygen therapy. <b>2008</b> , 102, 1021-5	29
1701	Effects of inspiratory muscle thixotropy on the 6-min walk distance in COPD. 2008, 102, 970-7	8
1700	Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. <b>2008</b> , 102, 1468-72	19
1699	Does correction of exercise-induced desaturation by O(2) always improve exercise tolerance in COPD? A preliminary study. <b>2008</b> , 102, 1276-86	16
1698	Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. <b>2008</b> , 102, 1099-108	191

1697	FEV1/FVC and FEV1 for the assessment of chronic airflow obstruction in prevalence studies: do prediction equations need revision?. <b>2008</b> , 102, 1568-74	13
1696	Increased intraepithelial T-cells in stable COPD. <b>2008</b> , 102, 1812-8	20
1695	Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. <b>2008</b> , 102, 1715-29	119
1694	Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. <b>2008</b> , 102, 1701-7	29
1693	One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)â <b>R</b> epublished article. <b>2008</b> , 4, 8-25	3
1692	Reproducibility of indirect calorimetry in underweight patients with chronic obstructive pulmonary disease. <b>2008</b> , 3, e40-e45	2
1691	Prevalence of COPD: first epidemiological study of a large region in Turkey. <b>2008</b> , 19, 499-504	52
1690	Patologâ de los m <sup>8</sup> culos respiratorios. <b>2008</b> , 12, 1-7	
1689	Principales indications, modalits de traitement et questions non rsolues de lâbxyghothfapie de longue dure ^domicile. <b>2008</b> , 4, 22-26	
1688	[Smoking, asthma and chronic obstructive pulmonary disease in aduts: a too frequent relation]. <b>2008</b> , 130, 636-7	O
1687	The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. <b>2008</b> , 21, 540-50	40
1686	Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. <b>2008</b> , 372, 1088-99	107
1685	Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. <b>2008</b> , 63, 599-605	97
1684	Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 962-9	708
1683	Cardiovascular Disease in the Elderly. 2008,	3
1682	Validation of the Portuguese version of the London Chest Activity of Daily Living Scale (LCADL) in chronic obstructive pulmonary disease patients. <b>2008</b> , 14, 27-47	27
1681	COPD: the glass is half-full. Introduction. <b>2008</b> , 102 Suppl 1, S1-2	3
1680	It's about timedirecting our attention toward modifying the course of COPD. <b>2008</b> , 102 Suppl 1, S37-48	6

1679 [Spirometric reference equations for Algerians aged 19 to 73 years]. <b>2008</b> , 25, 577-90	14
1678 Update on the Mechanisms of Muscle Dysfunction in COPD. <b>2008</b> , 44, 328-337	1
1677 [Should we screen for COPD in the population]. <b>2008</b> , 25, 787-90	2
What role may symptoms play in the diagnosis of airflow limitation? A study in an elderly population. <b>2008</b> , 26, 92-8	26
Plasma carbonyls do not correlate with lung function or computed tomography measures density in older smokers. <b>2008</b> , 13, 422-34	s of lung
Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical ludamage induced by smoking. <b>2008</b> , 13, 385-92	ung 41
1673 Evaluation of obstructive lung disease with vibration response imaging. <b>2008</b> , 45, 923-30	13
Time course and degree of hyperinflation with metronome-paced tachypnea in COPD pat <b>2008</b> , 5, 298-304	ients. 16
1671 Chronic Obstructive Pulmonary Disease. <b>2008</b> , 709-717	O
Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease. <b>2008</b> , 5, 229-34	23
Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, contro multicenter study. <b>2008</b> , 12, R62	olled, 117
Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstrupulmonary disease patients: a prospective clinical study. <b>2008</b> , 12, R140	uctive 8
Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysem Treatment Trial. <b>2008</b> , 5, 105-16	na 72
1666 Reversing concepts on COPD irreversibility. European Respiratory Journal, <b>2008</b> , 31, 695-6	13.6 16
Plasma ghrelin levels and weight loss in Chinese Uygur patients with chronic obstructive process. 2008, 36, 1371-7	pulmonary 13
Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchit meta-analysis. <b>2008</b> , 62, 442-50	tis: a 47
1663 Ventilatory Support for Chronic Respiratory Failure. <b>2008</b> ,	
$_{1662}$ Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. <b>20</b>	<b>008</b> , 5, 842-7 32

1661	SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations. <b>2008</b> , 54, 1331-8	60
1660	Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. <b>2008</b> , 63, 306-11	144
1659	Value of chest radiography in phenotyping chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 509-15	47
1658	Outcomes for COPD pharmacological trials: from lung function to biomarkers. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 416-69	621
1657	Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. European Respiratory Journal, 2008, 32, 953-61	94
1656	Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD. <b>2008</b> , 75, 138-44	42
1655	Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. <b>2008</b> , 76, 253-60	31
1654	Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. <b>2008</b> , 300, 2407-16	239
1653	Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 555-62	130
1652	COPD and biomarkers: the search goes on. <b>2008</b> , 63, 1032-4	10
1651	Area under the maximum expiratory flow-volume curvea sensitive parameter in the evaluation of airway patency. <b>2008</b> , 75, 40-7	14
1650	Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. <b>2008</b> , 87, 319-328	45
1649	Relationship between gastroesophageal reflux disease and COPD in UK primary care. <b>2008</b> , 134, 1223-1230	49
1648	Assessment of patients with chronic obstructive pulmonary disease. <b>2008</b> , 5, 884-90	6
1647	Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). <i>European Respiratory Journal</i> , <b>2008</b> , 31, 869-73	486
1646	Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). <b>2008</b> , 133, 343-9	179
1645	Safety of long-acting beta-agonists in stable COPD: a systematic review. <b>2008</b> , 133, 1079-87	70
1644	Importance of noninvasively measured respiratory muscle overload among the causes of hospital readmission of COPD patients. <b>2008</b> , 133, 941-7	13

1643	Coexisting asthma and COPD: confused clinicians or poor prognosticator?. <b>2008</b> , 134, 1-2	103
1642	Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. <b>2008</b> , 134, 746-752	199
1641	Serum interleukin-1beta as a marker for differentiation of asthma and chronic obstructive pulmonary disease. <b>2008</b> , 13, 713-27	15
1640	Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. <b>2008</b> , 178, 233-9	63
1639	Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. <b>2008</b> , 2, 37-48	31
1638	Pulmonary hypertension in COPD. European Respiratory Journal, 2008, 32, 1371-85	392
1637	High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. <b>2008</b> , 10, 883-90	39
1636	Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease. <b>2008</b> , 21, 329-34	6
1635	What evidence could validate the definition of COPD?. <b>2008</b> , 63, 756-7	6
1634	COPD as a lung disease with systemic consequencesclinical impact, mechanisms, and potential for early intervention. <b>2008</b> , 5, 235-56	203
1633	Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. <b>2008</b> , 63, 962-7	39
1632	Chronic Obstructive Pulmonary Disease Exacerbations. 2008,	2
1631	Abnormal sarcoplasmic reticulum Ca2+-sequestering properties in skeletal muscle in chronic obstructive pulmonary disease. <b>2008</b> , 295, C350-7	26
1630	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <b>2008</b> , 178, 332-8	566
1629	Bronchodilator responsiveness in patients with COPD. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 742-50 13.6	234
1628	Proportional classifications of COPD phenotypes. <b>2008</b> , 63, 761-7	158
1627	Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. <b>2008</b> , 63, 1046-51	323
1626	BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. <b>2008</b> , 63 Suppl 1, i1-i16	23

1625	Drugs (including oxygen) in severe COPD. European Respiratory Journal, 2008, 31, 1114-24	13.6	17
1624	A cross-sectional study of lung function and respiratory symptoms among chemical workers producing diacetyl for food flavourings. <b>2009</b> , 66, 105-10		32
1623	Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. <b>2008</b> , 63, 415-22		68
1622	Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. European Respiratory Journal, 2008, 32, 945-52	13.6	80
1621	FTIR spectroscopic analysis of sputum: preliminary findings on a potential novel diagnostic marker for COPD. <b>2008</b> , 2, 23-31		27
1620	Underestimation of airflow obstruction among young adults using FEV1/FVC . 2008, 63, 1040-5		96
1619	Fulfilling the promise of primary care spirometry. European Respiratory Journal, 2008, 31, 8-10	13.6	10
1618	Complex chronic comorbidities of COPD. European Respiratory Journal, 2008, 31, 204-12	13.6	433
1617	Impact of chronic airflow obstruction in a working population. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 1227-33	13.6	48
1616	COPD-related morbidity and mortality after smoking cessation: status of the evidence. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 844-53	13.6	178
1615	Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 1275-82	13.6	105
1614	Should we be using statistics to define disease?. <b>2008</b> , 63, 1031-2		3
1613	Validation and comparison of reference equations for the 6-min walk distance test. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 571-8	13.6	140
1612	Sleep abnormalities and treatment in emphysema. <b>2008</b> , 5, 536-42		38
1611	Oxygen-enhanced magnetic resonance imaging versus computed tomography: multicenter study for clinical stage classification of smoking-related chronic obstructive pulmonary disease. <b>2008</b> , 177, 1095-102		77
1610	Natural history of emphysema. <b>2008</b> , 5, 468-74		26
1609	Cardiovascular injury and repair in chronic obstructive pulmonary disease. 2008, 5, 824-33		79
1608	Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. <b>2008</b> , 177, 1292-3; author reply 1293		1

1607	Dietary factors for chronic obstructive pulmonary disease: epidemiological evidence. <b>2008</b> , 2, 645-53	14
1606	Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. <b>2008</b> , 5, 834-41	30
1605	Vascular disease in chronic obstructive pulmonary disease. <b>2008</b> , 5, 891-9	9
1604	Dynamic oxygen-enhanced MRI versus quantitative CT: pulmonary functional loss assessment and clinical stage classification of smoking-related COPD. <b>2008</b> , 190, W93-9	58
1603	Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. <b>2008</b> , 177, 269-78	194
1602	Autophagic proteins regulate cigarette smoke-induced apoptosis: protective role of heme oxygenase-1. <b>2008</b> , 4, 887-95	179
1601	Increased expression of placenta growth factor in COPD. <b>2008</b> , 63, 500-6	36
1600	Chronic LPS inhalation causes emphysema-like changes in mouse lung that are associated with apoptosis. <b>2008</b> , 39, 584-90	74
1599	Medication use patterns associated with spirometry in diagnosing COPD. <b>2008</b> , 5, 360-8	7
1598	Moxifloxacin: a respiratory fluoroquinolone. <b>2008</b> , 9, 1755-72	18
1597	Long-term effects of budesonide on inflammatory status in COPD. <b>2008</b> , 5, 97-104	14
1596	Systemic effects of COPD: just the tip of the Iceberg. <b>2008</b> , 5, 205-6	3
1595	Valida <b>à</b> da vers <b>ò</b> em portugu <b>s</b> da escala London Chest Activity of Daily Living (LCADL) em doentes com doen <b>à</b> pulmonar obstrutiva cr <b>à</b> ica. <b>2008</b> , 14, 27-47	26
1594	Comparing antibiotics for acute exacerbations of chronic obstructive pulmonary disease. 2008,	
1593	Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. <b>2008</b> , 134, 255-262	92
1592	Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. <b>2008</b> , 134, 497-506	31
1591	Killer cells in chronic obstructive pulmonary disease. <b>2008</b> , 114, 533-41	30
1590	Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. <b>2008</b> , 115, 225-32	61

1589	A prospective and randomized study for improvement of acute asthma by non-invasive positive pressure ventilation (NPPV). <b>2008</b> , 47, 493-501	72
1588	The use and abuse of office spirometry. <b>2008</b> , 17, 238-42	23
1587	Update on the management of COPD. <b>2008</b> , 133, 1451-1462	87
1586	Smoking and home oxygen therapya preventable public health hazard. <b>2008</b> , 29, 119-22	14
1585	Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. <b>2008</b> , 134, 43S-56S	455
1584	Variability in small airway epithelial gene expression among normal smokers. <b>2008</b> , 133, 1344-1353	44
1583	Health care costs among individuals with chronic obstructive pulmonary disease within several large, multi-state employers. <b>2008</b> , 50, 1130-8	12
1582	Pathologies des muscles respiratoires. <b>2008</b> , 3, 1-7	О
1581	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. 2008, 4, 312-320	
1580	Pulse oximetry in the preflight evaluation of patients with chronic obstructive pulmonary disease. <b>2008</b> , 79, 518-24	22
1579	Combined oximetry-cutaneous capnography in patients assessed for long-term oxygen therapy. <b>2008</b> , 133, 1421-1425	15
1578	Sleep and medical disorders. 186-207	O
1577	Neuromuscular electrical stimulation of the lower limbs in patients with chronic obstructive pulmonary disease. <b>2008</b> , 28, 79-91	69
1576	Are GOLDen slumbers drug induced?. 2008, 177, 1291; author reply 1291-2	6
1575	Inhaled Drug Therapy in Chronic Obstructive Pulmonary Disease. <b>2008</b> , 15, 239-247	
1574	Computed-tomography findings of emphysema: correlation with spirometric values. 2008, 14, 110-4	17
1573	Noninvasive mechanical ventilation in patients with chronic obstructive pulmonary disease and severe hypercapnic neurological deterioration in the emergency room. <b>2008</b> , 15, 127-33	14
1572	Indoor risk factors for cough and their relation to wheeze and sensitization in Chilean young adults. <b>2008</b> , 98, 680-6	5

## (2008-2008)

1571	Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. <b>2008</b> , 3, 127-36	55
1570	Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. <b>2008</b> , 3, 521-9	27
1569	Diagnostic and therapeutic approach to coexistent chronic obstructive pulmonary disease and obstructive sleep apnea. <b>2008</b> , 3, 269-75	7
1568	Safety, tolerability and risk benefit analysis of tiotropium in COPD. <b>2008</b> , 3, 575-84	24
1567	Effect of noninvasive mechanical ventilation in elderly patients with hypercapnic acute-on-chronic respiratory failure and a do-not-intubate order. <b>2008</b> , 3, 797-801	21
1566	Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. <b>2008</b> , 3, 671-82	38
1565	Optimizing economic outcomes in the management of COPD. <b>2008</b> , 3, 1-10	24
1564	[Breath of life: experience with chronic obstructive pulmonary disease in the context of urban poverty in Fortaleza, Cear&tate, Brazil]. <b>2008</b> , 24, 2809-18	4
1563	Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. <b>2008</b> , 3, 771-80	36
1562	Pulmonary hypertension associated with COPD. <b>2008</b> , 3, 55-70	48
1561	Comparison of spirometric changes in the response to bronchodilators of patients with asthma or chronic obstructive pulmonary disease. <b>2008</b> , 34, 675-82	4
1560	Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. <b>2008</b> , 3, 155-62	25
1559	Treatment of mild chronic obstructive pulmonary disease. <b>2008</b> , 3, 563-73	4
1559 1558	Treatment of mild chronic obstructive pulmonary disease. <b>2008</b> , 3, 563-73  Chronic Obstructive Pulmonary Disease. <b>2008</b> , 90-109	1
1558 1557	Chronic Obstructive Pulmonary Disease. <b>2008</b> , 90-109	1
1558 1557	Chronic Obstructive Pulmonary Disease. 2008, 90-109  Grand rounds: asbestos-related pericarditis in a boiler operator. 2008, 116, 86-9	2

1553	Optimizing antibiotic selection in treating COPD exacerbations. <b>2008</b> , 3, 31-44	23
1552	Ventilatory Management of Obstructive Airway Disease. <b>2008</b> , 177-190	
1551	Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. <b>2008</b> , 3, e2667	65
1550	Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. <b>2008</b> , 3, e3316	344
1549	Validation of the Modified Pulmonary Functional Status and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients with chronic obstructive pulmonary disease. <b>2008</b> , 34, 1008-18	115
1548	Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. <b>2008</b> , 49, 182-91	29
1547	Long-term oxygen therapy: are we prescribing appropriately?. <b>2008</b> , 3, 231-7	34
1546	Usefulness of inspiratory capacity measurement in COPD patients in the primary care setting. <b>2009</b> , 219	
1545	Chronic Obstructive Pulmonary Disease in Patients with Catheter Diagnosed Coronary Artery Disease: Prevalence and Risk Factors. <b>2009</b> , 3,	
1544	Lung Volume Reduction Surgery and Pulmonary Rehabilitation Improve Exercise Capacity and Reduce Dyspnea During Functional Activities in People with Emphysema. <b>2009</b> , 20, 5-11	2
1543	Improved Health-Related Quality of Life After Lung Volume Reduction Surgery and Pulmonary Rehabilitation. <b>2009</b> , 20, 16-22	1
1542	Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. <b>2009</b> , 119	1
1541	Targeted treatment in COPD: a multi-system approach for a multi-system disease. <b>2009</b> , 4, 321-35	44
1540	Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. <b>2009</b> , 4, 421-30	3
1539	Accuracy of clinical examination findings in the diagnosis of COPD. <b>2009</b> , 35, 404-8	12
1538	Long-Term Oxygen Therapy. <b>2009,</b> 677-687	
1537	Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies. <b>2009</b> , 185	О
1536	COMORBIDITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A ROLE OF CARDIOVASCULAR DISORDERS. <b>2009</b> , 5, 9-16	5

1535	Hypercapnia test and weaning outcome from mechanical ventilation in COPD patients. <b>2009</b> , 37, 726-32		6
1534	COPD and Asthma in the Elderly. 183-197		
1533	Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria. <b>2009</b> , 24, 621-6		41
1532	Predicting the need for supplemental oxygen during airline flight in patients with chronic pulmonary disease: a comparison of predictive equations and altitude simulation. <b>2009</b> , 16, 119-24		8
1531	Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. <b>2009</b> , 4, 245-51		52
1530	Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. <b>2009</b> , 4, 431-6		8
1529	Effect of three exercise programs on patients with chronic obstructive pulmonary disease. <b>2009</b> , 42, 263-71		31
1528	Antibiotics. <b>2009</b> , 663-676		
1527	A study of patient attitudes in the United Kingdom toward ventilatory support in chronic obstructive pulmonary disease. <b>2009</b> , 12, 1029-35		10
1526	Prevalence of COPD among symptomatic patients in a primary care setting. <b>2009</b> , 25, 2671-7		26
1525	Cor pulmonale. <b>2009</b> , 6, 177-85		51
1524	Emerging inhaled bronchodilators: an update. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 757-69 13.	6	68
1523	Post-hypercapnic alkalosis is associated with ventilator dependence and increased ICU stay. <b>2009</b> , 6, 437-40		12
1522	Peripheral T cell functions correlate with the severity of chronic obstructive pulmonary disease. <b>2009</b> , 182, 3270-7		72
1521	Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study.  European Respiratory Journal, 2009, 34, 588-97	6	183
1520	Positive expiratory pressure in patients with chronic obstructive pulmonary diseasea systematic review. <b>2009</b> , 77, 110-8		20
1519	Upregulation of lung dendritic cell functions in elastase-induced emphysema. <b>2009</b> , 149 Suppl 1, 25-30		5
1518	Validation of a structured questionnaire for COPD and prevalence of COPD in rural area of Mysore: A pilot study. <b>2009</b> , 26, 63-9		25

1517	Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. <b>2009</b> , 179, 566-71	228
1516	Re: "Immortal time bias in pharmacoepidemiology". <b>2009</b> , 170, 667-8; author reply 668-9	7
1515	Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. <b>2009</b> , 64, 910-5	57
1514	Pharmacology and Therapeutics of Airway Disease. 2009,	
1513	Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by increased pulmonary artery pressure. <b>2009</b> , 95, 137-41	38
1512	Role of TNF-⊞, sTNF-R55 and sTNF-R75 in inflammation of acute exacerbations of chronic obstructive pulmonary disease. <b>2009</b> , 78, 399-403	14
1511	Genuair is a good inhaler but an indirect comparison with other dry powder inhalers is inadequate. <b>2009</b> , 78, 249-51; discussion 252	
1510	Qualitative aspects of breathlessness in health and disease. <b>2009</b> , 64, 713-8	40
1509	Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 1338-44	68
1508	Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD.  European Respiratory Journal, <b>2009</b> , 33, 1329-37	76
1507	Role for interleukin-6 in COPD-related pulmonary hypertension. <b>2009</b> , 136, 678-687	126
1506	Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. <b>2009</b> , 136, 44-61	137
1505	Decreased small airway and alveolar CD83+ dendritic cells in COPD. <b>2009</b> , 136, 726-733	32
1504	Patient-reported dyspnea in COPD reliability and association with stage of disease. <b>2009</b> , 136, 1473-1479	69
1503	Chronic obstructive pulmonary disease: radiology-pathology correlation. <b>2009</b> , 24, 171-80	17
1502	The role of collaborative self-management in pulmonary rehabilitation. <b>2009</b> , 30, 700-7	23
1501	Preventing chronic obstructive pulmonary disease. <b>2009</b> , 3, 449-52	
1500	Differentiating COPD from asthma in clinical practice. <b>2009</b> , 121, 105-12	8

1499	Office management of COPD in primary care: a 2009 clinical update. <b>2009</b> , 121, 82-90	19
1498	Targeting leukotrienes for the treatment of COPD?. <b>2009</b> , 8, 297-306	22
1497	Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. <b>2009</b> , 180, 506-12	198
1496	Pulmonary rehabilitation and palliative care. <b>2009</b> , 30, 684-99	8
1495	Pulmonary rehabilitation and pharmacotherapy. <b>2009</b> , 30, 636-48	1
1494	Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. <b>2009</b> , 180, 846-52	56
1493	Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. <b>2009</b> , 180, 956-63	37
1492	Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 361-4	5 75
1491	A 20-year follow-up of a population study-based COPD cohort-report from the obstructive lung disease in Northern Sweden studies. <b>2009</b> , 6, 263-71	27
1490	Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. <b>2009</b> , 6, 320-9	136
1489	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation. <b>2009</b> , 11, 632; author reply 632-3	1
1488	Diffuse idiopathic pulmonary neuroendocrine hyperplasia, chronic eosinophilic pneumonia, and asthma. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1489-92	6 6
1487	Sleep disorders and their management in patients with COPD. <b>2009</b> , 3, 309-18	17
1486	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <b>2009</b> , 11, 130-9	324
1485	Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. <b>2009</b> , 6, 446-51	30
1484	COPD guidelines in relation to infections: a critical analysis. <b>2009</b> , 5, 317-321	2
1483	Emerging drugs in chronic obstructive pulmonary disease. <b>2009</b> , 14, 181-94	6
1482	Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. <b>2009</b> , 24, 2763-7	44

1481	The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. <b>2009</b> , 6, 104-11		30
1480	Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. <b>2009</b> , 64 Suppl 1, i1-51		231
1479	The role of body mass index in acute exacerbations of chronic obstructive pulmonary disease. <b>2009</b> , 26, 701-5		6
1478	Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1311-21	13.6	83
1477	How to increase the value of randomised trials in COPD research. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 552-8	13.6	6
1476	Quality of life, stage severity and COPD. European Respiratory Journal, 2009, 33, 953-5	13.6	13
1475	Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies. <b>2009</b> , 77, 4548-58		12
1474	A hypothesis for the initiation of COPD. European Respiratory Journal, 2009, 34, 310-5	13.6	40
1473	Effect of heliox breathing on flow limitation in chronic heart failure patients. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 1367-73	13.6	6
1472	A controlled trial of noninvasive ventilation for chronic obstructive pulmonary disease exacerbations. <b>2009</b> , 24, 473.e7-14		33
1471	Evaluation of a combined strategy directed towards health-care professionals and patients with chronic obstructive pulmonary disease (COPD): information and health education feedback for improving clinical monitoring and quality-of-life. <b>2009</b> , 9, 442		16
1470	Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study. <b>2009</b> , 9, 8		9
1469	Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. <b>2009</b> , 7, 40		39
1468	Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease. <b>2009</b> , 29, 1039-53		18
1467	Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. <b>2009</b> , 31, 1716-23		4
1466	[Phenotypic characterization and course of chronic obstructive pulmonary disease in the PAC-COPD Study: design and methods]. <b>2009</b> , 45, 4-11		41
1465	[Lactate dehydrogenase isozymes in skeletal muscle of patients with chronic obstructive pulmonary disease]. <b>2009</b> , 45, 75-80		3
1464	[Health-care quality standards in chronic obstructive pulmonary disease]. 2009, 45, 196-203		26

### (2009-2009)

1463	[The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40-to-80-year-olds: protocol summary]. <b>2009</b> , 45, 41-7	60
1462	[Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease]. <b>2009</b> , 45, 181-6	18
1461	[Phenotypic heterogeneity of chronic obstructive pulmonary disease]. 2009, 45, 129-38	17
1460	Nebulized respiratory medications: friend or foe?. <b>2009</b> , 30, 45-9	1
1459	Is that case of asthma really COPD, and does the diagnosis matter?. <b>2009</b> , 30, 409-413	1
1458	[Causes of mortality in COPD]. <b>2009</b> , 45 Suppl 4, 8-13	7
1457	[Anxiety and COPD]. <b>2009</b> , 45 Suppl 4, 51-3	4
1456	Adenosine receptors in COPD and asymptomatic smokers: effects of smoking cessation. <b>2009</b> , 454, 273-81	8
1455	Toll-like receptor 2 gene polymorphisms Arg677Trp and Arg753Gln in chronic obstructive pulmonary disease. <b>2009</b> , 187, 173-8	19
1454	An open-access microfluidic model for lung-specific functional studies at an air-liquid interface. <b>2009</b> , 11, 1081-9	74
1453	Factors associated with short-term recovery of health status among emergency department patients with acute exacerbations of chronic obstructive pulmonary disease. <b>2009</b> , 18, 191-9	5
1452	Interpretation of pulmonary function test: issues and controversies. <b>2009</b> , 37, 173-80	16
1451	Improved care of acute exacerbation of chronic obstructive pulmonary disease in two academic emergency departments. <b>2009</b> , 2, 111-6	6
1450	[Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease]. <b>2009</b> , 104, 119-24	2
1449	[What is proven in the treatment of COPD?]. 2009, 50, 1345-57	
1448	Iron lung versus mask ventilation in acute exacerbation of COPD: a randomised crossover study. <b>2009</b> , 35, 648-55	11
1447	Etiologies and outcome of acute respiratory failure in HIV-infected patients. 2009, 35, 1678-86	54
1446	Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. <b>2009</b> , 9, 178	38

1445	PLAUR polymorphisms and lung function in UK smokers. <b>2009</b> , 10, 112	22
1444	Evaluation of psychological and physiological predictors of fatigue in patients with COPD. <b>2009</b> , 9, 47	33
1443	Inhospital management of COPD exacerbations: a systematic review of the literature with regard to adherence to international guidelines. <b>2009</b> , 15, 1101-10	46
1442	Is your knowledge up-to-date? COPD. <b>2009</b> , 7, 303-7	
1441	Diagnosis and treatment considerations for women with COPD. <b>2009</b> , 63, 486-93	45
1440	Racial and ethnic differences in emergency care for acute exacerbation of chronic obstructive pulmonary disease. <b>2009</b> , 16, 108-15	8
1439	Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. <b>2009</b> , 14, 230-8	103
1438	Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. <b>2009</b> , 14, 239-44	14
1437	Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. <b>2009</b> , 14, 551-8	13
1436	Association of impaired respiratory function with urinary incontinence. <b>2009</b> , 14, 753-6	6
1435	Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. <b>2009</b> , 14, 969-74	33
1434	Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. <b>2009</b> , 64, 778-83	60
1433	Under-report and underdiagnosis of chronic respiratory diseases in an African country. <b>2009</b> , 64, 1061-7	32
1432	Aspects of healthcare utilisation in self-reported obstructive lung disease. <b>2009</b> , 3, 34-41	5
1431	Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study. <b>2009</b> , 13, R60	19
1430	Increase of matrix metalloproteinases in woodsmoke-induced lung emphysema in guinea pigs. <b>2009</b> , 21, 119-32	20
1429	Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. <b>2009</b> , 22, 177-82	13
1428	Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. <b>2009</b> , 22, 237-42	12

### (2009-2009)

1427	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. <b>2009</b> , 22, 522-5	6
1426	[Stress in elderly hospitalized patients with chronic respiratory disease: assessment in a public geriatric hospital]. <b>2009</b> , 44, 130-6	1
1425	Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. <b>2009</b> , 103, 85-90	60
1424	Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests. <b>2009</b> , 103, 251-7	16
1423	Telomere shortening in chronic obstructive pulmonary disease. <b>2009</b> , 103, 230-6	95
1422	Use of functional independence measure in rehabilitation of inpatients with respiratory failure. <b>2009</b> , 103, 471-6	16
1421	A model of quality assessment in patients on long-term oxygen therapy. <b>2009</b> , 103, 209-15	12
1420	Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. <b>2009</b> , 103, 12-21	40
1419	Primary care of the patient with chronic obstructive pulmonary disease in Italy. <b>2009</b> , 103, 582-8	18
1418	Airflow obstruction and exercise. <b>2009</b> , 103, 325-34	55
1417	Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. <b>2009</b> , 103, 542-51	52
	103, 542-51	
1416	103, 542-51  Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. 2009, 103, 736-42	52 1
1416 1415	Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. <b>2009</b> , 103, 736-42  Clinical, functional and biochemical changes during recovery from COPD exacerbations. <b>2009</b> , 103, 919-26  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with	52 1 59
1416 1415 1414	Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. <b>2009</b> , 103, 736-42  Clinical, functional and biochemical changes during recovery from COPD exacerbations. <b>2009</b> , 103, 919-26  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. <b>2009</b> , 103, 516-24  Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting.	52 1 59 58
1416 1415 1414 1413	Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. <b>2009</b> , 103, 736-42  Clinical, functional and biochemical changes during recovery from COPD exacerbations. <b>2009</b> , 103, 919-26  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. <b>2009</b> , 103, 516-24  Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. <b>2009</b> , 103, 866-72  COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot	52 1 59 58 25

1409	Noninvasive ventilation in pulmonary rehabilitation of COPD patients. <b>2009</b> , 103, 1329-36	42
1408	Remote daily real-time monitoring in patients with COPDa feasibility study using a novel device. <b>2009</b> , 103, 1320-8	43
1407	Clinical commentaryCOPD is not a systemic disease. Results from the AIMAR Expert Opinion Consensus/Dissensus Seminar "COPD is/is not a systemic disease?", Venice, Italy, 13-14 November 2008. <b>2009</b> , 103, 1270-5	1
1406	Characteristics of patients admitted for the first time for COPD exacerbation. <b>2009</b> , 103, 1293-302	42
1405	Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. <b>2009</b> , 103, 1286-92	12
1404	Quality of COPD care in hospital outpatient clinics in Denmark: The KOLIBRI study. <b>2009</b> , 103, 1657-62	24
1403	Evaluation of withdrawal of maintenance tiotropium in COPD. <b>2009</b> , 103, 1415-20	14
1402	Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. <b>2009</b> , 103, 1421-9	63
1401	Dietary habits of firstly admitted Spanish COPD patients. <b>2009</b> , 103, 1904-10	27
1400	Biomarkers of lung damage associated with tobacco smoke in induced sputum. <b>2009</b> , 103, 1592-613	37
1399	Skeletal muscle dysfunction in chronic obstructive pulmonary disease. <b>2009</b> , 5, 7-13	3
1398	Do vegetables and fruits reduce the risk of chronic obstructive pulmonary disease? A case-control study in Japan. <b>2009</b> , 49, 184-9	36
1397	Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. <b>2009</b> , 38, 34-47	79
1396	[Pulmonary function tests in chronic obstructive pulmonary disease]. <b>2009</b> , 38, 421-31	O
1395	[Acute exacerbations of chronic obstructive pulmonary disease]. 2009, 38, 485-95	5
1394	[Difficulties in the assessment of dyspnea and respiratory function in general practice]. <b>2009</b> , 38, 1041-8	1
1393	ED visit volume and quality of care in acute exacerbations of chronic obstructive pulmonary disease. <b>2009</b> , 27, 1040-9	9
1392	The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. <b>2009</b> , 122, 472-8	46

1391	Pulmonary rehabilitation improves functional status in oncology patients. 2009, 90, 837-41	21
1390	Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. <b>2009</b> , 54, S85-S96	284
1389	Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. <b>2009</b> , 124, 873-80; quiz 881-2	12
1388	Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. <b>2009</b> , 189, 225-34	61
1387	Use of spirometry in the diagnosis of chronic obstructive pulmonary disease and efforts to improve quality of care. <b>2009</b> , 154, 103-10	14
1386	[Post-hospital mortality in patients re-admitted due to COPD. Utility of BODE index]. 2009, 209, 364-70	15
1385	Sex differences in mortality in patients with COPD. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 528-35 13.6	95
1384	Lactate Dehydrogenase Isozymes in Skeletal Muscle of Patients With Chronic Obstructive Pulmonary Disease. <b>2009</b> , 45, 75-80	
1383	Phenotypic Heterogeneity of Chronic Obstructive Pulmonary Disease. <b>2009</b> , 45, 133-142	4
1382	Causes of Death and Risk Factors for Mortality in Patients With Severe Chronic Obstructive Pulmonary Disease. <b>2009</b> , 45, 181-185	2
1381	Health-Care Quality Standards in Chronic Obstructive Pulmonary Disease. <b>2009</b> , 45, 196-203	4
1380	Phenotypic Characterization and Course of Chronic Obstructive Pulmonary Disease in the PAC-COPD Study: Design and Methods. <b>2009</b> , 45, 4-11	11
1379	The EPI-SCAN Survey to Assess the Prevalence of Chronic Obstructive Pulmonary Disease in Spanish 40-to-80-Year-Olds: Protocol Summary. <b>2009</b> , 45, 41-47	6
1378	BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study. <b>2009</b> , 10, 1	68
1377	Role of ADAM and ADAMTS metalloproteinases in airway diseases. <b>2009</b> , 10, 127	37
1376	Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. <b>2009</b> , 10, 29	17
1375	Impact of statins and ACE inhibitors on mortality after COPD exacerbations. 2009, 10, 45	110
1374	Altered effector function of peripheral cytotoxic cells in COPD. <b>2009</b> , 10, 53	38

1373	Soy consumption and risk of COPD and respiratory symptoms: a case-control study in Japan. <b>2009</b> , 10, 56	15
1372	Paced-walk and step tests to assess exertional dyspnea in COPD. <b>2009</b> , 6, 330-9	28
1371	A self-management education program including an action plan for acute COPD exacerbations. <b>2009</b> , 6, 352-8	38
1370	Activities of life: the COPD patient. <b>2009</b> , 6, 192-200	42
1369	Definitions. <b>2009</b> , 1-7	1
1368	Diagnosis of Asthma and COPD. <b>2009</b> , 523-541	
1367	Systemic Manifestations. <b>2009</b> , 569-578	
1366	Treatment for Stable COPD. <b>2009</b> , 823-836	1
1365	Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. 2009, 360, 1329-35	185
1364	Chronic obstructive pulmonary disease: role of bacteria and updated guide to antibacterial selection in the older patient. <b>2009</b> , 26, 985-95	19
1363	Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. <b>2009</b> , 6, 404-15	48
1362	[Evaluation and follow up of hyperinflation in COPD]. <b>2009</b> , 26, 381-93; quiz 478, 482	6
1361	From large clinical trials to management of COPD in the real world. <b>2009</b> , 3, 39-46	2
1360	Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. <b>2009</b> , 25, 1235-45	51
1359	Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. <b>2009</b> , 27, 465-77	28
1358	Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. <b>2009</b> , 3, 59-63	15
1357	Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic obstructive lung disease. <b>2009</b> , 15, 1083-90	51
1356	Chronic obstructive pulmonary disease: towards pharmacogenetics. <b>2009</b> , 1, 112	9

1355 Impact of hospitalisations for exacerbations of COPD on health-related quality of life. <b>2009</b> , 103, 1201-8	3 50
1354 Increased apoptosis of neutrophils in induced sputum of COPD patients. <b>2009</b> , 103, 1130-5	26
1353 Documento de Consenso en Andalucâ: enfermedad pulmonar obstructiva crâica. <b>2009</b> , 35, 227-248	
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. <b>2009</b> , 374, 695-703	469
1351 Screening for and early detection of chronic obstructive pulmonary disease. <b>2009</b> , 374, 721-32	231
Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. <b>2009</b> , 374, 704-11	353
1349 [The gap between the high impact and low awareness of COPD in the population]. <b>2009</b> , 26, 521-9	3
[Long term survival in chronic obstructive pulmonary disease after ventilation in intensive care]. <b>2009</b> , 26, 257-65	2
1347 Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. <b>2009</b> , 6, 17-25	118
1346 Systemic Inflammation in COPD. <b>2009</b> , 16, 233-242	5
1346 Systemic Inflammation in COPD. <b>2009</b> , 16, 233-242  1345 Interventional treatment options for advanced emphysema: imaging manifestations. <b>2009</b> , 24, 195-205	2
Interventional treatment options for advanced emphysema: imaging manifestations. <b>2009</b> , 24, 195-205  C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease	2
Interventional treatment options for advanced emphysema: imaging manifestations. <b>2009</b> , 24, 195-205  C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. <b>2009</b> , 15, 120-5	2 26
Interventional treatment options for advanced emphysema: imaging manifestations. <b>2009</b> , 24, 195-205  C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. <b>2009</b> , 15, 120-5  Discriminate use of antibiotics for exacerbation of COPD. <b>2009</b> , 15, 126-32	2 26 10
1345 Interventional treatment options for advanced emphysema: imaging manifestations. 2009, 24, 195-205  C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. 2009, 15, 120-5  Discriminate use of antibiotics for exacerbation of COPD. 2009, 15, 126-32  Current opinion: Pharmacological approaches in asthma and COPD. 2009, 6, 24-35  Comparison of pedometer and activity diary for measurement of physical activity in chronic	2 26 10 4
1345 Interventional treatment options for advanced emphysema: imaging manifestations. 2009, 24, 195-205  1344 C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. 2009, 15, 120-5  1343 Discriminate use of antibiotics for exacerbation of COPD. 2009, 15, 126-32  1342 Current opinion: Pharmacological approaches in asthma and COPD. 2009, 6, 24-35  Comparison of pedometer and activity diary for measurement of physical activity in chronic obstructive pulmonary disease. 2009, 29, 57-61  Resting and exercise response to altitude in patients with chronic obstructive pulmonary disease.	2 26 10 4

1337	Tabagisme et maladies respiratoires. <b>2009</b> , 6, 1-20	1
1336	Physical activity and clinical and functional status in COPD. <b>2009</b> , 136, 62-70	114
1335	Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. <b>2009</b> , 136, 1029-1038	77
1334	Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. <b>2009</b> , 136, 71-78	30
1333	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. <b>2009</b> , 11, 632-633	
1332	Decision support for teletraining of COPD patients. 2009,	1
1331	Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. <b>2009</b> , 169, 1403-10	42
1330	The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. <b>2010</b> , 19, 10-20	70
1329	Clinical definition of COPD exacerbations and classification of their severity. <b>2009</b> , 102, 277-82	17
1328	COPD prevalence in southeastern Kentucky: the burden of lung disease study. <b>2009</b> , 135, 102-107	38
1327	Investigating the natural history of lung function: facts, pitfalls, and opportunities. 2009, 135, 1330-1341	26
1326	Angiotensin-converting enzyme I/D polymorphism in chronic obstructive pulmonary disease. <b>2009</b> , 14 Suppl 4, 177-81	13
1325	Improving the process and outcome of care in COPD: development of a standardised assessment tool. <b>2009</b> , 18, 208-15	77
1324	Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). <b>2009</b> , 18, 198-207	12
1323	Sleep and COPD. <b>2009</b> , 5, 207-212	
1322	Dfinitions et classifications des bronchopneumopathies chroniques obstructives. <b>2009</b> , 6, 1-6	
1321	Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. <b>2009</b> , 135, 384-390	22
1320	Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. <b>2009</b> , 135, 368-377	111

### (2010-2009)

1319	Leptin in non-autoimmune inflammation. <b>2009</b> , 8, 285-91	7
1318	Androgens and chronic obstructive pulmonary disease. <b>2010</b> , 17, 257-61	20
1317	Do symptoms predict COPD in smokers?. <b>2010</b> , 137, 1345-53	45
1316	Point: should we abandon FEVâ/JFVC . <b>2010</b> , 138, 1037-40	37
1315	Kinŝithfapie pfiopfatoire de l'opf'thoracique pulmonaire. <b>2010</b> , 6, 1-14	
1314	Exacerbations de la bronchopneumopathie chronique obstructive. <b>2010</b> , 7, 1-17	
1313	The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. <b>2010</b> , 138, 47-51	66
1312	Description of the disease and diagnostic and epidemiologic aspects. <b>2010</b> , 22 Suppl 1, 4-7	
1311	Impacto do exercĉio fŝico combinado na percepŝi do estado de sade da pessoa com doenŝi pulmonar obstrutiva crĥica. <b>2010</b> , 16, 737-757	3
1310	Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. <b>2010</b> , 16, 123-33	62
1309	Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. <b>2010</b> , 30, 195-202	34
1308	Interstitial lung disease and pulmonary rehabilitation. <b>2010</b> , 30, 141-6	19
1307	Sex and Gender Differences in Chronic Obstructive Pulmonary Disease. <b>2010</b> , 17, 1-6	
1306	Primary care management of chronic obstructive pulmonary disease: an integrated goal-directed approach. <b>2010</b> , 16, 83-8	12
1305	Primary care management of chronic obstructive pulmonary disease to reduce exacerbations and their consequences. <b>2010</b> , 340, 309-18	15
1304	Earlier diagnosis and earlier treatment of COPD in primary care. <b>2011</b> , 20, 15-22	59
1303	Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. <b>2010</b> , 19, 326-34	44
1302	Altered surfactant protein-A expression in type II pneumocytes in COPD. <b>2010</b> , 137, 37-45	33

1301	Indacaterol for chronic obstructive pulmonary disease (COPD). <b>2010</b> , 46, 139-50	23
1300	Prevalence of airway obstruction in the elderly: results from a cross-sectional spirometric study of nine age cohorts between the ages of 60 and 93 years. <b>2010</b> , 19, 231-6	10
1299	Patient-reported respiratory symptoms and pre-bronchodilator airflow limitation among smokers in Switzerland. <b>2010</b> , 19, 163-9	2
1298	Relationship between BODE index, quality of life and inflammatory cytokines in COPD patients. <b>2010</b> , 5, 84-91	12
1297	The use of roflumilast in COPD: a primary care perspective. <b>2010</b> , 19, 342-51	18
1296	Disease severity and symptoms among patients receiving monotherapy for COPD. <b>2011</b> , 20, 46-53	45
1295	Significant improvement in arterial stiffness after endurance training in patients with COPD. <b>2010</b> , 137, 585-92	54
1294	The chronic ventilator service. <b>2010</b> , 163-172	
1293	Telemedicine. <b>2010</b> , 206-216	
1292	Life-long physical activity involvement reduces the risk of chronic obstructive pulmonary disease: a case-control study in Japan. <b>2010</b> , 7, 622-6	8
1291	Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. <b>2010</b> , 747-790	
1290	Efficacy of perioperative administration of long-acting bronchodilator on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease. Preliminary results of a randomized control study. <b>2010</b> , 40, 923-30	22
1289	Clinical practice. Outpatient management of severe COPD. <b>2010</b> , 362, 1407-16	53
1288	Chest diseases diagnosis using artificial neural networks. <b>2010</b> , 37, 7648-7655	92
1287	Guidelines versus clinical practice in antimicrobial therapy for COPD. <b>2010</b> , 188, 173-8	2
1286	Langzeitsauerstofftherapie. <b>2010</b> , 7, 457-468	
1285	Phagocytosis of dying cells: influence of smoking and static magnetic fields. <b>2010</b> , 15, 1147-64	15
1284	Association of GSTM1 and GSTT1 polymorphisms with chronic obstructive pulmonary disease in a Tunisian population. <b>2010</b> , 48, 647-57	9

1283 Het nut van de orale prednisontest bij de behandeling van COPD in de eerste lijn. **2010**, 53, 272-276

Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. <b>2010</b> , 38, 76-82	34
Fixed-pressure nCPAP in patients with obstructive sleep apnea (OSA) syndrome and chronic obstructive pulmonary disease (COPD): a 24-month follow-up study. <b>2010</b> , 14, 115-23	27
1280 [Exacerbation of chronic obstructive pulmonary disease]. <b>2010</b> , 46 Suppl 7, 21-5	6
1279 [Pharmacological treatment of COPD. Where are we now?]. <b>2010</b> , 46 Suppl 10, 3-7	
1278 [Limitations of current treatment: unmet needs in the treatment of COPD]. <b>2010</b> , 46 Suppl 10, 8-13	2
1277 [Toward personalized and integrated treatment of patients with COPD]. <b>2010</b> , 46 Suppl 10, 14-8	2
1276 [Patient-reported parameters in chronic obstructive pulmonary disease]. <b>2010</b> , 46 Suppl 8, 15-9	
Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. <b>2010</b> , 125, 286-327	85
The use of spirometry testing prior to cardiac surgery may impact the Society of Thoracic Surgeons risk prediction score: a prospective study in a cohort of patients at high risk for chronic lung disease. <b>2010</b> , 139, 686-91	13
Reversibility of inspiratory lung function parameters after short-term bronchodilators in COPD. <b>2010</b> , 173, 58-63	3
Health status in COPD cannot be measured by the St George's Respiratory Questionnaire alone: an evaluation of the underlying concepts of this questionnaire. <b>2010</b> , 11, 98	33
1271 Early detection of COPD in primary carethe Copenhagen COPD Screening Project. <b>2010</b> , 10, 524	9
1270 Diagnosis of COPD in hospitalised patients. <b>2010</b> , 46, 64-9	25
[Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. <b>2010</b> , 46, 522-30	52
1268 [Combined pulmonary fibrosis and emphysema]. <b>2010</b> , 46, 646-51	8
Toll-like receptor 3 is involved in airway epithelial cell response to nontypeable Haemophilus influenzae. <b>2010</b> , 260, 98-104	13
Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). <b>2010</b> , 5, 261-7	20

1265	Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. <b>2010</b> , 128, 131-6	25
1264	Multidrug resistance-associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPD. <b>2010</b> , 11, 60	17
1263	Random variation of inspiratory lung function parameters in patients with COPD: a diagnostic accuracy study. <b>2010</b> , 10, 28	7
1262	Does mild COPD affect prognosis in the elderly?. <b>2010</b> , 10, 35	9
1261	Singing teaching as a therapy for chronic respiratory diseasea randomised controlled trial and qualitative evaluation. <b>2010</b> , 10, 41	73
1260	The impact of care pathways for exacerbation of Chronic Obstructive Pulmonary Disease: rationale and design of a cluster randomized controlled trial. <b>2010</b> , 11, 111	32
1259	Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. <b>2010</b> , 16, 902-8	50
1258	Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung. <b>2010</b> , 160, 1985-96	35
1257	Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. <b>2010</b> , 13, 965-75	82
1256	Health status instrument vs. prognostic instrument for assessing chronic obstructive pulmonary disease in clinical practice. <b>2010</b> , 64, 1465-1466	2
1255	Clinical characteristics and molecular analysis of 21 Chinese children with congenital agammaglobulinemia. <b>2010</b> , 72, 454-9	11
1254	Real-time, once-daily monitoring of symptoms and FEV in cystic fibrosis patientsa feasibility study using a novel device. <b>2010</b> , 4, 74-82	19
1253	Roflumilast: clinical benefit in patients suffering from COPD. <b>2010</b> , 4, 197-201	8
1252	Productive cough is an independent risk factor for the development of COPD in former smokers. <b>2010</b> , 15, 313-8	12
1251	The highs and lows of gas exchange during sleep. <b>2010</b> , 15, 191-3	3
1250	Local inflammation occurs before systemic inflammation in patients with COPD. <b>2010</b> , 15, 478-84	34
1249	Heart failure and COPD: partners in crime?. <b>2010</b> , 15, 895-901	21
1248	Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. <b>2010</b> , 15, 1072-8	20

# (2010-2010)

1247	Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. <b>2010</b> , 6, 13-22	10
1246	The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. <b>2010</b> , 5, 165-78	6
1245	Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects. <b>2010</b> , 5, 209-15	28
1244	[Sleep and chronic lung diseases: diffuse interstitial lung diseases, bronchial asthma, and COPD]. <b>2010</b> , 36 Suppl 2, 53-6	1
1243	Decision support for teletraining of COPD patients. <b>2010</b> , 49, 96-102	14
1242	Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests. <b>2010</b> , 30, 193-7	24
1241	Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. <b>2010</b> , 25	2
1240	Skeletal Muscle Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. <b>2010</b> , 68, 125	8
1239	Direct costs of chronic obstructive pulmonary disease among managed care patients. <b>2010</b> , 5, 341-9	87
1238	Budesonide/formoterol combination in COPD: a US perspective. <b>2010</b> , 5, 357-66	19
1237	Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients. <b>2010</b> , 5, 407-13	17
1236	Lack of association of ischemic heart disease with COPD when taking into account classical cardiovascular risk factors. <b>2010</b> , 5, 387-94	16
1235	Lung volume reduction surgery: an overview. <b>2010</b> , 56, 719-23	3
1234	Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin, C-reactive protein and tissue hypoxia. <b>2010</b> , 5, 29-39	37
1233	Integrated management strategies for chronic obstructive pulmonary disease. <b>2010</b> , 3, 181-8	2
1232	Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. <b>2010</b> , 182, 325-31	433
1231	Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD). <b>2010</b> , 22, 291-7	9
1230	Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 89-95	64

1229	Preclinical vascular disease identifies smokers at risk for COPD. <b>2010</b> , 107, 8503-4		3
1228	Low erythropoietin plasma levels during exacerbations of COPD. <b>2010</b> , 80, 190-7		16
1227	A link between impaired lung function and increased cardiac stress. <b>2010</b> , 79, 355-62		8
1226	Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. <b>2010</b> , 79, 475-81		41
1225	Pulmonary hypertension in chronic obstructive pulmonary disease: Three case reports. <b>2010</b> , 2, 80		
1224	Alpha-1 antitrypsin deficiency: whom to test, whom to treat?. <b>2010</b> , 31, 343-7		12
1223	Nebulized corticosteroids in the management of acute exacerbation of COPD. <b>2010</b> , 27, 230-5		4
1222	Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. <b>2010</b> , 31, 321-33		21
1221	Arformoterol tartrate in the treatment of COPD. <b>2010</b> , 4, 155-62		5
1220	Acting on comparative effectiveness research in COPD. <b>2010</b> , 303, 2409-10		14
1220	Acting on comparative effectiveness research in COPD. <b>2010</b> , 303, 2409-10  Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7	13.6	26
	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory</i>	13.6	
1219	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7  A guideline-based decision support system for generating referral recommendations from	13.6	
1219 1218	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7  A guideline-based decision support system for generating referral recommendations from routinely recorded home telehealth measurement data. <b>2010</b> , 2010, 6166-9  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy	13.6	26 7
1219 1218 1217	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7  A guideline-based decision support system for generating referral recommendations from routinely recorded home telehealth measurement data. <b>2010</b> , 2010, 6166-9  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. <b>2010</b> , 182, 790-6  Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of	13.6	26 7 145
1219 1218 1217 1216	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7  A guideline-based decision support system for generating referral recommendations from routinely recorded home telehealth measurement data. <b>2010</b> , 2010, 6166-9  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. <b>2010</b> , 182, 790-6  Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. <b>2010</b> , 6, 381-92  Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines?.	13.6	26 7 145
1219 1218 1217 1216	Socioeconomic risk factors for lung function decline in a general population. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 480-7  A guideline-based decision support system for generating referral recommendations from routinely recorded home telehealth measurement data. <b>2010</b> , 2010, 6166-9  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. <b>2010</b> , 182, 790-6  Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. <b>2010</b> , 6, 381-92  Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines?. <b>2010</b> , 13, 21-6  Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary	13.6	26 7 145 12 16

1211	Hospitalizations for acute exacerbations of chronic obstructive pulmonary disease: how you count matters. <b>2010</b> , 7, 164-71		34
<b>121</b> 0	Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma. <b>2010</b> , 42, 47-60		8
1209	Tanreqing injection combined with conventional Western medicine for acute exacerbations of chronic obstructive pulmonary disease: a systematic review. <b>2010</b> , 16, 1309-19		17
1208	Significant bronchodilator responsiveness and "reversibility" in a population sample. <b>2010</b> , 7, 323-30		8
1207	Polymeric nanocarriers for drug delivery to the lung. <b>2010</b> , 20, 171-180		30
1206	Combined effect of dietary supplementation with pressurized whey and exercise training in chronic obstructive pulmonary disease: a randomized, controlled, double-blind pilot study. <b>2010</b> , 13, 589-98		43
1205	Beyond peak VO2: ventilatory inefficiency (VE/VCO2 slope) measured during cardiopulmonary exercise test to refine risk stratification in lung resection candidates. <b>2010</b> , 38, 19-20		8
1204	Prioritised research agenda for prevention and control of chronic respiratory diseases. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 995-1001	13.6	94
1203	Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. <b>2010</b> , 4, 279-89		12
1202	The relationship of dietary patterns with adult lung function and COPD. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 277-84	13.6	90
1201	COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. <b>2010</b> , 65, 221-8		269
1200	Interval versus continuous training in individuals with chronic obstructive pulmonary diseasea systematic review. <b>2010</b> , 65, 157-64		123
1199	Customizing inhaled therapy to meet the needs of COPD patients. <b>2010</b> , 122, 83-93		23
1198	Prevalence and clinical correlates of bronchoreversibility in severe emphysema. <i>European Respiratory Journal</i> , <b>2010</b> , 35, 1048-56	13.6	35
1197	Outcomes of severe COPD exacerbations requiring hospitalization. <b>2010</b> , 31, 286-94		25
1196	Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. <b>2010</b> , 51, 143-9		14
1195	Prevention of exacerbations of COPD with pharmacotherapy. <b>2010</b> , 19, 119-26		11
1194	The endocrinologic changes in critically ill chronic obstructive pulmonary disease patients. <b>2010</b> , 7, 240-7	7	12

1193	Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. <b>2010</b> , 2010, 173498		17
1192	Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer. <b>2010</b> , 38, 14-9		57
1191	Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. <b>2010</b> , 303, 2359-67		144
1190	Impact of changes in physical activity on health-related quality of life among patients with COPD. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 292-300	13.6	125
1189	Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. <b>2010</b> , 36, 373-80		35
1188	Evaluation of a novel method to assess corticosteroid responsiveness in chronic obstructive pulmonary disease. <b>2010</b> , 5, 232-7		
1187	Recent improvement in long-term survival after a COPD hospitalisation. <b>2010</b> , 65, 298-302		48
1186	Innovations to achieve excellence in COPD diagnosis and treatment in primary care. <b>2010</b> , 122, 150-64		16
1185	Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. <b>2010</b> , 103, 379-85		23
1184	Theophylline and cardiac stress in patients with dyspnea: an observational study. <b>2010</b> , 86, 189-95		4
1183	A review of quality of care evaluation for the palliation of dyspnea. <b>2010</b> , 181, 534-8		55
1182	Identifying chronic obstructive pulmonary disease in primary care of urban underserved patients: tools, applications, and challenges. <b>2010</b> , 102, 570-8		13
1181	High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. <b>2010</b> , 137, 333-40		60
1180	International classification of disease coding for obstructive lung disease: does it reflect appropriate clinical documentation?. <b>2010</b> , 138, 188-92		13
1179	Chronic renal failure: a neglected comorbidity of COPD. <b>2010</b> , 137, 831-7		122
1178	Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. <b>2010</b> , 137, 39S-51S		147
1177	Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. <b>2010</b> , 303, 2035-42		137
1176	Lung function loss associated with occupational dust exposure in metal smelting. <b>2010</b> , 181, 1162-3		6

1175	Pulmonary rehabilitation: an underutilized resource in primary COPD care. <b>2010</b> , 38, 54-60	7
1174	Dietary modulation of oxidative stress in chronic obstructive pulmonary disease patients. <b>2010</b> , 44, 1296-303	20
1173	Frequent exacerbations of chronic obstructive pulmonary diseasea distinct phenotype?. <b>2010</b> , 363, 1183-4	18
1172	Percent emphysema, airflow obstruction, and impaired left ventricular filling. <b>2010</b> , 362, 217-27	396
1171	Genetic ancestry in lung-function predictions. <b>2010</b> , 363, 321-30	182
1170	COPD in the elderly patient. <b>2010</b> , 31, 596-606	41
1169	Dietary Nutrients in Relation to Chronic Obstructive Pulmonary Disease: Emerging Epidemiological Evidence. <b>2010</b> , 6, 124-132	1
1168	Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Evaluation of Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary	4
1167	Critical comparisons of the clinical performance of oxygen-conserving devices. <b>2010</b> , 181, 1061-71	19
1166	Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. <b>2010</b> , 13, 403-17	16
1165	Donnès rèentes sur la BPCO. <b>2010</b> , 2, S7-S11	
1164	[Chronic obstructive pulmonary disease (COPD) in the elderly]. <b>2010</b> , 27, 855-73	13
1163	Physiologie et exploration fonctionnelle respiratoire. <b>2010</b> , 2, 30-41	
1162	[Intrahospital mortality during acute exacerbations of COPD. Study EABPCO-CPHG of the College of the Lung specialists of General hospitals (CPHG)]. <b>2010</b> , 27, 709-16	5
1161	Prise en charge de la BPCO ; apport de lâ[hdacatfol. <b>2010</b> , 2, S13-S19	
1160	The spectrum of nonasthmatic inflammatory airway diseases in adults. <b>2010</b> , 43, 131-46, x-xi	
1159	Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. <b>2010</b> , 85, 1122-9	34
1158	[Management of acute exacerbations of COPD]. <b>2010</b> , 27, 939-53	27

1157	Caracter <b>ŝ</b> ticas clâicas de dos poblaciones diagnosticadas de enfermedad pulmonar obstructiva cr <b>ĥ</b> ica por criterios espiromtricos GOLD o por el lâite inferior de la normalidad. <b>2010</b> , 13, 159-164	
1156	Dfinitions, classification, facteurs pronostiques. <b>2010</b> , 27, S11-S18	1
1155	Noninvasive Ventilation in Acute Respiratory Failure. <b>2010</b> , 415-440	
1154	Analysis of hospitalizations for COPD exacerbation: opportunities for improving care. <b>2010</b> , 7, 85-92	30
1153	Airway obstructive diseases in older adults: from detection to treatment. <b>2010</b> , 126, 702-9	35
1152	The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. <b>2010</b> , 7, 214-28	169
1151	Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. <b>2010</b> , 11, 149	89
1150	Factors affecting the relationship between psychological status and quality of life in COPD patients. <b>2010</b> , 8, 108	53
1149	Roflumilast: in chronic obstructive pulmonary disease. <b>2010</b> , 70, 1615-27	9
1148	Een richtlijn heeft niet altijd gelijk. <b>2010</b> , 53, 298-298	
1147	¿Cîmo rejuvenecer los pulmones de los fumadores?. <b>2010</b> , 13, 61-63	
1146	Diagnosis of COPD in Hospitalised Patients. <b>2010</b> , 46, 64-69	5
1145	Combined Pulmonary Fibrosis and Emphysema. <b>2010</b> , 46, 646-651	2
1144	Geographical Variations in the Prevalence of COPD in Spain: Relationship to Smoking, Death Rates and other Determining Factors. <b>2010</b> , 46, 522-530	9
1143	The cardiovascular risk of tiotropium: is it real?. <b>2010</b> , 9, 783-92	16
1142	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <b>2010</b> , 363, 1128-38	1840
1141	Proteomics-based biomarkers in chronic obstructive pulmonary disease. <b>2010</b> , 9, 2798-808	38
1140	Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. <b>2010</b> , 68, 20-7	59

1139	Somatic DNA alterations in lung epithelial barrier cells in COPD patients. <b>2010</b> , 23, 208-14	16
1138	Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. <b>2010</b> , 23, 159-64	20
1137	The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. <b>2010</b> , 23, 257-67	220
1136	Evoluciñ de la capacidad aerbica del paciente EPOC tras entrenamiento de la musculatura periffica. <b>2010</b> , 44, 122-129	
1135	Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. <b>2010</b> , 104, 121-6	29
1134	Exercise capacity and cytochrome oxidase activity in muscle mitochondria of COPD patients. <b>2010</b> , 104, 83-90	9
1133	Impact of chronic obstructive pulmonary disease (COPD) on attention functions. 2010, 104, 52-60	37
1132	Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. <b>2010</b> , 104, 40-6	70
1131	Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. <b>2010</b> , 104, 253-9	73
1130	Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. <b>2010</b> , 104, 397-403	13
1129	Mass of intercostal muscles associates with risk of multiple exacerbations in COPD. <b>2010</b> , 104, 378-88	28
1128	Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. <b>2010</b> , 104, 518-24	23
1127	How often is diagnosis of COPD confirmed with spirometry?. <b>2010</b> , 104, 550-6	93
1126	Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. <b>2010</b> , 104, 816-21	35
1125	The MRC dyspnoea scale by telephone interview to monitor health status in elderly COPD patients. <b>2010</b> , 104, 1027-34	18
1124	The clinical utility of long-term humidification therapy in chronic airway disease. <b>2010</b> , 104, 525-33	89
1123	Predictors of mortality in COPD. <b>2010</b> , 104, 773-9	117
1122	Preselection of patients at risk for COPD by two simple screening questions. <b>2010</b> , 104, 1012-9	8

1121	Physical inactivity in patients with COPD, a controlled multi-center pilot-study. <b>2010</b> , 104, 1005-11	259
1120	Sub-clinical left and right ventricular dysfunction in patients with COPD. <b>2010</b> , 104, 1171-8	78
1119	Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. <b>2010</b> , 104, 995-1004	84
1118	Energy expenditure and impact of bronchodilators in COPD patients. <b>2010</b> , 104, 1490-4	2
1117	Dynamic hyperinflation after metronome-paced hyperventilation in COPDa 2 year follow-up. <b>2010</b> , 104, 1700-5	10
1116	Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. <b>2010</b> , 104, 1896-902	76
1115	Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. <b>2010</b> , 11, 441-9	18
1114	Lung function in young adults predicts airflow obstruction 20 years later. <b>2010</b> , 123, 468.e1-7	38
1113	How do COPD and healthy-lung patients tolerate the reduced volume ventilation strategy during OLV ventilation. <b>2010</b> , 54, 1128-36	2
1112	Manejo general y extrahospitalario del paciente con infecciñ de las vâs respiratorias. <b>2010</b> , 10, 3847-3852	
1111	Impact of combined exercise on chronic obstructive pulmonary patientsâlstate of health. <b>2010</b> , 16, 737-757	3
1110	Malondialdehyde and superoxide dismutase correlate with FEV(1) in patients with COPD associated with wood smoke exposure and tobacco smoking. <b>2010</b> , 22, 868-74	45
1109	Microsomal epoxide hydrolase gene polymorphisms and susceptibility to chronic obstructive pulmonary disease in the Tunisian population. <b>2010</b> , 14, 857-63	7
1108	Gateway to Quality Living for the Elderly: Charting an Innovative Approach to Evidence-Based E-Health Technologies for Serving the Chronically Ill. <b>2010</b> ,	5
1107	Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. <b>2010</b> , 7, 141-53	46
1106	Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10):	2
1105	Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. <b>2010</b> , 13, 591-8	13
1104	Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. <b>2010</b> , 28, 41-6	30

#### (2011-2010)

Acute exacerbations of chronic obstructive pulmonary disease in elderly patients often require treatment with antibacterials. **2010**, 26, 14-16

1102 A new method for examining the cost savings of reducing COPD exacerbations. <b>2010</b> , 28, 733-49	24
Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. <b>2010</b> , 10, 155-62	5
Obesity and COPD: associated symptoms, health-related quality of life, and medication use. <b>2011</b> , 8, 275-84	64
Combining both generic and disease-specific properties: development of the McGill COPD quality of life questionnaire. <b>2011</b> , 8, 255-63	9
Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. <b>2011</b> , 14, 99-106	24
1097 Recommendations for epidemiological studies on COPD. <i>European Respiratory Journal</i> , <b>2011</b> , 38, 1261	<b>-77</b> 3.6 95
1096 Utility estimation in chronic obstructive pulmonary disease: a preference for change?. <b>2011</b> , 29, 917-32	2 24
Evidence-based risk assessment and recommendations for physical activity clearance: respiratory disease. <b>2011</b> , 36 Suppl 1, S80-100	10
1094 Simultaneous Activity and Respiratory Monitoring Using an Accelerometer. <b>2011</b> ,	13
Value of arterial blood gas analysis in patients with acute dyspnea: an observational study. <b>2011</b> , 15, R145	25
Role of clinical frailty on long-term mortality of elderly subjects with and without chronic obstructive pulmonary disease. <b>2011</b> , 23, 118-25	67
1091 Relationship of vitamin D status to adult lung function and COPD. <b>2011</b> , 66, 692-8	81
Il percorso diagnostico-assistenziale della broncopneumopatia cronica ostruttiva riacutizzata in Medicina Interna. <b>2011</b> , 5, 199-214	
1089 COPD: a multifactorial systemic disease. <b>2011</b> , 5, 217-24	57
$_{f 1088}$ [Efficacy and patterns of ambulatory oxygen usage - experience of a university hospital]. <b>2011</b> , 17, 159	9-67 5
1087 Rehabilitation for chronic obstructive pulmonary disease patients. <b>2011</b> , 18, 177-187	3
1086 Management of patients with end-stage chronic obstructive pulmonary disease. <b>2011</b> , 38, 277-97, viii-i	ix 3

1085 Complessit<sup>^</sup> del paziente con insufficienza respiratoria cronica associata a BPCO. **2011**, 5, 159-170

Metodologia clinica, strumenti di valutazione e gestione dei pazienti anziani affetti da BPCO e comorbilit <sup>^</sup> croniche. <b>2011</b> , 5, 171-178		1
Association of genetic polymorphism of GSTT1, GSTM1 and GSTM3 in COPD patients in a north Indian population. <b>2011</b> , 8, 167-72		17
$_{ m 1082}$ Cinesiterapia perioperatoria del paziente sottoposto a chirurgia toracica polmonare. <b>2011</b> , 18, 1-14		
1081 Linee guida sulla BPCO non associata a comorbilit^croniche. <b>2011</b> , 5, 14-21		
1080 BPCO e depressione/ansia. <b>2011</b> , 5, 81-90		
High prevalence of COPD symptoms in the general population contrasting with low awareness of the disease. <b>2011</b> , 28, e58-65		7
1078 BPCO, sindrome delle apnee ostruttive del sonno e disturbi del sonno. <b>2011</b> , 5, 151-158		
Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. <b>2011</b> , 57, 2127-38		104
1076 Undiagnosed airflow limitation in patients at cardiovascular risk. <b>2011</b> , 104, 619-26		9
Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. <b>2011</b> , 12, 1913-32		14
Development of a decision tree to assess the severity and prognosis of stable COPD. <i>European</i> Respiratory Journal, <b>2011</b> , 38, 1294-300	13.6	39
Patient knowledge in chronic obstructive pulmonary disease: back to basics. <b>2011</b> , 8, 375-9		15
1072 Six-minute walking distance in women with COPD. <b>2011</b> , 8, 300-5		8
1071 Preventing exacerbations of COPDadvice from Hippocrates. <b>2011</b> , 365, 753-4		11
Neural respiratory drive as a physiological biomarker to monitor change during acute exacerbations of COPD. <b>2011</b> , 66, 602-8		73
Association of oxidative stress markers and C-reactive protein with multidimensional indexes in COPD. <b>2011</b> , 8, 101-8		13
1068 Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. <b>2011</b> , CD002309		43

1067	Chronic obstructive pulmonary disease: a concise review. <b>2011</b> , 95, 1125-41	34
1066	Chronic Obstructive Pulmonary Disease. <b>2011</b> , 660-668	O
1065	Airway clearance in COPD: need for a breath of fresh air? A systematic review. <b>2011</b> , 8, 196-205	23
1064	[The importance of dyspnoea in the diagnosis of chronic obstructive pulmonary diseasea descriptive analysis of a stable cohort in Portugal (SAFE trial)]. <b>2011</b> , 17, 131-8	2
1063	Exercises commonly used in rehabilitation of patients with chronic obstructive pulmonary disease: cardiopulmonary responses and effect over time. <b>2011</b> , 92, 111-7	10
1062	Ethnicity and risk of hospitalization for asthma and chronic obstructive pulmonary disease. <b>2011</b> , 21, 615-22	22
1061	Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. <b>2011</b> , 32, 818-28	19
1060	Effect of nasal continuous positive airway pressure on inflammatory mediators in patients with overlap syndrome. <b>2011</b> , 12, 99-104	2
1059	Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. <b>2011</b> , 22, 103-7	35
1058	[Combination of pulmonary fibrosis and emphysema: Is tobacco once again the protagonist?]. <b>2011</b> , 136, 18-20	1
1057	[Bacterial flora in acute exacerbations of chronic obstructive pulmonary disease (COPD) in Kunming, China]. <b>2011</b> , 41, 186-91	1
1056	Spinal manipulative therapy for elderly patients with chronic obstructive pulmonary disease: a case series. <b>2011</b> , 34, 413-7	19
1055	Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. <b>2011</b> , 24, 118-22	8
1054	24-hour bronchodilation following a single dose of the novel (P)-agonist olodaterol in COPD. <b>2011</b> , 24, 666-72	54
1053	[Dyspnoea and psychopathology in the elderly patient with chronic obstructive pulmonary disease]. <b>2011</b> , 46, 21-6	
1052	Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD. <b>2011</b> , 105, 250-8	1
1051	The cyclooxygenase-2-765C promoter polymorphism protects against the development of chronic obstructive pulmonary disease. <b>2011</b> , 105, 506-10	5
1050	Costs of COPD exacerbations in the emergency department and inpatient setting. <b>2011</b> , 105, 454-60	68

1049	Health-related quality of life in patients by COPD severity within primary care in Europe. <b>2011</b> , 105, 57-66	159
1048	Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure. <b>2011</b> , 105, 427-34	56
1047	Prevalence of COPD in Copenhagen. <b>2011</b> , 105, 410-7	45
1046	Airway cell patterns in patients suffering from COPD and OSAS (Overlap Syndrome). <b>2011</b> , 105, 303-9	6
1045	New horizons in early stage COPDimproving knowledge, detection and treatment. <b>2011</b> , 105, 1576-87	35
1044	Prognostic assessment in COPD: health related quality of life and the BODE index. <b>2011</b> , 105, 916-21	43
1043	Lower limit of normal or FEV1/FVC 2011, 105, 907-15	104
1042	Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence?. <b>2011</b> , 105, 1268-74	12
1041	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <b>2011</b> , 105, 1176-88	23
1040	The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. <b>2011</b> , 105, 1022-9	38
1039	Reduced apoptosis of CD8+ T-lymphocytes in the airways of smokers with mild/moderate COPD. <b>2011</b> , 105, 1491-500	13
1038	The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. <b>2011</b> , 105, 1662-70	25
1037	Prevalence of obstructive lung disease in HIV population: a cross sectional study. <b>2011</b> , 105, 1655-61	41
1036	Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. <b>2011</b> , 105, 1648-54	109
1035	Efficacy and patterns of ambulatory oxygen usage âlexperience of a university hospital. <b>2011</b> , 17, 159-167	5
1034	Documento de consenso sobre enfermedad pulmonar obstructiva cr <del>ĥ</del> ica en Andalucê-2010. <b>2011</b> , 37, 468-495	
1033	Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. <b>2011</b> , 12, 367-72	74
1032	Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. <b>2011</b> , 105 Suppl 1, S31-7	63

	e importance of dyspnoea in the diagnosis of chronic obstructive pulmonary disease âla scriptive analysis of a stable cohort in Portugal (SAFE Trial). <b>2011</b> , 17, 131-138	3
1030 <b>K</b> ii	nesiterapia perioperatoria en cirug <b>à</b> torêica pulmonar. <b>2011</b> , 32, 1-14	
1029 <b>Ca</b>	rdiovascular morbidity in COPD: A study of the general population. <b>2010</b> , 7, 5-10	42
4038	ficacy of diaphragmatic breathing in patients with chronic obstructive pulmonary disease. <b>2011</b> , 237-44	22
	otimization of ventilator setting by flow and pressure waveforms analysis during noninvasive ntilation for acute exacerbations of COPD: a multicentric randomized controlled trial. <b>2011</b> , 15, R283	25
	ronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the tential for simvastatin in disease management. <b>2011</b> , 8, 1205-20	35
1025 <b>Lo</b>	bectomy for patients with limited lung function. <b>2011</b> , 23, 191-5	1
	elow What FEV1 Should Arterial Blood be Routinely Taken to Detect Chronic Respiratory Failure COPD?. <b>2011</b> , 47, 325-329	1
1023 Ph	ysical Activity and its Relationship With the State of Health of Stable COPD Patients. <b>2011</b> , 47, 335-342	1
	gh Value of Combined Serum C-Reactive Protein and BODE Score for Mortality Prediction in tients With Stable COPD. <b>2011</b> , 47, 427-432	2
1011	lidation of the Yale Physical Activity Survey in Chronic Obstructive Pulmonary Disease Patients. <b>11</b> , 47, 552-560	4
1020 Tr	eating COPD in Chronic Patients in a Primary-Care Setting. <b>2011</b> , 47, 561-570	2
1019 <b>A</b> 0	ortic calcification, arterial stiffness and bone mineral density in patients with COPD?. <b>2011</b> , 5, 30	7
1018 Th	e Pharmacotherapy of Chronic Obstructive Pulmonary Disease in the Elderly: An Update. <b>2011</b> , 3, CMT.S340	81
1017 <b>Di</b>	agnosing and treating COPD: understanding the challenges and finding solutions. <b>2011</b> , 4, 729-39	31
	creased leptin/leptin receptor pathway affects systemic and airway inflammation in COPD former nokers. <b>2011</b> , 4, 51-9	8
1015 Аг	formoterol Tartrate: A Review of Pharmacology, Analysis and Clinical Studies. <b>2011</b> , 9,	
	tal inspiratory and expiratory impedance in patients with severe chronic obstructive pulmonary sease. <b>2011</b> , 66, 2085-91	11

1013 Respiratory impairment and mortality in older persons: a novel spirometri	c approach. <b>2011</b> , 59, 1089-95	22
Clinical characteristics and long-term outcomes related to sputum eosino asthmatics. <b>2011</b> , 1, 16-24	philia in Korean	4
Prevalence of Chronic Obstructive Pulmonary Disease in Korea: The Resul National Health and Nutrition Examination Survey. <b>2011</b> , 71, 328	t of Forth Korean	15
Management of patients during and after exacerbations of chronic obstruther the role of primary care physicians. <b>2011</b> , 4, 665-76	ictive pulmonary disease:	8
1009 Combined pulmonary fibrosis and emphysema syndrome: a radiologic per	spective. <b>2011</b> , 75, 220-34	5
Changing patterns in long-acting bronchodilator trials in chronic obstructi <b>2011</b> , 6, 35-45	ve pulmonary disease.	4
1007 Spirometric testing on World COPD Day. <b>2011</b> , 6, 141-6		5
Components of physical capacity in patients with chronic obstructive pulm relationship with phenotypic expression. <b>2011</b> , 6, 105-12	nonary disease:	13
1005 Early detection of COPD in general practice. <b>2011</b> , 6, 123-7		42
1004 Carotid arterial stiffness in patients with chronic obstructive pulmonary d	isease. <b>2011</b> , 98, 117-27	12
Characteristics of COPD patients admitted to the ICU of a referral hospita in Brazil. <b>2011</b> , 37, 217-22	l for respiratory diseases	7
Tiotropium reduces risk of exacerbations irrespective of previous use of ir placebo-controlled clinical trials. <b>2011</b> , 6, 269-75	nhaled anticholinergics in	4
Predictive properties of different multidimensional staging systems in pal obstructive pulmonary disease. <b>2011</b> , 6, 521-6	tients with chronic	34
Optimizing management of chronic obstructive pulmonary disease in the 6, 47-61	upcoming decade. <b>2011</b> ,	7
999 Guideline for the management of chronic obstructive pulmonary disease a	âl͡2011 update. <b>2011</b> , 101, 61	2
Factors associated with good self-rated health and quality of life in subjective COPD. <b>2011</b> , 6, 511-9	ts with self-reported	25
Bronchodilator efficacy and safety of indacaterol 150 <b>B</b> once daily in patie analysis of pooled data. <b>2011</b> , 6, 431-8	nts with COPD: an	8
Cost trends among commercially insured and Medicare Advantage-insured obstructive pulmonary disease: 2006 through 2009. <b>2011</b> , 6, 533-42	d patients with chronic	20

995	Can a self-management education program for patients with chronic obstructive pulmonary disease improve quality of life?. <b>2011</b> , 18, e77-81	20
994	Long-Term Oxygen Therapy in COPD: Factors Affecting and Ways of Improving Patient Compliance. <b>2011</b> , 2011, 325362	46
993	Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. <b>2011</b> , 18, 69-78	162
992	The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. <b>2011</b> , 2011, 861926	107
991	Combined Analysis of EPHX1, GSTP1, GSTM1 and GSTT1 Gene Polymorphisms in Relation to Chronic Obstructive Pulmonary Disease Risk and Lung Function Impairment. <b>2011</b> , 30, 253-263	16
990	Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?. <b>2011</b> , 2, 36	27
989	Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. <b>2011</b> , 6, e16021	38
988	Genes and gene ontologies common to airflow obstruction and emphysema in the lungs of patients with COPD. <b>2011</b> , 6, e17442	21
987	Ventilator-associated Pneumonia and Cuff Shape. <b>2011</b> , 184, 485-486	1
986	Best practices in chronic obstructive pulmonary disease. <b>2011</b> , 36, 16-22; quiz 22-3	3
985	Worksite wellness program for respiratory disease prevention in heavy-construction workers. <b>2011</b> , 53, 274-81	8
984	Relationship between inhaled <b>a</b> gonists and ventilator-associated pneumonia: a cohort study. <b>2011</b> , 39, 725-30	19
983	WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease. 2011, CD004403	2
982	Genetic polymorphisms of xenobiotic-metabolizing enzymes influence the risk of pulmonary emphysema. <b>2011</b> , 21, 876-83	5
981	COPD-Lite, COPD-Hard, or COPD-for-What?. <b>2011</b> , 184, 486-487	1
980	COPD and air travel: oxygen equipment and preflight titration of supplemental oxygen. <b>2011</b> , 140, 84-90	23
979	Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease. <b>2011</b> , 6, 48-61	8
978	Exhaled nitric oxide parameters and functional capacity in chronic obstructive pulmonary disease. <b>2011</b> , 5, 016003	41

977	Rħabilitation respiratoire dans la bronchopneumopathie chronique obstructive. <b>2011</b> , 8, 1-10	O
976	Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD. <b>2011</b> , 139, 36-42	25
975	Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. <b>2011</b> , 140, 91-99	21
974	Reconsidering sex-based stereotypes of COPD. <b>2011</b> , 20, 370-8	26
973	Twelve-year cumulative incidence of airflow obstruction among Japanese males. <b>2011</b> , 50, 1537-44	10
972	COPD, smoking behaviour, and the importance of teachers as role-models for adolescents. <b>2011</b> , 6, 79-81	1
971	Anxiety and depression in COPD patients and correlation with sputum and BAL cytology. <b>2011</b> , 6, 226-31	14
970	Impact of an educational intervention on the quality of spirometry performance in a general practice: an audit. <b>2011</b> , 20, 210-3	13
969	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <b>2011</b> , 20, 291-8	32
968	Year in review 2010: interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer. <b>2011</b> , 16, 553-63	
967	A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. <b>2011</b> , 16, 532-9	22
966	Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. <b>2011</b> , 16, 659-65	125
965	Prevalence of anxiety and depression among chronic bronchitis patients and the associated factors. <b>2011</b> , 16, 1103-10	12
964	The complementary and alternative medicine use among asthma and chronic obstructive pulmonary disease patients in the southern region of Turkey. <b>2011</b> , 17, 571-82	17
963	CD4+/CD25+ cells in systemic inflammation in COPD. <b>2011</b> , 73, 59-65	15
962	Measuring whole-body neutrophil redistribution using a dedicated whole-body counter and ultra-low doses of 111Indium. <b>2011</b> , 41, 77-83	10
961	(P) -adrenoceptor agonists: current and future direction. <b>2011</b> , 163, 4-17	113
960	Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit. <b>2011</b> , 17, 1201-8	181

959	Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. <b>2011</b> , 35, 124-46	73
958	Course of normal and abnormal fatigue in patients with chronic obstructive pulmonary disease, and its relationship with domains of health status. <b>2011</b> , 85, 281-5	41
957	[Complexity in chronic obstructive pulmonary disease. Individualized treatment, new approaches, phenotypes and comorbidities]. <b>2011</b> , 211 Suppl 2, 13-21	1
956	Several clinical interests regarding lung volume reduction surgery for severe emphysema: meta-analysis and systematic review of randomized controlled trials. <b>2011</b> , 6, 148	13
955	Significance of bioinformatics in research of chronic obstructive pulmonary disease. <b>2011</b> , 1, 35	11
954	Impact of care pathways for in-hospital management of COPD exacerbation: a systematic review. <b>2011</b> , 48, 1445-56	20
953	Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. <b>2011</b> , 33, 1365-70	35
952	The 'stage-by-stage' deposition of drugs from commercial single-active and combination dry powder inhaler formulations. <b>2011</b> , 43, 225-35	11
951	Below what FEV1 should arterial blood be routinely taken to detect chronic respiratory failure in COPD?. <b>2011</b> , 47, 325-9	5
950	[Physical activity and its relationship with the state of health of stable COPD patients]. <b>2011</b> , 47, 335-42	13
949	High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. <b>2011</b> , 47, 427-32	16
948	[Validation of the Yale Physical Activity Survey in chronic obstructive pulmonary disease patients]. <b>2011</b> , 47, 552-60	30
947	[Treating COPD in chronic patients in a primary-care setting]. <b>2011</b> , 47, 561-70	13
946	Analysis of the 8.1 ancestral MHC haplotype in severe, pneumonia-related sepsis. <b>2011</b> , 139, 282-9	5
945	The effectiveness of nurse-led, home-based pulmonary rehabilitation in patients with COPD in Turkey. <b>2011</b> , 36, 159-65	29
944	Glutathione S-transferase copy number variation alters lung gene expression. <i>European Respiratory Journal</i> , <b>2011</b> , 38, 15-28	16
943	De MRC-dyspnoescore bij de beoordeling van COPD. <b>2011</b> , 6, 83-85	
942	Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques. <b>2011</b> , 21, 954-62	33

941	Development and validation of the living with chronic obstructive pulmonary disease questionnaire. <b>2011</b> , 20, 1043-52	26
940	Handgrip strength measurement as a predictor for successful dry powder inhaler treatment: application in older individuals with COPD. <b>2011</b> , 44, 245-9	10
939	The relationship of the BODE index to oxygen saturation during daily activities in patients with chronic obstructive pulmonary disease. <b>2011</b> , 189, 269-77	7
938	Gehtests. <b>2011</b> , 8, 78-84	
937	Pulmonale Hypertonie bei chronischen Lungenerkrankungen. <b>2011</b> , 8, 113-127	
936	Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. <b>2011</b> , 38, 1344-52	53
935	The frail person and his caregiver: cure, care or simultaneous care? A conceptual article. 2011, 9, 6-12	4
934	Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. <b>2011</b> , 26, 635-42	125
933	Determinants of spirometry use and accuracy of COPD diagnosis in primary care. <b>2011</b> , 26, 1272-7	34
932	The role of ALOX5AP, LTA4H and LTB4R polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers. <b>2011</b> , 12, 173	11
931	FUMEPOC: early detection of chronic obstructive pulmonary disease in smokers. <b>2011</b> , 11, 413	6
930	Smoking cessation can improve quality of life among COPD patients: validation of the clinical COPD questionnaire into Greek. <b>2011</b> , 11, 13	25
929	Detection and follow-up of chronic obstructive pulmonary disease (COPD) and risk factors in the Southern Cone of Latin America: the pulmonary risk in South America (PRISA) study. <b>2011</b> , 11, 34	14
928	No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. <b>2011</b> , 11, 7	10
927	The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort. <b>2011</b> , 11, 322	21
926	The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. <b>2011</b> , 11, 37	92
925	Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. <b>2011</b> , 9, 26	64
924	Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. <b>2011</b> , 9, 7	69

923	Low bone mineral density in men with chronic obstructive pulmonary disease. <b>2011</b> , 12, 101	47
922	Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. <b>2011</b> , 12, 136	42
921	E pluribus plurima: multidimensional indices and clinical phenotypes in COPD. <b>2011</b> , 12, 152	1
920	Diffusion-weighted hyperpolarized 129Xe MRI in healthy volunteers and subjects with chronic obstructive pulmonary disease. <b>2011</b> , 65, 1154-65	129
919	C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). <b>2011</b> , 53, 190-5	21
918	Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. <b>2011</b> , 183, 323-9	134
917	Combination therapy for COPD: emerging evidence from recent clinical trials. <b>2011</b> , 1, 879-890	4
916	Xanthine derivatives in the heart: blessed or cursed?. <b>2011</b> , 18, 3695-706	16
915	Acute Exercise Testing of COPD Patients: The Effect on Systemic Inflammatory Proteins. 2011, 7, 464-474	1
914	Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. <b>2011</b> , 183, 1138-46	80
913	Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. <b>2011</b> , 8, 363-7	62
912	"COPD-Lite": do you like the taste?. <b>2011</b> , 184, 486; author reply 486-7	1
911	Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. <b>2011</b> , 184, 1358-66	145
910	Primary care perspective on chronic obstructive pulmonary disease management. <b>2011</b> , 123, 145-52	2
909	Safety of chronic obstructive pulmonary disease medications: a primary care perspective. <b>2011</b> , 123, 72-9	13
908	Clinic practice guidelines: more of the same?. <b>2011</b> , 184, 492-4	1
907	Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. <b>2011</b> , 8, 356-62	15
906	Chronic obstructive pulmonary disease case finding in Mexico in an at-risk population. <b>2011</b> , 15, 818-23	19

905	COPD Identification By The Analysis Of Breath With An Electronic Nose. <b>2011</b> ,	1
904	Chronic obstructive pulmonary disease Th1 cells display impaired response to endotoxin. <b>2011</b> , 183, 148-50	7
903	Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. <b>2011</b> , 183, 43-9	88
902	Lung densitometry to assess progression of emphysema in chronic obstructive pulmonary disease: time to apply in the clinic?. <b>2011</b> , 183, 1578-80	9
901	Effects of written action plan adherence on COPD exacerbation recovery. <b>2011</b> , 66, 26-31	106
900	Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studies. <b>2011</b> , 2, 244-53	86
899	An in vitro assessment of aerosol delivery through patient breathing circuits used with medical air or a helium-oxygen mixture. <b>2011</b> , 24, 225-34	10
898	Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. <b>2011</b> , 8, 400-7	81
897	Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. <b>2011</b> , 183, 1025-31	83
896	Respiratory care year in review 2010: part 1. asthma, COPD, pulmonary function testing, ventilator-associated pneumonia. <b>2011</b> , 56, 488-502	14
895	A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. <b>2011</b> , 183, 491-9	226
894	Use of lambda-mu-sigma-derived Z score for evaluating respiratory impairment in middle-aged persons. <b>2011</b> , 56, 1771-7	18
893	The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. <b>2011</b> , 184, 1015-21	155
892	The safety and efficacy of arformoterol and formoterol in COPD. <b>2010</b> , 7, 17-31	19
891	Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. <b>2011</b> , 56, 477-87	50
890	Detecting mild COPD: don't waste resources. <b>2011</b> , 20, 6-8	11
889	Making ERS guidelines relevant and accessible: involving patients and the public. <b>2011</b> , 9-11	2
888	Ageing and COPD affect different domains of nutritional status: the ECCE study. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 1340-5	19

## (2011-2011)

887	Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. <b>2011</b> , 306, 1775-81		101
886	Pulmonary hypertension in smoking mice over-expressing protease-activated receptor-2. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 823-34	13.6	12
885	Influence of secular trends and sample size on reference equations for lung function tests. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 658-64	13.6	111
884	Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. <b>2011</b> , 55, 4149-53		18
883	Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease. <b>2011</b> , 48, 705-9		42
882	Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?. <b>2011</b> , 66, 961-9		68
881	Effects of upper body resistance training on pulmonary functions in sedentary male smokers. <b>2011</b> , 28, 169-73		10
880	A Review of Salmeterol–Fluticasone Propionate in Combination: Its Use in the Treatment of Chronic Obstructive Pulmonary Disease. <b>2011</b> , 3, 181-190		
879	GOLD and the fixed ratio. European Respiratory Journal, 2011, 38, 481-2; author reply 482-4	13.6	6
878	Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. <b>2011</b> , 4, 552-61		45
877	Noninvasive ventilation in chronic respiratory failure: effects on quality of life. <b>2011</b> , 81, 402-10		31
876	Increased adipose tissue expression of proinflammatory CD40, MKK4 and JNK in patients with very severe chronic obstructive pulmonary disease. <b>2011</b> , 81, 386-93		17
875	Asthma masquerading as chronic obstructive pulmonary disease: a study of smokers fulfilling the GOLD definition of chronic obstructive pulmonary disease. <b>2011</b> , 82, 19-27		17
874	What's nice about the new NICE guideline?. <b>2011</b> , 66, 93-6		2
873	Serum 25-hydroxy vitamin D and exercise capacity in COPD. <b>2011</b> , 66, 544-5		15
872	Lung function impairment, COPD hospitalisations and subsequent mortality. <b>2011</b> , 66, 585-90		105
871	Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. <b>2011</b> , 171, 914-20		45
870	Pilot study of a new device to titrate oxygen flow in hypoxic patients on long-term oxygen therapy. <b>2011</b> , 56, 429-34		30

869 Pharmacological Therapy: Bronchodilators. **2011**, 99-114

868	COPD. <b>2011</b> ,	3
867	Long-Term Care Medicine. <b>2011</b> ,	1
866	Chronic obstructive pulmonary disease and its comorbidities. <b>2011</b> , 72, 137-45	17
865	Explicit criteria for hospital admission in exacerbations of chronic obstructive pulmonary disease. <b>2011</b> , 15, 680-6	8
864	Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. <b>2011</b> , 139, 52-9	140
863	Bronchodilator reversibility in COPD. <b>2011</b> , 140, 1055-1063	60
862	Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. <b>2011</b> , 8, 338-49	16
861	Chronic obstructive pulmonary disease (COPD) and old age?. <b>2011</b> , 8, 143-51	19
860	Effect of radiological extent and severity of bronchiectasis on pulmonary function. <b>2011</b> , 6, 284-90	15
859	Reduced soluble receptor for advanced glycation end-products in COPD. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 516-22	96
858	Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. <b>2011</b> , 82, 237-45	44
857	Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer. <b>2011</b> , 71, 2572-81	32
856	Pulmonary rehabilitation in the United Kingdom. <b>2011</b> , 8, 193-9	20
855	The scientific basis and challenges of combination inhaled products. <b>2011</b> , 21, 293-300	2
854	Evaluation of the respiratory muscles efficiency during an incremental flow respiratory test. <b>2011</b> , 2011, 3820-3	Ο
853	Maladie pulmonaire obstructive chronique. <b>2011</b> , 147-155	
852	Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. <b>2011</b> , 66, 430-7	207

851	Immunological basis of reversible and fixed airways disease. <b>2011</b> , 121, 285-96		14
850	Linking microscopic spatial patterns of tissue destruction in emphysema to macroscopic decline in stiffness using a 3D computational model. <b>2011</b> , 7, e1001125		34
849	Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. <b>2011</b> , 109, 543-53		100
848	Properties of the COPD assessment test in a cross-sectional European study. <i>European Respiratory Journal</i> , <b>2011</b> , 38, 29-35	13.6	241
847	Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. <b>2011</b> , 6, 131-6		56
846	Prevalence of chronic obstructive pulmonary disease in rural women of Tamilnadu: implications for refining disease burden assessments attributable to household biomass combustion. <b>2011</b> , 4, 7226		55
845	Lung cancer in patients with chronic obstructive pulmonary disease incidence and predicting factors. <b>2011</b> , 184, 913-9		205
844	Is the 6-minute pegboard and ring test valid to evaluate upper limb function in hospitalized patients with acute exacerbation of COPD?. <b>2018</b> , 13, 1663-1673		11
843	Co-Morbidities as Predictors of Airflow Limitation among Smokers in England. 2018, 6,		
842	The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	53
842		13.6	53
	conceptual model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.	13.6	
841	conceptual model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. <b>2018</b> , 13, 1965-1977  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with	13.6	4
841	conceptual model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. <b>2018</b> , 13, 1965-1977  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. <b>2018</b> , 13, 1195-1205  Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3	13.6	4 59
841 840 839	conceptual model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. <b>2018</b> , 13, 1965-1977  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. <b>2018</b> , 13, 1195-1205  Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. <b>2018</b> , 314, L505-L513  Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and	13.6	4 59 22
841 840 839 838	conceptual model. European Respiratory Journal, 2018, 52,  Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. 2018, 13, 1965-1977  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. 2018, 13, 1195-1205  Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. 2018, 314, L505-L513  Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and nonsmokers without lung function impairment? A population-based study. 2018, 44, 213-219  Mobility limitations related to reduced pulmonary function among aging people with chronic	13.6	4 59 22 3
841 840 839 838	Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. 2018, 13, 1965-1977  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. 2018, 13, 1195-1205  Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. 2018, 314, L505-L513  Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and nonsmokers without lung function impairment? A population-based study. 2018, 44, 213-219  Mobility limitations related to reduced pulmonary function among aging people with chronic obstructive pulmonary disease. 2018, 13, e0196152  Patterns of Time Use across the Chronic Obstructive Pulmonary Disease Severity Spectrum. 2018,	13.6	4 59 22 3 5

833	Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A. <b>2018</b> , 59, 695-705	15
832	Comorbidities and COPD severity in a clinic-based cohort. <b>2018</b> , 18, 117	29
831	Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial. <b>2018</b> , 18, 71	30
830	A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. <b>2018</b> , 19, 38	3
829	Understanding and measuring symptoms and health status in asthma COPD overlap: content validity of the EXACT and SGRQ. <b>2017</b> , 2, 18	2
828	Altered skeletal muscle mitochondrial phenotype in COPD: disease vs. disuse. <b>2018</b> , 124, 1045-1053	15
827	Use of a Home-Based Manual as Part of a Pulmonary Rehabilitation Program. 2018, 63, 1485-1491	4
826	Fatigue Management. <b>2018</b> ,	1
825	Whole-genome methylation profiling of peripheral blood mononuclear cell for acute exacerbations of chronic obstructive pulmonary disease treated with corticosteroid. <b>2018</b> , 28, 78-85	3
824	Palliative Care in Advanced Lung Diseases: A Void That Needs Filling. <b>2018</b> , 15, 1265-1268	4
823	Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway. <b>2018</b> , 18, 3143-3152	25
822	Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <b>2018</b> , 379, 592-593	9
821	Long-term oxygen therapy in COPD patients: population-based cohort study on mortality. <b>2018</b> , 13, 979-988	8
820	Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease. <b>2018</b> , 18, 129	17
819	Factors associated with hospital mortality in critically ill patients with exacerbation of COPD. <b>2018</b> , 13, 2361-2366	16
818	EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD). <b>2018</b> , 140, 127-131	13
817	Prevalence and features of asthma-COPD overlap in the United States 2007-2012. <b>2018</b> , 12, 2369-2377	17
816	Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment. <b>2018</b> , 56, 292-306	11

815	Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	64
814	Palliative Care for Chronic Obstructive Pulmonary Disease. Signs of Progress, but Still a Long Way to Go. <b>2018</b> , 198, 1356-1358		5
813	Usefulness of The Piko-6 Portable Device for Early COPD Detection in Primary Care. <b>2018</b> , 54, 460-466		8
812	Endobronchial Valves Therapy for Advanced Emphysema: A Meta-Analysis of Randomized Trials. <b>2019</b> , 26, 81-89		9
811	Substantial variation exists in spirometry interpretation practices for airflow obstruction in accredited lung function laboratories across Australia and New Zealand. <b>2019</b> , 49, 41-47		4
810	Chronic Obstructive Pulmonary Disease. <b>2019</b> , 93-112		
809	Physiological and clinical characteristics of patients with COPD admitted to an inpatient pulmonary rehabilitation program: A real-life study. <b>2019</b> , 25, 71-78		11
808	Using Video Telehealth to Facilitate Inhaler Training in Rural Patients with Obstructive Lung Disease. <b>2019</b> , 25, 230-236		8
807	Secretome of Mesenchymal Stem Cells and its Impact on Chronic Obstructive Pulmonary Disease. <b>2019</b> , 139-157		
806	Diffuse smoking-related lung diseases: insights from a radiologic-pathologic correlation. <b>2019</b> , 10, 73		9
805	Stem Cell Transplantation for Autoimmune Diseases and Inflammation. 2019,		1
804	Non-Invasive Ventilatory Support In the Elderly. <b>2019</b> , 8, 153-159		О
803	Wearable Bioimpedance Measurement for Respiratory Monitoring During Inspiratory Loading. <b>2019</b> , 7, 89487-89496		23
802	Effectiveness of a Pulmonary Rehabilitation Program on Persistent Asthma Stratified for Severity. <b>2019</b> , 64, 1523-1530		6
801	Annotating and detecting phenotypic information for chronic obstructive pulmonary disease. <b>2019</b> , 2, 261-271		3
800	Cigarette smoke exposure reduces leukemia inhibitory factor levels during respiratory syncytial viral infection. <b>2019</b> , 14, 1305-1315		8
799	Integrated Palliative Care of Respiratory Disease. 2019,		
798	Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. <b>2019</b> , 20, 166		4

797	Emphysema phenotypes and lung cancer risk. <b>2019</b> , 14, e0219187		10
796	Airway Management and Mechanical Ventilation in the Neurocritical Care Unit. 2019, 50-61		
795	Validity of the diagnosis of pneumonia in hospitalised patients with COPD. 2019, 5,		9
794	TERT gene polymorphisms are associated with chronic obstructive pulmonary disease risk in the Chinese Li population. <b>2019</b> , 7, e773		5
793	Automatic tailoring of the lowest PEEP to abolish tidal expiratory flow limitation in seated and supine COPD patients. <b>2019</b> , 155, 13-18		6
79²	A novel approach towards non-obstructive detection and classification of COPD using ECG derived respiration. <b>2019</b> , 42, 1011-1024		5
791	Mind-Body Exercise (Wuqinxi) for Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2018</b> , 16,		12
790	Assessment of Work of Breathing in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <b>2019</b> , 16, 418-428		1
789	To Evaluate the Effect of Chronic Obstructive Pulmonary Disease on Retinal and Choroidal Thicknesses Measured by Optical Coherence Tomography. <b>2019</b> , 2019, 7463815		O
788	Atherosclerotic calcification in major vessel beds in chronic obstructive pulmonary disease: The Rotterdam Study. <b>2019</b> , 291, 107-113		6
787	Ischaemic Heart Disease Induced by Intralobar Pulmonary Sequestration. <b>2019</b> , 55, 536-549		
<del>7</del> 86	Incidence and Impact of Pulmonary Embolism During Severe COPD Exacerbation. 2019, 64, 1531-1536		9
785	Physiological and Symptomatic Responses to Arm versus Leg Activities in People with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. <b>2019</b> , 16, 390-405		О
7 <sup>8</sup> 4	Plasma metabolomics and clinical predictors of survival differences in COPD patients. <b>2019</b> , 20, 219		13
783	Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	3.6	22
782	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <b>2019</b> , 55, 409-413		
781	Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease. <b>2019</b> , 20, 195		6
780	Efficacy of osteopathic treatment in patients with stable moderate-to-severe chronic obstructive pulmonary disease: a randomized controlled pilot study. <b>2019</b> , 17,		6

779	Time-course of upper respiratory tract viral infection and COPD exacerbation. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	19
778	Postoperative outcomes of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass grafting surgery: A meta-analysis. <b>2019</b> , 98, e14388		10
777	The Comorbidity of Chronic Obstructive Pulmonary Disease and Peripheral Artery Disease - A Systematic Review. <b>2019</b> , 16, 292-302		2
776	Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. <b>2019</b> , 14, 2121-2129		6
775	Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials. <b>2019</b> , 13, 1753466619875925		6
774	Need for Portable Oxygen Titration Using 6-Minute Walk Tests. <b>2019</b> , 55, 539-540		
773	Assessment Of Changes In Regional Xenon-Ventilation, Perfusion, And Ventilation-Perfusion Mismatch Using Dual-Energy Computed Tomography After Pharmacological Treatment In Patients With Chronic Obstructive Pulmonary Disease: Visual And Quantitative Analysis. <b>2019</b> , 14, 2195-2203		5
772	Correlations between serum amyloid A, C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease. <b>2019</b> , 33, e22831		9
771	First series of minimally invasive, robot-assisted tracheobronchoplasty with mesh for severe tracheobronchomalacia. <b>2019</b> , 157, 791-800		12
770	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. <b>2019</b> , 38, 637-647		6
769	[The impact of acute exacerbations of COPD on mortality]. 2019, 36, 7-14		1
768	Longitudinal change of FEV and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD. <b>2019</b> , 14, 361-369		2
767	Reducing Chronic Obstructive Pulmonary Disease Hospital Readmissions. An Official American Thoracic Society Workshop Report. <b>2019</b> , 16, 161-170		37
766	Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. <b>2019</b> , 14, 939-951		3
765	Development of a new quantification method for organic acids in urine as potential biomarkers for respiratory illness. <b>2019</b> , 1122-1123, 29-38		7
764	Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder. <b>2019</b> , 16, 1151-1157		2
763	MyLung: Design and Testing of a Mobile-Based Assistive Technology for COPD Patients. <b>2019</b> , 172-188	3	
762	Does hand grip strength decrease in chronic obstructive pulmonary disease exacerbation? A cross-sectional study. <b>2019</b> , 49, 802-808		6

761	8-Hydroxy-2âEdeoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease. <b>2019</b> , 49, 93-100	11
760	New evidence on the chemoprevention of înhaled steroids and the risk of lung cancer in COPD.  European Respiratory Journal, <b>2019</b> , 53,	4
759	Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap. <b>2019</b> , 20, 107	4
758	The Effects of a Nurse-Led Education and Counseling Program on Dyspnea, Health Status, and Care Dependency in Patients With Chronic Obstructive Pulmonary Disease: A Feasibility Study. <b>2019</b> , 31, 249-256	1
757	Consequences of Changing the GOLD Reports (2007-2011-2017) on the Treatment Regimen of Patients with COPD. <b>2019</b> , 16, 126-132	2
756	Adipose Tissue-Derived Stem Cells Have the Ability to Differentiate into Alveolar Epithelial Cells and Ameliorate Lung Injury Caused by Elastase-Induced Emphysema in Mice. <b>2019</b> , 2019, 5179172	7
755	Determinants of study completion and response to a 12-month behavioral physical activity intervention in chronic obstructive pulmonary disease: A cohort study. <b>2019</b> , 14, e0217157	1
754	Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. <b>2019</b> , 57, 101802	8
753	Use of the terms "overdiagnosis" and "misdiagnosis" in the COPD literature: a rapid review. <b>2019</b> , 15, e8-e19	5
75 <sup>2</sup>	Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation. <b>2019</b> , 39,	3
751	Dynamic Hyperinflation Impairs Cardiac Performance During Exercise in COPD. <b>2019</b> , 39, 187-192	4
75°	Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. <b>2019</b> , 14, 615-629	8
749	Physical Activity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease. <b>2019</b> , 51, 833-840	14
748	Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. <b>2019</b> , 24, 658-666	11
747	Adherence to Continuous Positive Airway Pressure in patients with Obstructive Sleep Apnoea. A ten year real life study. <b>2019</b> , 150, 95-100	5
746	Exercise in Interstitial Lung Diseases. <b>2019</b> , 97-110	
745	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	32
744	A comparison of methodologies for the real-time identification of hospitalized patients with acute exacerbations of COPD. <b>2019</b> , 14, 693-698	1

743	Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. <b>2019</b> , 20, 60	9
742	Effects of Aging and Smoking Duration on Cigarette Smoke-Induced COPD Severity. <b>2019</b> , 34, e90	9
741	Association of HTR2A-1438G/A Genetic Polymorphism With Smoking and Chronic Obstructive Pulmonary Disease. <b>2019</b> , 55, 128-133	
740	The importance of obtaining a sputum sample and how it can aid diagnosis and treatment. <b>2019</b> , 28, 295-298	2
739	Impact of COPD on Outcome in Patients Undergoing Transfemoral versus Transapical TAVI. <b>2019</b> , 67, 251-256	2
738	Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease. <b>2019</b> , 16, 1479973118815692	1
737	Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study. <b>2019</b> , 5,	7
736	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <b>2019</b> , 55, 409-413	10
735	A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. <b>2019</b> , 14, 371-380	8
734	Exercise and Sports Pulmonology. <b>2019</b> ,	1
733	Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise. <b>2019</b> , 25, 144-149	10
732	From BPMN process models to DMN decision models. <b>2019</b> , 83, 69-88	19
731	Correlation between Physical Activity and Lung Function in Dusty Areas: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort. <b>2019</b> , 82, 311-318	13
730	Early Prediction of Lung Diseases. 2019,	3
729	¿Por qu'la rehabilitaciñ respiratoria no llega a todos los pacientes de enfermedad pulmonar obstructiva crñica que lo necesitan? Revisiñ de la literatura. <b>2019</b> , 67, 325-332	
728	Study of Pulmonary Function Test in Type 2 Diabetics and COPD with Diabetes. <b>2019</b> , 09,	
727	Sleep in chronic respiratory disease: COPD and hypoventilation disorders. 2019, 28,	25
726	The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS. <b>2019</b> , 20, 254	4

7 <del>2</del> 5	The Effects of Repeated Dyspnea Exposure on Response Inhibition. <b>2019</b> , 10, 663	6
724	Statins versus placebo for people with chronic obstructive pulmonary disease. <b>2019</b> , 7, CD011959	12
7 <del>2</del> 3	Diaphragmatic plication for iatrogenic respiratory insufficiency after cardiothoracic surgery. <b>2019</b> , 11, 3704-3711	7
722	Longitudinal changes in structural lung abnormalities using MDCT in chronic obstructive pulmonary disease with asthma-like features. <b>2019</b> , 14, e0227141	1
721	Remote Pulmonary Function Test Monitoring in Cloud Platform via Smartphone Built-in Microphone. <b>2019</b> , 15, 1176934319888904	7
720	Inpatient Databases. <b>2019</b> , 290-304	
719	Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. <b>2019</b> , 14, 2927-2938	3
718	Pulmonary rehabilitation for chronic obstructive pulmonary disease: effects of a high versus low intensity programme. <b>2019</b> , 26, 1-13	
717	Ultrasound Assessment Of Diaphragmatic Function During Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Pilot Study. <b>2019</b> , 14, 2479-2484	9
716	The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population. <b>2019</b> , 14, 2849-2861	7
715	Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. <b>2019</b> , 20, 273	10
714	Management of chronic obstructive pulmonary disease-A position statement of the South African Thoracic Society: 2019 update. <b>2019</b> , 11, 4408-4427	5
713	Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation: A Randomized Double-blind Controlled Trial. <b>2019</b> , 26, 434-442	4
712	[Frailty is associated with increased mortality in chronic obstructive pulmonary disease]. <b>2019</b> , 54, 237-238	O
711	A Comparative Analysis Between EDR and Respiration Signal: A Pilot Study with Normal Subjects. <b>2019</b> , 595-604	1
710	Internet of Things and Personalized Healthcare Systems. <b>2019</b> ,	4
709	Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. <b>2019</b> , 22, 303-313	7
708	Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. <b>2019</b> , 8, 721-733	O

## (2020-2019)

707	Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study. <b>2019</b> , 20, 192-201		3
706	Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. <b>2019</b> , 74, 439-446		36
705	Postoperative Respiratory Failure and Treatment. <b>2019</b> , 895-923		2
704	Association of HTR2A-1438G/A Genetic Polymorphism With Smoking and Chronic Obstructive Pulmonary Disease. <b>2019</b> , 55, 128-133		2
703	Association of IL-6, IL-8, MMP-13 gene polymorphisms with knee osteoarthritis susceptibility in the Chinese Han population. <b>2019</b> , 39,		13
702	An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease. <b>2019</b> , 32, 40-46		1
701	CT Imaging-Based Low-Attenuation Super Clusters in Three Dimensions and the Progression of Emphysema. <b>2019</b> , 155, 79-87		8
700	A complex intervention of self-management for patients with COPD or CHF in primary care improved performance and satisfaction with regard to own selected activities; A longitudinal follow-up. <b>2019</b> , 75, 175-186		10
699	Risks of Benzodiazepines in Chronic Obstructive Pulmonary Disease with Comorbid Posttraumatic Stress Disorder. <b>2019</b> , 16, 82-90		11
698	Outcomes after lung transplantation for patients with occupational lung diseases. <b>2019</b> , 33, e13460		10
697	The Ratio Serum Creatinine/Serum Cystatin C (a Surrogate Marker of Muscle Mass) as a Predictor of Hospitalization in Chronic Obstructive Pulmonary Disease Outpatients. <b>2019</b> , 97, 302-309		20
696	Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. <b>2019</b> , 38, 145-155		26
695	Exercise Training After Pulmonary Endarterectomy for Patients with Chronic Thromboembolic Pulmonary Hypertension. <b>2019</b> , 97, 234-241		8
694	Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis. <b>2019</b> , 199, 842-853		36
693	Application of N-Acetylcysteine in Pulmonary Disorders. <b>2019</b> , 255-276		3
692	Airway morphology and inspiratory flow features in the early stages of Chronic Obstructive Pulmonary Disease. <b>2019</b> , 66, 60-65		12
691	Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	34
690	Relationship between resting heart rate and arterial stiffness in patients with chronic obstructive pulmonary disease: Implications for pulmonary rehabilitation. <b>2020</b> , 4, 83-90		1

689	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. 2020, 57, 1365-137	<b>′1</b> 5
688	Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease. <b>2020</b> , 29, 607-617	7
687	A study on the validity and reliability of the Turkish version of the Clinical Chronic Obstructive Pulmonary Disease Questionnaire. <b>2020</b> , 33, 379-385	
686	COUNTERPOINT: Can Screening for COPD Improve Outcomes? No. <b>2020</b> , 157, 9-12	4
685	Overlap syndrome: the coexistence of OSA further impairs cardiorespiratory fitness in COPD. <b>2020</b> , 24, 1451-1462	3
684	The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. <b>2020</b> , 161, 105857	16
683	Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial. <b>2020</b> , 17, 7-14	2
682	Diagnostic Validity of Cardiopulmonary Exercise Testing for Screening Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease. <b>2020</b> , 40, 189-194	3
681	Comparison of machine learning algorithms for the identification of acute exacerbations in chronic obstructive pulmonary disease. <b>2020</b> , 188, 105267	15
680	Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: Relationship with pulmonary function and clinical events. <b>2020</b> , 15, e0239066	2
679	Epidemiology of Chronic Obstructive Pulmonary Disease. <b>2020</b> , 41, 315-327	14
678	Adherence to inhalers and comorbidities in COPD patients. A cross-sectional primary care study from Greece. <b>2020</b> , 20, 253	6
677	Effect of once-daily fluticasone furoate/vilanterol vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial. <b>2020</b> , 14, 1753466620965145	1
676	Review of Mathematical Modeling of the Inflammatory Response in Lung Infections and Injuries. <b>2020</b> , 6,	6
675	Assessment of comorbidities and prognosis in patients with COPD diagnosed with the fixed ratio and the lower limit of normal: a systematic review and meta-analysis. <b>2020</b> , 21, 189	2
674	Protein succination as a potential surrogate biomarker of airway obstruction. The ilervas project. <b>2020</b> , 172, 106124	1
673	Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study. <b>2020</b> , 10, 18973	4
672	Lung weights and undiagnosed lung lesions in medico-legal autopsies in Dar es Salaam, Tanzania. <b>2020</b> , 2, 100120	

671	Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. <b>2020</b> , 14, 1753466	62 <del>0</del> 916990
670	DNA Methylation: A Potential Biomarker of Chronic Obstructive Pulmonary Disease. <b>2020</b> , 8, 585	7
669	A New Nasal Restriction Device Called FeelBreathe Improves Breathing Patterns in Chronic Obstructive Pulmonary Disease Patients during Exercise. <b>2020</b> , 17,	1
668	Surgical treatment of bilateral vanishing lung syndrome: a case report. <b>2020</b> , 15, 201	
667	Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD. <b>2020</b> , 15, 1823-1829	О
666	Elucidation of the Mechanism by Which a Gene MicroRNA-Binding Site Single Nucleotide Polymorphism Affects the Risk of Osteoarthritis. <b>2020</b> , 24, 467-477	2
665	Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. <b>2020</b> , 41, 421-438	45
664	Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. <b>2020</b> , 21, 280	3
663	Increased airway T lymphocyte microparticles in chronic obstructive pulmonary disease induces airway epithelial injury. <b>2020</b> , 261, 118357	3
662	The Identification and Cost of Acute Chronic Obstructive Pulmonary Disease Exacerbations in a United States Population Healthcare Claims Database. <b>2020</b> , 17, 499-508	2
661	Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD. <b>2020</b> , 10, 17415	1
660	A Non-contact Spirometer with Time-of-Flight Sensor for Assessment of Pulmonary Function. <b>2020</b> , 2020, 4114-4117	1
659	Evaluation of the Vibe Actigraph in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. <b>2020</b> , 8, 2700708	1
658	Determination of the phenotypic age in residents of Mexico City: effect of accelerated ageing on lung function and structure. <b>2020</b> , 6,	3
657	Pharmacological management of human respiratory syncytial virus infection. <b>2020</b> , 21, 2293-2303	4
656	Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study. <b>2020</b> , 21, 220	3
655	Advances in imaging for lung emphysema. <b>2020</b> , 8, 1467	3
654	Coal Dust-Induced Systematic Hypoxia and Redox Imbalance among Coal Mine Workers. <b>2020</b> , 5, 28204-2821	1 3

653	Drug Safety of Benzodiazepines in Asian Patients With Chronic Obstructive Pulmonary Disease. <b>2020</b> , 11, 592910	1
652	Decreased COPD prevalence in Sweden after decades of decrease in smoking. <b>2020</b> , 21, 283	12
651	COPD as an exemplar of a chronic health condition. <b>2020</b> , 145-180	
650	Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. <b>2020</b> , 5, CD002309	13
649	Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. <b>2020</b> , 173, 105988	13
648	Reliability and Usefulness of Different Biomarkers of Oxidative Stress in Chronic Obstructive Pulmonary Disease. <b>2020</b> , 2020, 4982324	13
647	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <b>2020</b> , 6,	3
646	Alcohol and Tobacco. <b>2020</b> ,	2
645	A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. <b>2020</b> , 20, 119	5
644	Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. <b>2020</b> , 21, 131	11
643	Two faces of the same coin: a qualitative study of patients' and carers' coexistence with chronic breathlessness associated with chronic obstructive pulmonary disease (COPD). <b>2020</b> , 19, 64	7
642	Physiological response to eccentric and concentric cycling in patients with chronic obstructive pulmonary disease. <b>2020</b> , 45, 1232-1237	6
641	Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. <b>2020</b> , 7,	О
640	Effects of a Rehabilitation Programme with a Nasal Inspiratory Restriction Device on Exercise Capacity and Quality of Life in COPD. <b>2020</b> , 17,	4
639	A survival analysis of patients with an acute exacerbation of chronic obstructive pulmonary disease discharged from the respiratory intensive care unit. <b>2020</b> , 9, 1812-1820	О
638	CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. <b>2020</b> , 21, 149	23
637	How to Stage Airflow Limitation in Stable Chronic Obstructive Pulmonary Disease Male Patients?. <b>2020</b> , 14, 1557988320922630	2
636	Evaluation of disability in patients exposed to fluoroquinolones. <b>2020</b> , 21, 40	1

635	Endothelial HIF-2∃ as a Key Endogenous Mediator Preventing Emphysema. <b>2020</b> , 202, 983-995		8
634	A Cross-sectional Study of Hospital Performance on ICU Utilization Practices for Patients with Chronic Obstructive Pulmonary Disease. <b>2020</b> , 198, 637-644		O
633	Relationship Between Particulate Matter (PM) and Hospitalizations and Mortality of Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis. <b>2020</b> , 359, 354-364		10
632	Earlier palliative home care is associated with patient-centred medical resource utilisation and lower costs in the last 30 days before death in COPD: a population-level decedent cohort study. European Respiratory Journal, <b>2020</b> , 55,	13.6	3
631	Examination of COPD management in patients hospitalized with an acute exacerbation of COPD. <b>2020</b> , 1-10		
630	Risk Factors Associated with Development of Pulmonary Arterial Hypertension and Corpulmonale in Patients with Chronic Obstructive Pulmonary Disease. <b>2020</b> , 15, 289-298		
629	Arterial and transcutaneous variability and agreement between multiple successive measurements of carbon dioxide in patients with chronic obstructive lung disease. <b>2020</b> , 280, 103486		0
628	Visual Emphysema at Chest CT in GOLD Stage 0 Cigarette Smokers Predicts Disease Progression: Results from the COPDGene Study. <b>2020</b> , 296, 641-649		4
627	Automated Home Oxygen Delivery for Patients with COPD and Respiratory Failure: A New Approach. <b>2020</b> , 20,		1
626	Subjective sleep quality is associated with disease status in COPD patients. The cross-sectional Greek UNLOCK study. <b>2020</b> , 24, 1599-1605		3
625	Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review. <b>2020</b> , 20, 79-91		5
624	Using the BODE Index and Comorbidities to Predict Health Utilization Resources in Chronic Obstructive Pulmonary Disease. <b>2020</b> , 15, 389-395		8
623	The efficacy of manual therapy (Chuna) for chronic obstructive pulmonary disease: Protocol for a systematic review. <b>2020</b> , 99, e18832		2
622	Etiology and characteristics of patients with bronchiectasis in Taiwan: a cohort study from 2002 to 2016. <b>2020</b> , 20, 45		16
621	The association of delta neutrophil index with the prognosis of acute exacerbation of chronic obstructive pulmonary disease. <b>2020</b> , 20, 47		5
620	Use of inhaled devices during a hospital exacerbation of COPD: a summary of an interdisciplinary audit held at ICS Maugeri Pavia, Italy (March-June 2019). <b>2020</b> , 90,		
619	Demographic, Clinical and Management Characteristics of Newly Diagnosed COPD Patients in Turkey: A Real-Life Study. <b>2020</b> , 15, 261-267		1
618	Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease. <b>2020</b> , 21, 50		23

617	Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing. <b>2020</b> , 37, 38	О
616	The Emerging Role of Radiomics in COPD and Lung Cancer. <b>2020</b> , 99, 99-107	20
615	Multimorbidity in COPD, does sleep matter?. <b>2020</b> , 73, 7-15	9
614	Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD. <b>2020</b> , 15, 43-56	4
613	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. <b>2020</b> , 15, 99-106	3
612	Patterns and predictors of low physical activity in patients with stable COPD: a longitudinal study. <b>2020</b> , 14, 1753466620909772	2
611	Stability and Predictors of Poor 6-min Walking Test Performance over 2 Years in Patients with COPD. <b>2020</b> , 9,	2
610	Guidance for the Better Care of Patients with Chronic Obstructive Pulmonary Disease. <b>2020</b> , 201, 1022-1023	1
609	Usefulness of Measurement of End-tidal CO Using a Portable Capnometer in Patients with Chronic Respiratory Failure Receiving Long-term Oxygen Therapy. <b>2020</b> , 59, 1711-1720	О
608	British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. <b>2020</b> , 75, 370-404	14
607	Endothelial dysfunction is not a predictor of outcome in chronic obstructive pulmonary disease. <b>2020</b> , 21, 90	3
606	Combining Bioimpedance and Myographic Signals for the Assessment of COPD During Loaded Breathing. <b>2021</b> , 68, 298-307	10
605	Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. <b>2021</b> , 37, 145-155	1
604	Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic obstructive pulmonary disease. <b>2021</b> , 24, 52-59	5
603	Epicardial adipose tissue is associated with increased systolic pulmonary artery pressure in patients with chronic obstructive pulmonary disease. <b>2021</b> , 15, 406-412	0
602	Patterns of Physical Activity Progression in Patients With COPD. <b>2021</b> , 57, 214-223	4
601	Clinical outcomes and survival following placement of self-expandable metallic stents for central airway stenosis and fistula. <b>2021</b> , 12, 48-56	2
600	Adiponectin is Associated with Neutrophils to Lymphocyte Ratio in Patients with Chronic Obstructive Pulmonary Disease. <b>2021</b> , 18, 70-75	2

## (2021-2021)

599	Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease. <b>2021</b> , 59, 135-144	1
598	The determinants of dyspnoea evaluated by the mMRC scale: The French Palomb cohort. <b>2021</b> , 79, 100803	О
597	A mobile health application to support self-management in patients with chronic obstructive pulmonary disease: a randomised controlled trial. <b>2021</b> , 35, 90-101	8
596	An Analytical Study Carried Out to Identify Symptoms of Occupational Lung Diseases and Preventive Measures among Workers Involved in Marble Industries in Rajsamand District of Rajasthan. <b>2021</b> , 8, 53-57	
595	THE ROLE OF GLUTATION-S-TRANSFERASE MU1 AND TETA1 POLYMORPHISMS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 41-56	1
594	Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD). <b>2021</b> , 12, 54	12
593	Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study. <b>2021</b> , 8,	1
592	Longitudinal Evaluation of the Relationship Between Low Socioeconomic Status and Incidence of Chronic Obstructive Pulmonary Disease: Korean Genome and Epidemiology Study (KoGES). <b>2020</b> , 15, 3447-3454	2
591	The Heterogeneity of COPD Patients in a Community-Based Practice and the Inadequacy of the Global Initiative for Chronic Obstructive Lung Disease Criteria: A Real-World Experience. <b>2021</b> , 8, 396-407	3
590	Short-term and long-term impact of diagnosed and undiagnosed chronic obstructive pulmonary disease on coronary artery bypass grafting surgery. <b>2021</b> ,	O
589	The five-repetition sit-to-stand test is a predictive factor of severe exacerbations in COPD. <b>2021</b> , 12, 2040622320986718	2
588	Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments. <b>2021</b> , 76, 228-238	6
587	Developing a Multidisciplinary Approach to the COPD Care Pathway. <b>2021</b> , 44, 121-127	
586	Chronic lung diseases: prospects for regeneration and repair. <b>2021</b> , 30,	5
585	Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial. <b>2021</b> , 8,	5
584	Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients. <b>2021</b> , 7, 133-143	1
583	[Oxygen Therapy in Lung Transplantation Candidates - A Single Center Retrospective Analysis of 807 Patients]. <b>2021</b> , 75, 360-368	1
582	REVIEW ON DRY POWDER INHALERS: CURRENT ADVANCES AND LIMITATIONS. <b>2021</b> , 63-67	

581	Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	3
580	The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives. <b>2021</b> , 1-27		2
579	Assessment of Ventilatory Heterogeneity in Chronic Obstructive Pulmonary Disease Using the Inspired Sinewave Test. <b>2021</b> , 16, 401-413		2
578	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. <b>2021</b> , 22, 213		O
577	The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study. <b>2021</b> , 16, 701-713		1
576	Referral criteria to palliative care for patients with respiratory disease: a systematic review. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	4
575	Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran. <b>2021</b> , 21, 105		1
574	Distinct Mechanical Properties of the Respiratory System Evaluated by Forced Oscillation Technique in Acute Exacerbation of COPD and Acute Decompensated Heart Failure. <b>2021</b> , 11,		2
573	Patterns of Physical Activity Progression in Patients With COPD. <b>2021</b> , 57, 214-223		1
572	Transitions between COPD groups: A cross-sectional study in Turkey. <b>2021</b> , 178, 106310		
571	Integrative microbiomics in bronchiectasis exacerbations. <b>2021</b> , 27, 688-699		26
570	Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. 1-47		
569	Unwrapping the phase portrait features of adventitious crackle for auscultation and classification: a machine learning approach. <b>2021</b> , 47, 103-115		3
568	Indocyanine green imaging for pulmonary segmentectomy. <b>2021</b> , 6, 151-158		5
567	The Maugeri daily activity profile: a tool to assess physical activity in patients with chronic obstructive pulmonary disease. <b>2021</b> ,		
566	IL-17-Mediated Inflammation Promotes Cigarette Smoke-Induced Genomic Instability. <b>2021</b> , 10,		3
565	Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross-sectional study. <b>2021</b> , 30, 3493-3505		1
564	Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. <b>2021</b> , 46, 39-48		59

563	Aortic enlargement in chronic obstructive pulmonary disease (COPD) and emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD study. <b>2021</b> , 331, 214-220	4
562	Hypoxia and Inflammation: Insights From High-Altitude Physiology. <b>2021</b> , 12, 676782	13
561	Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV. <b>2021</b> , 16, 1437-1447	1
560	Differential Diagnosis of Asthma and COPD Based on Multivariate Pulmonary Sounds Analysis. <b>2021</b> , 68, 1601-1610	1
559	Validation of the rapid assessment of physical activity questionnaire in older patients with chronic obstructive pulmonary disease.	
558	Renewed vision on pulmonary rehabilitation service delivery for chronic obstructive pulmonary disease management beyond COVID-19. <b>2021</b> , 7, 107-116	О
557	Protein Biomarkers for COPD Outcomes. <b>2021</b> , 159, 2244-2253	8
556	A Novel Model-Based Questionnaire Based on Low-Dose CT Screening Data for Chronic Obstructive Pulmonary Disease Diagnosis in Shimane, Japan. <b>2021</b> , 16, 1823-1833	
555	Automatic detection of obstructive and restrictive lung disease from features extracted from ECG and ECG derived respiration signals. <b>2021</b> , 102791	2
554	Diseases of the Respiratory Tract. <b>2021</b> , 469-504	
553	Identification of Macrophage Polarization-Related Genes as Biomarkers of Chronic Obstructive Pulmonary Disease Based on Bioinformatics Analyses. <b>2021</b> , 2021, 9921012	1
552	Prevalence and Determinants of Mental Health among COPD Patients in a Population-Based Sample in Spain. <b>2021</b> , 10,	1
551	FEV Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn. <b>2021</b> , 203, 1573-1576	1
550	Eosinophilic phenotype was associated with better early clinical remission in elderly patients but not middle-aged patients with acute exacerbations of COPD. <b>2021</b> , 75, e14415	2
549	Stem cell therapy for chronic obstructive pulmonary disease. <b>2021</b> , 134, 1535-1545	3
548	Chronic respiratory disease surveys in adults in low- and middle-income countries: A systematic scoping review of methodological approaches and outcomes. <b>2021</b> , 11, 04026	5
547	Quantitative Analysis of Adipose Depots by Using Chest CT and Associations with All-Cause Mortality in Chronic Obstructive Pulmonary Disease: Longitudinal Analysis from MESArthritis Ancillary Study. <b>2021</b> , 299, 703-711	7
546	Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. <b>2021</b> , 15, 992-1002	6

545	Prognostic Value of Neutrophil:Lymphocyte and Platelet:Lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD. <b>2021</b> , 14, 2839-2848	5
544	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. <b>2021</b> , 16, 1755-1770	9
543	Machine Learning Methods for the Diagnosis of Chronic Obstructive Pulmonary Disease in Healthy Subjects: Retrospective Observational Cohort Study. <b>2021</b> , 9, e24796	1
542	Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. <b>2021</b> , 22,	6
541	Pulmonary biofilm-based chronic infections and inhaled treatment strategies. <b>2021</b> , 604, 120768	3
540	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. <b>2021</b> , 8,	1
539	Lung Function Impairment and the Risk of Incident Dementia: The Rotterdam Study. <b>2021</b> , 82, 621-630	3
538	Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. <b>2021</b> , 22, 191	1
537	Breathing Sound-based Exercise Intensity Monitoring via Smartphones. <b>2021</b> ,	0
536	Cutoff Points for Step Count to Predict 1-year All-Cause Mortality in Patients with Idiopathic Pulmonary Fibrosis. <b>2021</b> , 100, 1151-1157	1
535	Predictive factors and economic impact of prolonged air leak after pulmonary resection. 2021, 1	1
534	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. <b>2021</b> , 160, 187-198	64
533	Comparative analysis of the bronchoalveolar microbiome in Portuguese patients with different chronic lung disorders. <b>2021</b> , 11, 15042	O
532	Validity of the Handheld Expiratory Flowmeter for COPD Screening in the Primary Care Setting of China. <b>2021</b> , 16, 2039-2047	1
531	Portable High-Flow Nasal Oxygen during Walking in Patients with Severe Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. <b>2021</b> , 100, 1158-1164	
530	Correlation between Telomere Length and Chronic Obstructive Pulmonary Disease-Related Phenotypes: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort. <b>2021</b> , 84, 188-199	2
529	Impact of insomnia and obstructive sleep apnea on the risk of acute exacerbation of chronic obstructive pulmonary disease. <b>2021</b> , 58, 101444	2
528	Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study. <b>2021</b> , 21, 733	1

527	Adherence to Low Carbohydrate Diet in Relation to Chronic Obstructive Pulmonary Disease. <b>2021</b> , 8, 690880	О
526	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <b>2021</b> , 57, 533-533	
525	The role of exosomes from BALF in lung disease. <b>2021</b> ,	1
524	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <b>2021</b> , 57, 533-539	1
523	COPD Exacerbation History and Impact on Future Exacerbations - 8-Year Retrospective Observational Database Cohort Study from Germany. <b>2021</b> , 16, 2407-2417	4
522	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. <b>2021</b> , 8,	1
521	The association between sleep quality, health status and disability due to breathlessness in chronic obstructive pulmonary disease patients. <b>2021</b> , 15, 1168-1174	1
520	Prediction of cardiovascular risk in patients with chronic obstructive pulmonary disease: a study of the National Health and Nutrition Examination Survey database. <b>2021</b> , 21, 417	1
519	Research Advances in COPD Drugs and Novel Targets. <b>2021</b> , 11, 2140008	2
518	Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. <b>2021</b> , 14,	4
517	An Exploration of Lung Volume Effects on Swallowing in Chronic Obstructive Pulmonary Disease. <b>2021</b> , 30, 2155-2168	0
516	Bronchodilator Response in Patients with COPD, Asthma-COPD-Overlap (ACO) and Asthma, Evaluated by Plethysmographic and Spirometric z-Score Target Parameters. <b>2021</b> , 16, 2487-2500	1
515	A qualitative study of pulmonary function tests between smokers and non smokers in Telangana state. <b>2021</b> , 8, 219-225	
514	Roles of the physical environment in health-related quality of life in patients with chronic obstructive pulmonary disease. <b>2022</b> , 203, 111828	4
513	Epidemiological Study of Respiratory Diseases Among Dust Exposed Workers. <b>2022</b> , 438-449	
512	Clinical Assessment of the Patient With Respiratory Sleep Disorder. <b>2022</b> , 75-85	
511	Effects of the Health Belief Model-Based Intervention on Anxiety, Depression, and Quality of Life in Chronic Obstructive Pulmonary Disease. <b>2021</b> , 28, 129-136	1
510	Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. <b>2021</b> , 325, 59-68	16

509	Telerehabilitation for chronic respiratory disease. <b>2021</b> , 1, CD013040	32
508	Pulmonary hypertension in eosinophilic noneosinophilic COPD. <b>2021</b> , 7,	1
507	Comparing antibiotics for acute exacerbations of chronic obstructive pulmonary disease.	2
506	Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. <b>2018</b> , 12, CD012620	30
505	In-Hospital Databases. 244-258	7
504	Assessing Structure-Function Relations in Mice Using the Forced Oscillation Technique and Quantitative Histology. <b>2017</b> , 1639, 77-91	4
503	Sleep in Patients With Pulmonary Disease. <b>2007</b> , 171-189	1
502	Common Clinical Conditions in Long-Term Care. <b>2011</b> , 75-121	1
501	Skeletal Muscle Dysfunction. <b>2012</b> , 137-159	1
500	Automatic Segmentation and Measurement of the Lungs in healthy persons and in patients with Chronic Obstructive Pulmonary Disease in CT Images. <b>2007</b> , 370-373	2
499	Identification and Quantification of Pulmonary Emphysema through Pseudocolors. 2008, 957-964	5
498	Tele-Control at Home. <b>2012</b> , 171-183	1
497	NHG-Standaard COPD. <b>2011</b> , 1099-1127	0
496	Need for Portable Oxygen Titration During 6-Minute Walk Tests. <b>2019</b> , 55, 539-540	1
495	Susceptibility to frequent exacerbation in COPD patients: Impact of the exacerbations history, vaccinations and comorbidities?. <b>2020</b> , 169, 106018	4
494	Increased MUC1 plus a larger quantity and complex size for MUC5AC in the peripheral airway lumen of long-term tobacco smokers. <b>2020</b> , 134, 1107-1125	7
493	[Guideline for Long-Term Oxygen Therapy - S2k-Guideline Published by the German Respiratory Society]. <b>2020</b> , 74, 813-841	8
492	Optimizing chronic obstructive pulmonary disease management in primary care. <b>2011</b> , 104, 121-7	13

## (2016-2020)

491	Lung volume reduction eligibility in patients with COPD completing pulmonary rehabilitation: results from the UK National Asthma and COPD Audit Programme. <b>2020</b> , 10, e040942	1
490	Does this patient really have chronic obstructive pulmonary disease?. <b>2015</b> , 56, 194-6; quiz 197	2
489	Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. <b>2018</b> , 3,	19
488	The use of multidimensional indices. 143-160	1
487	The challenge of palliative care. 297-322	1
486	Impact of Integrated Care Model (ICM) on Direct Medical Costs in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD). <b>2017</b> , 23, 2850-2862	9
485	Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease. <b>2019</b> , 35, 500-505	6
484	TIMP-1 and MMP-9 expressions in COPD patients complicated with spontaneous pneumothorax and their correlations with treatment outcomes. <b>2020</b> , 36, 192-197	1
483	The role of mucolytics in COPD. <b>2006</b> , 2006,	1
482	Effects of Inhalable Microparticles of on Chronic Obstructive Pulmonary Disease in a Mouse Model. <b>2013</b> , 34, 54-68	6
481	Application of Taesikbub and Lung-doyinbub in ?Dong-Ui-Bo-Gam? as a Korean Traditional Pulmonary Rehabilitation Exercise. <b>2018</b> , 39, 41-50	4
480	Effects of GHX02 on Chronic Obstructive Pulmonary Disease Mouse Model. <b>2018</b> , 39, 126-135	3
479	Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. <b>2010</b> , 5, e13251	71
478	Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. <b>2012</b> , 7, e43892	116
477	Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. <b>2014</b> , 9, e89866	35
476	Pulmonary Impairment in Tuberculosis Survivors: The Korean National Health and Nutrition Examination Survey 2008-2012. <b>2015</b> , 10, e0141230	15
475	How Reliable Are Current Data for Assessing the Actual Prevalence of Chronic Obstructive Pulmonary Disease?. <b>2016</b> , 11, e0149302	10
474	Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial. <b>2016</b> , 11, e0156999	3

473	Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. <b>2016</b> , 11, e0160770	42
472	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. <b>2016</b> , 11, e0161129	16
471	Age-related changes in CD4+CD25+FOXP3+ regulatory T cells and their relationship with lung cancer. <b>2017</b> , 12, e0173048	18
470	Endothelial progenitor cells in chronic obstructive pulmonary disease and emphysema. <b>2017</b> , 12, e0173446	19
469	Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. <b>2017</b> , 12, e0180437	8
468	Impact of childhood wheezing on lung function in adulthood: A meta-analysis. <b>2018,</b> 13, e0192390	11
467	Trabecular bone score in active or former smokers with and without COPD. <b>2019</b> , 14, e0209777	3
466	CLINICAL EFFICACY OF NEBULIZED BUDESONIDE IN ACUTE EXACERBATION OF COPD. <b>2014</b> , 3, 4121-4131	1
465	Visual Assessment of CT Findings in Smokers With Nonobstructed Spirometric Abnormalities in The COPDGene Study. <b>2014</b> , 1, 88-96	9
464	Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. <b>2014</b> , 1, 23-32	22
463	The COPD Foundation Pocket Consultant Guide. <b>2014</b> , 1, 83-87	3
462	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. <b>2014</b> , 1, 229-238	30
461	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT Trial. <b>2015</b> , 2, 122-130	5
460	Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease. <b>2016</b> , 3, 653-667	8
459	The Short-term Impact of Symptom-defined COPD Exacerbation Recovery on Health Status and Lung Function. <b>2018</b> , 5, 27-37	8
458	Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnea syndrome. <b>2008</b> , 34, 567-74	13
457	Influñcia do tabagismo na for <b>à</b> muscular respirat <del>f</del> ia em idosos. <b>2012</b> , 19, 326-331	2
456	Clinical implications of airway hyperresponsiveness in COPD. <b>2006</b> , 1, 49-60	22

455	Apoptotic mechanisms in the pathogenesis of COPD. <b>2006</b> , 1, 161-71	43
454	Changing the burden of COPD mortality. <b>2006</b> , 1, 219-33	45
453	Newer fluoroquinolones in the treatment of acute exacerbations of COPD. <b>2006</b> , 1, 243-50	3
452	Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. <b>2006</b> , 1, 267-78	21
451	Biological targets for therapeutic interventions in COPD: clinical potential. <b>2006</b> , 1, 321-34	8
450	Strategies for improving outcomes of COPD exacerbations. <b>2006</b> , 1, 335-42	16
449	Pharmacological treatment of chronic obstructive pulmonary disease. <b>2006</b> , 1, 409-23	28
448	Role of N-acetylcysteine in the management of COPD. <b>2006</b> , 1, 425-34	44
447	Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. <b>2007</b> , 2, 11-8	10
446	Influenza infection and COPD. <b>2007</b> , 2, 55-64	45
445	Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens. <b>2020</b> , 27, 2931-2948	1
		-
444	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. <b>2009</b> , 3, 1-9	14
444		
	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. <b>2009</b> , 3, 1-9  Correlation of Plasma Protein Carbonyls and C-Reactive Protein with GOLD Stage Progression in	14
443	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. 2009, 3, 1-9  Correlation of Plasma Protein Carbonyls and C-Reactive Protein with GOLD Stage Progression in COPD Patients. 2009, 3, 61-6  Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with	14 17
443	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. 2009, 3, 1-9  Correlation of Plasma Protein Carbonyls and C-Reactive Protein with GOLD Stage Progression in COPD Patients. 2009, 3, 61-6  Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. 2010, 4, 86-91	14 17 12
443 442 441	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. 2009, 3, 1-9  Correlation of Plasma Protein Carbonyls and C-Reactive Protein with GOLD Stage Progression in COPD Patients. 2009, 3, 61-6  Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. 2010, 4, 86-91  Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD. 2012, 6, 150-4  Course of COPD Assessment Test (CAT) Scores During Bacterial Exacerbations of Chronic	14 17 12
443 442 441 440	Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification. 2009, 3, 1-9  Correlation of Plasma Protein Carbonyls and C-Reactive Protein with GOLD Stage Progression in COPD Patients. 2009, 3, 61-6  Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. 2010, 4, 86-91  Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD. 2012, 6, 150-4  Course of COPD Assessment Test (CAT) Scores During Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease Treated in Outpatient Setting. 2015, 9, 39-45  The differentiation of chronic obstructive pulmonary disease from asthma: a review of current	14 17 12 10

437	Support System for Early Diagnosis of Chronic Obstructive Pulmonary Disease Based on the Service-Oriented Architecture Paradigm and Business Process Management Strategy: Development and Usability Survey Among Patients and Health Care Providers. <b>2020</b> , 22, e17161	9
436	Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial. <b>2020</b> , 8, e18465	10
435	Evaluating a Web-Based Coaching Program Using Electronic Health Records for Patients With Chronic Obstructive Pulmonary Disease in China: Randomized Controlled Trial. <b>2017</b> , 19, e264	8
434	[Pulmonary rehabilitation in patients with chronic obstructive pulmonary disease]. 2008, 65, 533-8	1
433	omorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. <b>2019</b> , 91, 44-47	4
432	A randomised controlled study of Bronchoscopic Lung Volume Reduction with endobronchial valves for patients with Heterogeneous emphysema and Intact interlobar Fissures: the BeLieVeR-HIFi study. <b>2015</b> , 2, 1-34	3
431	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. <b>2019</b> , 23, 1-146	5
430	Health-Related Quality of Life and Related Factors in Persons with Preserved Ratio Impaired Spirometry: Data from the Korea National Health and Nutrition Examination Surve. <b>2020</b> , 57,	3
429	[Development of a patient-reported outcome scale for stable chronic obstructive pulmonary disease and its clinical applicability]. <b>2011</b> , 9, 857-65	2
428	Moxifloxacin in the Outpatient Treatment of Moderate Exacerbations of Chronic Obstructive Pulmonary Disease. <b>2018</b> , 6, 2017-2022	3
427	Determination of whether supplemental oxygen therapy is beneficial during exercise training in patients with COPD: A systematic review and meta-analysis. <b>2019</b> , 18, 4081-4089	8
426	Is hypercapnea a predictor of better survival in the patients who underwent mechanical ventilation for chronic obstructive pulmonary disease (COPD)?. <b>2006</b> , 21, 1-9	4
425	The association between airflow obstruction and radiologic change by tuberculosis. 2014, 6, 471-6	12
424	Oxygen therapy for COPD. <b>2014</b> , 6, 1632-9	6
423	Chronic obstructive pulmonary disease and obstructive sleep apnoea-the overlap syndrome. <b>2016</b> , 8, 236-42	20
422	Anesthetic considerations in the patients of chronic obstructive pulmonary disease undergoing laparoscopic surgeries. <b>2016</b> , 10, 7-12	9
421	Study the association of chronic obstructive pulmonary disease with early endothelial dysfunction and its impact on cardiovascular system by estimating urinary albumin creatinine ratio. <b>2017</b> , 34, 138-143	2
420	Squat-to-stand test in functional assessment of stable chronic obstructive pulmonary disease patients. <b>2017</b> , 34, 251-255	1

419	How appropriate is the gold standard for diagnosis of airway obstruction?. 2008, 25, 139-41	4
418	Forced Expiratory Volume in 6 s (FEV6) and FEV1/FEV6 Values as a Viable Alternative for Forced Vital Capacity (FVC) and FEV1/FVC Values During Pregnancy in South East Nigeria: A Preliminary Study. <b>2014</b> , 4, 516-21	2
417	The Effects of Statins on Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. <b>2017</b> , 6, 27-30	11
416	Balance training: its influence on pulmonary rehabilitation. <b>2019</b> , 24, 8-13	2
415	Functional and radiological characteristics of asthma combined chronic obstructive pulmonary disease overlap. <b>2019</b> , 13, 596-604	1
414	Effect of different classes of obesity on the pulmonary functions among adult Egyptians: a cross-sectional study. <b>2019</b> , 13, 510-515	1
413	Dyspnea, Eosinopenia, Consolidation, Acidemia and Atrial Fibrillation Score and BAP-65 Score, Tools for Prediction of Mortality in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Comparative Pilot Study. <b>2017</b> , 21, 671-677	11
412	Pulmonary Functions and Respiratory Symptoms of the Women Exposed to Mine Tailings. <b>2020</b> , 45, 311-314	1
411	Trial of Atorvastatin on Serum Interleukin-6, Total Antioxidant Capacity, C-Reactive Protein, and Alpha-1 Antitrypsin in Patients with Chronic Obstructive Pulmonary Disease. <b>2018</b> , 7, 141-146	1
410	Chronic obstructive pulmonary disease in adults with human immunodeficiency virus infection: a systematic review. <b>2011</b> , 03, 218-227	2
409	Effect of Inhaled Tiotropium as the Perioperative Management of Patients Undergoing Pulmonary Resection for Primary Lung Cancer. <b>2014</b> , 05, 845-859	2
408	Emphysema versus Chronic Bronchitis in COPD: Clinical and Radiologic Characteristics. <b>2014</b> , 04, 155-162	1
407	Systemic Inflammatory Markers and Disease Severity in Chronic Obstructive Pulmonary DiseaseâThe Effect of Acute Exercise and Pulmonary Rehabilitation. <b>2015</b> , 05, 19-31	2
406	Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease. <b>2017</b> , 34, 206-211	11
405	Assessment of a pharmacist-driven point-of-care spirometry clinic within a primary care physicians office. <b>2011</b> , 9, 221-7	12
404	Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. <b>2012</b> , 4, 66-71	8
403	Short-term effects of tiotropium on the pulmonary function and quality of life (QOL) in patients at risk and with mild chronic obstructive pulmonary disease (COPD). <b>2013</b> , 21, 14-19	2
402	Effect of Pulmonary Rehabilitation in Patients with Asthma COPD Overlap Syndrome: A Randomized Control Trial. <b>2020</b> , 35, e136	5

401	Airway Clearance with Expiratory Flow Accelerator Technology: Effectiveness of the "Free Aspire" Device in Patients with Severe COPD. <b>2019</b> , 20, 209-215	4
400	Evaluation of Indian Prediction Models for Lung Function Parameters: A Statistical Approach. <b>2019</b> , 85,	1
399	The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands. <b>2012</b> , 12, e191	12
398	The Most Common Detected Bacteria in Sputum of Patients with the Acute Exacerbation of COPD. <b>2013</b> , 25, 226-9	12
397	The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease. <b>2016</b> , 17, 41-46	9
396	Pre-treatment before coronary artery bypass surgery improves post-operative outcomes in moderate chronic obstructive pulmonary disease patients. <b>2013</b> , 24, 184-7	8
395	Managment acute exacerbation of chronic obstructive pulmonary disease. 2018, 24, 62-74	1
394	Daily activities are sufficient to induce dynamic pulmonary hyperinflation and dyspnea in chronic obstructive pulmonary disease patients. <b>2012</b> , 67, 319-25	21
393	Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. <b>2015</b> , 5, 020415	345
392	Global and regional estimates of COPD prevalence: Systematic review and metaâ\nalysis. 2015, 5,	438
391	Oxidative/Nitrosative stress and the pathobiology of chronic obstructive pulmonary disease. <b>2013</b> , 7, 580-8	14
390	Mathematically arterialised venous blood is a stable representation of patient acid-base status at steady state following acute transient changes in ventilation. <b>2021</b> , 1	
389	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. 2021,	1
388	A wearable eddy current based pulmonary function sensor for continuous non-contact point-of-care monitoring during the COVID-19 pandemic. <b>2021</b> , 11, 20144	1
387	From National to Regional Criteria for H-LTOT. <b>2005</b> , 27-41	1
386	Telemedicine and LTOT in Italy: a 20-Year Experience. <b>2005</b> , 69-83	4
385	Summary of international clinical recommendations on diagnosis and treatment of chronic obstructive lung disease. <b>2005</b> , 108-118	
384	Perfil radiolĝico do candidato ideal ^cirurgia redutora de volume pulmonar no enfisema: uma revis <b>®</b> sistem <b>ĉ</b> ica. <b>2005</b> , 31, 197-204	1

Pathophysiology of airflow limitation in COPD. 2005, 42-69 383 The clinical use of anticholinergics. 2005, 124-140 382 381 Anticholinergic Bronchodilators. 2005, 65-82 Bronchodilating therapy of stable chronic obstructive lung disease. 2005, 115-121 380 Criteri nazionali e regionali per lâBssigenoterapia domiciliare a lungo termine. 2006, 31-46 379 Telemedicina e OTLT in Italia: una Esperienza ventennale. 2006, 73-88 378 1 377 **2006**, 81-87 Lung Transplantation for Chronic Obstructive Pulmonary Disease. 2006, 103-162 376 Medikamentŝe Therapie der COPD. 2007, 249-255 375 Pulmonary disorders. 2007, 563-576 374 Perspektiven und Forschungspotenziale: COPD. 2007, 445-449 373 Community-Acquired Respiratory Complications in the Intensive Care Unit: Pneumonia and Acute 372 Exacerbations of COPD. 2007, 435-448 Rèntra<sup>†</sup> nement <sup>^</sup> l'effort de l'insuffisant respiratoire chronique obstructif. **2007**, 135-147 371 Sleep and respiratory disorders. 2007, 13-21 370 Recommendations for the management of cough in adults. 2007, 10-39 369 368 COPD as a systemic disease. 2007, 104-116 Reduction of exacerbations of COPD under long-term administration of N-acetylcysteine. 2007, 89-97 367 Effects of combined therapy with nebulized 2-agonist and anticholinergics in severe exacerbation 366 of chronic obstructive pulmonary disease. A randomized controlled trial. 2007, 56-65

365	Management of Chronic Obstructive Pulmonary Disease Exacerbations and Acute Bronchitis. 2008, 33-43	
364	Chronic Obstructive Pulmonary Disease: Epidemiology, Physiology, and Clinical Evaluation. <b>2008</b> , 491-516	
363	MEDICAL MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2008, 603-611	
362	Spezielle Therapieformen. <b>2008</b> , 623-700	
361	Prevalence of chronic obstructive pulmonary disease and its major risk factors among the inhabitants of high. <b>2008</b> , 51-56	
360	COPD and cardiovascular diseases: mechanisms of association. <b>2008</b> , 5-13	3
359	Efficacy and safety of short-acting anticholinergics in patients with acute exacerbation of chronic obstructive pulmonary disease receiving maintenance therapy with tiotropium. <b>2008</b> , 62-68	
358	Nutritional insufficiency in patients having chronic obstructive pulmonary disease. <b>2008</b> , 7, 14-19	
357	Drug therapy of stable chronic obstructive pulmonary disease. <b>2008</b> , 73-82	
356	Long-acting beta2-agonists for chronic obstructive pulmonary disease: serious adverse events. <b>2008</b> ,	
355	Invasive Mechanical Ventilation and Weaning at COPD Exacerbation. 2008, 315-328	
354	Risk Factors for Hospital Admission. <b>2008</b> , 239-252	
353	Combined therapy with ipratropium bromide and <b>Q</b> -agonists in exacerbation of chronic obstructive pulmonary disease. <b>2008</b> , 101-106	
352	About administration of nebulised suspension of budesonide on exacerbation of chronic obstructive pulmonary disease. <b>2008</b> , 94-100	
351	Non-invasive lung ventilation in acute respiratory failure in patients with chronic obstructive pulmonary disease. <b>2008</b> , 5-14	1
350	Effect of long-term treatment with tiotropium bromide on lung function in patients with chronic obstructive pulmonary disease (the UPLIFT trial). <b>2008</b> , 90-94	
349	Effects of fixed combinations of inhaled steroids and long-acting <b>Q</b> -agonists in chronic obstructive pulmonary disease. <b>2008</b> , 101-108	
348	NHG-Standaard COPD. <b>2009</b> , 301-329	

347	Apoptosis in Lung Injury and Disease. <b>2009</b> , 523-545	
346	Bronchopneumopathie chronique obstructive et activit°physique. <b>2009</b> , 205-220	
345	What Are the Benefits of Different Ventilatory Techniques?. <b>2009</b> , 148-155	
344	Chronic Obstructive Pulmonary Disease. <b>2009</b> , 131-139	
343	Rèntraî nement îl'effort de l'insuffisant respiratoire chronique obstructif. <b>2009</b> , 159-171	
342	Chronic Obstructive Airways Disease. <b>2009</b> , 29-40	
341	<del>四日                                    </del>	
340	Risk stratification in ambulatory patients with heart failure and chronic obstructive pulmonary disease: evaluation of predictive value of standard prognostic markers for 5-years survival. <b>2009</b> , 15, 132-137	0
339	Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. <b>2009</b> , 304-317	
338	Treatment of Stable COPD. <b>2009</b> , 357-386	
337	Interrelationships Between Periodontal Disease and Adverse Pregnancy Outcomes, Respiratory Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. <b>2010</b> , 159-190	
337	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer	
	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. <b>2010</b> , 159-190	
336	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. <b>2010</b> , 159-190  COPD Exacerbation. <b>2010</b> , 253-259	
336 335	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. 2010, 159-190  COPD Exacerbation. 2010, 253-259  Enfermedad pulmonar obstructiva crâica: Concepto, factores etiolâicos y patogenia. 2010, 171-177	
336 335 334	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. 2010, 159-190  COPD Exacerbation. 2010, 253-259  Enfermedad pulmonar obstructiva crâica: Concepto, factores etiolĝicos y patogenia. 2010, 171-177  Chronic Obstructive Pulmonary Disease and Acute Exacerbations. 2010, 877-883	O
336 335 334 333	Disease, Rheumatoid Arthritis, Renal Disease, Cancer, Infl ammatory Bowel Disease, Alzheimer Disease; Assessing Confounding and Effect Modification. 2010, 159-190  COPD Exacerbation. 2010, 253-259  Enfermedad pulmonar obstructiva crâica: Concepto, factores etiolĝicos y patogenia. 2010, 171-177  Chronic Obstructive Pulmonary Disease and Acute Exacerbations. 2010, 877-883  Asthma and Chronic Obstructive Pulmonary Disease. 2010, 362-375	0

329	Enfermedad pulmonar obstructiva cr <del>â</del> ica: Tratamiento en la fase estable. <b>2010</b> , 190-196
328	Pneumologie. <b>2010</b> , 201-229
327	Chronic Obstructive Pulmonary Disease. <b>2010</b> , 904-912
326	<del>四個用</del> <del>11<b>月2</b></del> 010, 13-65
325	<b>日便是即使工作</b> <b>2010</b> , 96-107
324	<del>阻 <b>似那%</b>-</del> - <del>即食<b>服2010</b>,</del> 102-106
323	Non-Pharmacological and Surgical Management of COPD. <b>2011</b> , 249-270
322	Management Guidelines for Chronic Obstructive Pulmonary Disease. <b>2011</b> , 81-98
321	Smoking Cessation. <b>2011</b> , 149-165
320	Exacerbations of COPD. <b>2011</b> , 191-209
319	Update on the management of chronic obstructive pulmonary disease. <b>2010</b> , 2, 2
319	Update on the management of chronic obstructive pulmonary disease. <b>2010</b> , 2,  Home Management Issues. <b>2011</b> , 211-224
318	Home Management Issues. <b>2011</b> , 211-224
318	Home Management Issues. 2011, 211-224  Clinical Assessment of COPD. 2011, 21-31
318 317 316	Home Management Issues. 2011, 211-224  Clinical Assessment of COPD. 2011, 21-31  Pharmacological Therapy: Novel Approaches. 2011, 129-147
318 317 316 315	Home Management Issues. 2011, 211-224  Clinical Assessment of COPD. 2011, 21-31  Pharmacological Therapy: Novel Approaches. 2011, 129-147  Outcome Measures and Prognostic Markers for COPD. 2011, 59-79

311	il paziente arretto da BPCO. <b>2011</b> , 91-110	0
310	Psychological Co-morbidities of COPD. <b>2011</b> , 415-453	
309	SELECTED REFERENCES. 2011, 311-315	
308	Postoperative Respiratory Failure and Treatment. <b>2011</b> , 609-633	1
307	Chronic Obstructive Pulmonary Disease. <b>2011</b> , 634-642	
306	Effectiveness of perioperative management in our hospital: two cases of lung cancer complicated by COPD and an advanced age. <b>2011</b> , 25, 800-805	
305	New pharmacological treatments for patients with chronic obstructive pulmonary disease (COPD). <b>2011</b> , 155, 43-50	
304	omparative characteristics of induced sputum cellular composition in patients with mild and moderate stable COPD, patients with chronic bronchitis and smokers. <b>2011</b> , 19, 83	
303	[Concept and significance of a subjective and multiple index system of clinical evaluation for traditional Chinese medicine]. <b>2011</b> , 9, 588-91	
302	Inactivity. <b>2012</b> , 161-170	
301	Pharmacologic Treatment Strategies. <b>2012</b> , 211-252	
300	The Respiratory System. <b>2012</b> , 321-394	
299	Netter Collection, Medizinischer Atlas, Atmungssystem - Pages 313-319. <b>2012</b> , 313-319	
298	Bronchopneumopathie chronique obstructive et place de la ventilation non invasive chez la personne ĝie en ranimation. <b>2012</b> , 261-277	
297	Effect of Impaired Lung Function on the Development and Progression of Endobronchial Premalignant Lesions. <b>2012</b> , 03, 364-371	
296	The Cooperating Roles: The Lung Physician. <b>2012</b> , 105-115	
295	The Patient Candidate for Long-Term Oxygen Therapy. <b>2012</b> , 1-32	
294	The factors affecting the poor walking distance which reflect restrictions on going out in patients with chronic obstructive pulmonary disease <b>2012</b> , 2, 107-112	

293	âllriple Therapyâlln the Management of COPD: Inhaled Steroid, Long-Acting Anticholinergic and Long-Acting <b>Q</b> -Agonist. 333-342
292	Long- And Ultra-Long-Acting <b>Q</b> 2-Agonists. 81-101
291	Long-acting beta2-agonists for chronic obstructive pulmonary disease: serious adverse events.
290	Long-acting therapy for chronic obstructive pulmonary disease: an overview.
289	Determina <b>n</b> do limiar anaer <b>n</b> io pela variabilidade da frequñcia card <b>a</b> ca de pacientes com DPOC durante exercĉio em cicloerg <b>a</b> etro. <b>2012</b> , 25, 717-725
288	What Is the Role of Opioids in Treatment of Refractory Dyspnea in Advanced Chronic Obstructive Pulmonary Disease?. <b>2013</b> , 111-119
287	Immunopathology of COPD. <b>2013</b> , 1-27
286	Respiratory Physiotherapy in a Web Browser, Feasibility Study. <b>2013</b> , 03, 150-153
285	Chronic Obstructive Pulmonary Disease. <b>2013</b> , 138-145
284	TO STUDY THE RISK OF CARDIOVASCULAR MORBIDITY & MORTALITY IN STABLE COPD PATIENTS. <b>2013</b> , 2, 1088-1110
283	Current Pharmacotherapy for COPD. <b>2014</b> , 1-23
282	Phase III Clinical Efficacy of Indacaterol: Patient-Centered Outcomes. <b>2014</b> , 107-115
281	Postoperative Respiratory Failure after Major Abdominal Surgery: Definition, Diagnosis and Prevention. <b>2014</b> , 43-60
280	Overlap Syndrome. <b>2013</b> , 4, 37-42
279	Pharmacological Treatment: an Update. <b>2014</b> , 311-321
278	Effect of Pulmonary Rehabilitation on Dyspnea. <b>2014</b> , 193-206
277	Perioperative Care of the Orthopedic Patient with Chronic Pulmonary Disease. <b>2014</b> , 139-149
276	The COPD Foundation: Celebrating a Decade of Progress and Looking Ahead to a Cure. <b>2014</b> , 1, 4-16

Introduction to Oxidative Stress and Antioxidant Therapy in Respiratory Disorder. 2014, 1-26 275 Participaciñ de las metaloproteinasas de matriz extracelular en la EPOC. 2014, 73, 128-137 274 Encyclopedia of Medical Immunology. 2014, 238-240 273 Pathophysiology of Chronic Obstructive Pulmonary Disease. 2014, 339-352 272 TO STUDY THE RISK OF CARDIOVASCULAR MORBIDITY & MORTALITY IN STABLE COPD PATIENTS 271 BASED ON ESTABLISHED CARDIOVASCULAR RISK FACTORS IN CENTRAL INDIA, 2014. 3, 2434-2444 Shescence cellulaire et physiopathologie des maladies respiratoires chroniques : ría dans la bronchopneumopathie chronique obstructive. 2014, 198, 659-671 Efficacy and Tolerability of Eight Antimicrobial Regimens in the Outpatient Treatment of 269 Exacerbations of Chronic Obstructive Pulmonary Disease. 2014, 2, 519-524 268 COPD Exacerbation. **2015**, 373-379 Aplicaciñ del test de caminata de 6 minutos en la valoraciñ del sujeto con EPOC. 2014, 1, 120 267 The impact of pulmonary functions on outcome of intubated patients with chronic obstructive 266 pulmonary disease. 2015, 9, 125-132 Anesthetic Considerations for Patients with Respiratory Disease. 49-60 265 COPD (summary). 264 Prevalence of chronic respiratory disorders in a rural area of North West India: A population-based 263 3 study. 2016, 5, 416-419 Bronchopneumopathie chronique obstructive et activit'physique. 2016, 267-294 262 Combined Pulmonary Fibrosis and Emphysema (CPFE). 2016, 205-215 261 Severity of Chronic Obstructive Pulmonary Disease and the Prognosis of Non-Small Cell Lung 260 Cancer Patients. 2016, 05, 13-20 Chronic Obstructive Pulmonary Disease Following Bronchopulmonary Dysplasia. 2016, 93-105 259 Time and Economic Burden of Comorbidities Among COPD Inpatients. 2016, 187-195 258

257	SLEEP STUDIES IN COPD PATIENTS. <b>2016</b> , 5, 1759-1762	
256	Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 1). <b>2016</b> , 26, 153-179	
255	Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2). <b>2016</b> , 26, 267-291	
254	Influence of Different Body Positioning on Dynamic Lung Functions in Chronic Obstructive Pulmonary Disease Patients and in Normal Subjectsâ Comparative Study. <b>2016</b> , 5,	
253	Chronic obstructive pulmonary disease. <b>2016</b> , 59-71	1
252	Role of mean platelet volume in patients with chronic obstructive pulmonary disease. <b>2016</b> , 10, 251-260	
251	Diagnosis of chronic obstructive pulmonary disease professional genesis with the data updated version GOLD 2016. <b>2016</b> , 2016, 21-31	O
250	Pneumologie. <b>2017</b> , 371-425	
249	Occupational Health Surveillance: Lung Function Testing in Seafood Workers. <b>2016</b> , 11, 825-833	
248	Phenotypes of COPD. <b>2017</b> , 147-168	
247	Pharmacological Therapy and Anxiolytics in Patients with Respiratory Diseases. 2017, 167-182	
247 246	Pharmacological Therapy and Anxiolytics in Patients with Respiratory Diseases. 2017, 167-182  Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images Using Convolutional Neural Network.	
	Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images	
246	Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images Using Convolutional Neural Network.  TO STUDY THE CORRELATION BETWEEN SPIROMETRY AND CAT SCORE IN PATIENTS OF COPD.	
246 245	Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images Using Convolutional Neural Network.  TO STUDY THE CORRELATION BETWEEN SPIROMETRY AND CAT SCORE IN PATIENTS OF COPD.  2017, 6, 1636-1638	
246 245 244	Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images Using Convolutional Neural Network.  TO STUDY THE CORRELATION BETWEEN SPIROMETRY AND CAT SCORE IN PATIENTS OF COPD. 2017, 6, 1636-1638  Utility Inspiratory Capacity by Simple Spirometry as an indirect Measure of Air Trapping. 2017, 3, 007-010  Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary	
246 245 244 243	Computer Aided Diagnosis System for Chronic Obstructive Pulmonary Disease from CT Images Using Convolutional Neural Network.  TO STUDY THE CORRELATION BETWEEN SPIROMETRY AND CAT SCORE IN PATIENTS OF COPD.  2017, 6, 1636-1638  Utility Inspiratory Capacity by Simple Spirometry as an indirect Measure of Air Trapping. 2017, 3, 007-010  Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary Emphysema. 2017, 3, 001-006  ASSOCIATION OF ELEVATED CARDIAC BIOMARKERS WITH MORTALITY AFTER ACUTE	

239	CLINICAL EVALUATION OF NEBULISED BUDESONIDE IN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASEÂ RANDOMISED STUDY. <b>2017</b> , 6, 6561-6565	
238	HRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE CLEAN-UP WORKERS OF CHORNOBYL NPP ACCIDENT IN A REMOTE POST6ACCIDENT PERIOD (CLINICAL STUDY). <b>2018</b> , 23, 490-498	1
237	Effects of Aging and Smoking Duration on Cigarette Smoke-Induced COPD Severity. 2018, 33,	
236	[Sleep and its' disturbanses in chronic obstructive pulmonary disease]. 2018, 118, 113-118	
235	The role of lactate clearance on deciding discharge in exacerbation of chronic obstructive pulmonary disease: Retrospective cohort study.	
234	Spirometric Values of Greek People and Comparison with ECSC and GLI Values in COPD People. <b>2018</b> , 12, 29-38	Ο
233	Outcome of pulmonary rehabilitation in patients with stable chronic obstructive pulmonary disease at Chest Department, Zagazig University Hospitals (2014âØ016). <b>2018</b> , 12, 279-287	1
232	Diagnosis of Chest Diseases Using Artificial Neural Networks. <b>2019</b> , 113-119	
231	Using multiphoton microscopy to assess pulmonary emphysema in mouse models. 2018,	
	Kronik Obstrβtif Akciër Hastalar– ile Sal-kl– Bireylerin Solunum l <b>Yβββ</b> Termodinamik Analizi. 145-151	
230	KTOTIK ODSCI <b>B</b> CII AKCIBI HASCAIAI – NE SALFKI – BITEYIETIN SOLUTIUNI L <b>I BPP</b> TETINOUNIAINIK AHALIZI. 145-151	2
229	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. <b>2018</b> , 20,	1
	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded,	
229	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. <b>2018</b> , 20,	
229	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. 2018, 20,  Chronic Obstructive Pulmonary Disease. 2019, 121-138  Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical	1
229 228 227	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. 2018, 20,  Chronic Obstructive Pulmonary Disease. 2019, 121-138  Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice. 2019, 96-104	1
229 228 227 226	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. 2018, 20,  Chronic Obstructive Pulmonary Disease. 2019, 121-138  Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice. 2019, 96-104  Pruebas de funcià respiratoria, ¿cuèy a quih?. 2019, 78, 81-96	1
229 228 227 226	Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. 2018, 20,  Chronic Obstructive Pulmonary Disease. 2019, 121-138  Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice. 2019, 96-104  Pruebas de funciñ respiratoria, ¿cuèy a quiñ?. 2019, 78, 81-96  Evaluating Cognition in Patients with Chronic Obstructive Pulmonary Disease. 2019, 661-674  Safety and efficacy of Azithromycin in prevention of chronic obstructive pulmonary disease	1

221	Blood circulation in the lungs: radiologic methods of diagnosing microcirculation changes in the small circle of circulation. <b>2019</b> , 18, 5-16	
220	B-type natriuretic peptide as a predictor of severity in admitted patients with acute exacerbation of COPD. <b>2019</b> , 13, 289-297	
219	Assessment of Pulmonary Function, Nutritional Status and Quality of Life of Elderly Men with COPD- A Pilot Study. <b>2019</b> , 8, 2568-2572	
218	Usefulness of different prognostic scores for AECOPD: APACHE II, BAP65, 2008, and CAPS scores. <b>2019</b> , 13, 498-504	
217	Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients. <b>2019</b> , 13, 610-615	
216	YalFlarda Koah Ve Beslenme Yakla⊞mlar <sup>_</sup> .	
215	Association between comorbid conditions and mortality of patients administred to the intensive care unit in acute exacerbations of chronic obstructive pulmonary disease. <b>2020</b> , 2020, 97-102	
214	EVALUATION OF THE QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN OVERWEIGHT PATIENTS. <b>2020</b> , 73, 1668-1670	
213	Inspiratory muscle training combined with pursed lip technique in women with chronic obstructive pulmonary disease: a case study. <b>2020</b> , 56, 116-127	
212	Impact of Outpatient Prescribing of Antibiotics for Acute Exacerbation of Chronic Obstructive Pulmonary Disease on 30-Day Re-exacerbation Rates. <b>2020</b> , Publish Ahead of Print,	
211	Endoscopic Treatment of Chronic Obstructive Pulmonary Disease. <b>2022</b> , 468-487	
<b>2</b> 10	ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial Setting. <b>2020</b> , 7, 118-129	
209	Motive, die Alkohol- und/oder Tabakabhñgige zum Arzt fβren. <b>2020</b> , 131-171	
208	Chronic obstructive pulmonary disease. <b>2020</b> , 4098-4141	
207	Future Call for Renewed Vision on Pulmonary Rehabilitation Service Beyond COVID-19.	
206	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. <b>2020</b> , 201, 473-481	
205	Motives of Alcohol- and/or Tobacco-Addicted Patients to Seek Medical Help. <b>2020</b> , 129-180	
204	Emerging Nanotechnology in Chronic Respiratory Diseases. <b>2020</b> , 449-468	

203	Perioperative Care of the Orthopedic Patient with Chronic Pulmonary Disease. <b>2020</b> , 183-193	
202	An analysis of how senior students of the Medical Institute know basic concepts of bronchopulmonary system diseases. <b>2020</b> , 9, 240-245	
201	Therapie bronchopulmonaler Erkrankungen. 309-355	
200	Screening and case finding. 1-25	
199	Nutrition et insuffisance respiratoire. <b>2007</b> , 849-866	
198	Bronchiektasen. <b>2007</b> , 1105-1110	
197	The deleterious effects of chronic obstructive pulmonary disease and obstructive sleep apnea: pathophysiology and implications on treatment. <b>2020</b> , 14,	О
196	Chronic Obstructive Pulmonary Disease Patients Treated with Korean Medicine Pulmonary Rehabilitation: Two case reports. <b>2020</b> , 41, 162-172	2
195	The impact of occupational and other environmental exposures on the aetiology of COPD, bronchitis and bronchiolitis. <b>2020</b> , 86-103	
194	PULMONER HASTALIKLARDA TELEREHABŪĪTASYON.	
193	Sarcopenia in older people with chronic airway diseases: the Rotterdam study. 2021, 7,	1
192	Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial. <b>2006</b> , 8, 86	1
191	Tackling COPD: a multicomponent disease driven by inflammation. <b>2006</b> , 8, 54	9
190	Inhaled corticosteroids and mortality in COPD: are we there yet?. <b>2006</b> , 61, 735	1
189	Differential assessment and management of asthma vs chronic obstructive pulmonary disease. <b>2009</b> , 11, 20	19
188	Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. <b>2009</b> , 4, 119-25	8
187	Clinical applications of azithromycin microspheres in respiratory tract infections. 2007, 2, 551-9	13
186	Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. <b>2009</b> , 4, 185-201	6

185	Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. <b>2007</b> , 2, 335-45	12
184	Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. <b>2007</b> , 2, 263-72	29
183	Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. <b>2007</b> , 2, 329-34	12
182	Comparison and optimal use of fixed combinations in the management of COPD. <b>2007</b> , 2, 107-16	2
181	Fixed combination therapies in COPDeffect on quality of life. <b>2007</b> , 2, 551-7	
180	Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. <b>2007</b> , 2, 453-62	36
179	Genetics of chronic obstructive pulmonary disease. <b>2007</b> , 2, 541-50	17
178	Usefulness of inspiratory capacity measurement in COPD patients in the primary care setting. <b>2009</b> , 2, 219-25	3
177	Improved health-related quality of life after lung volume reduction surgery and pulmonary rehabilitation. <b>2009</b> , 20, 16-22	1
176	Lung volume reduction surgery and pulmonary rehabilitation improve exercise capacity and reduce dyspnea during functional activities in people with emphysema. <b>2009</b> , 20, 5-12	1
175	Frequency of the mdr-1 C>T gene polymorphism in patients with COPD. <b>2010</b> , 65, 1115-7	4
174	Identifying adults at risk of COPD who need confirmatory spirometry in primary care: Do symptom-based questions help?. <b>2011</b> , 57, e51-7	9
173	Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. <b>2010</b> , 2, 25-36	6
172	Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. <b>2012</b> , 37, 149-61	16
171	Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. <b>2012</b> , 12, 1-64	6
170	Sleep-disordered breathing and COPD: the overlap syndrome. <b>2010</b> , 55, 1333-44; discussion 1344-6	71
169	Systemic inflammation in peripheral arterial disease with or without coexistent chronic obstructive pulmonary disease: analysis of selected markers. <b>2012</b> , 8, 477-83	11
168	Chronic obstructive pulmonary disease. <b>2013</b> , 137, 251-69	39

167	Relationship between serum vitamin D and forced expiratory volume in patients with chronic obstructive pulmonary disease (COPD). <b>2012</b> , 3, 451-5	8
166	The view of patients with Choronic Obstructive Pulmonary Disease (COPD) on Complementary and Alternative Medicine (CAM) in Eastern Turkey. <b>2013</b> , 10, 116-21	2
165	The Effect of Amlodipine and Sildenafil on the NT-ProBNP Level of Patients with COPD-Induced Pulmonary Hypertension. <b>2014</b> , 13, 161-8	4
164	The association between forced expiratory volume in one second (FEV1) and pulse oximetric measurements of arterial oxygen saturation (SpO2) in the patients with COPD: A preliminary study. <b>2014</b> , 19, 257-61	4
163	Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis. <b>2014</b> , 5, 71-86	8
162	Presence of depression and its risk factors in patients with chronic obstructive pulmonary disease. <b>2014</b> , 139, 402-8	10
161	Chronic obstructive pulmonary disease: an overview. <b>2008</b> , 1, 34-42	10
160	Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette Smoke. <b>2012</b> , 11, 6-17	2
159	The role of Interleukin 15 in protein degradation in skeletal muscles in rats of chronic obstructive pulmonary disease. <b>2015</b> , 8, 1976-84	1
158	Efficacy of a simple and inexpensive exercise training program for advanced chronic obstructive pulmonary disease patients in community hospitals. <b>2015</b> , 7, 637-43	3
157	Budesonide mitigates pathological changes in animal model Of COPD through reducing neutrophil elastase expression. <b>2015</b> , 8, 5227-35	1
156	Eosinopenia as a Marker of Outcome in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <b>2015</b> , 10, 10-3	12
155	Telomere Shortening in Blood Leukocytes of Patients with Chronic Obstructive Pulmonary Disease. <b>2015</b> , 14, 10-6	4
154	Coaching patients during pulmonary function testing: A practical guide. <b>2015</b> , 51, 65-8	8
153	Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease. <b>2015</b> , 31, 325-36	7
152	The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials. <b>2016</b> , 30, 332	
151	Efficacy and safety of conventional long acting $\mathbf{Q}$ - agonists: systematic review and meta-analysis. <b>2016</b> , 7, 64-70	
150	Pharmacological Management and Prevention Of Exacerbations of Chronic Obstructive Pulmonary Disease in Hospitalized Patients. <b>2016</b> , 41, 703-712	2

149	Anthropometric Indicators Associated with Dyspnea and Spirometric Parameters in Patients with Chronic Obstructive Pulmonary Disease. <b>2016</b> , 15, 134-140	1
148	Quality of Chronic Obstructive Pulmonary Disease-Related Health Care in Rural and Urban Veterans Affairs Clinics. <b>2017</b> , 34, 27-32	2
147	Flow and volume response to bronchodilator in patients with COPD. <b>2018</b> , 89, 332-336	4
146	Temporary remission of autoimmune pulmonary alveolar proteinosis after infectious episodes. <b>2017</b> , 34, 85-90	
145	Pulmonary hypertension: From an orphan disease to a global epidemic. <b>2020</b> , 2020, e202005	3
144	Effect of chronic obstructive pulmonary disease combined with ventilator-associated pneumonia on patient outcomes: A systematic review and meta-analysis. <b>2020</b> , 20, 273	2
143	Impact of Air Pollution Generated by Brick Kilns on the Pulmonary Health of Workers. <b>2021</b> , 11, 210906	
142	Prognostic value of the five-repetition sit-to-stand test for mortality in people with chronic obstructive pulmonary disease. <b>2021</b> , 65, 101598	1
141	Evaluation of the cross-sectional area of small pulmonary vessels in the diagnosis of chronic obstructive pulmonary disease by quantitative computed tomography: A case-control study. <b>2021</b> , 100, e27622	
140	The influence of HIV infection and antiretroviral treatment on pulmonary function in individuals in an urban setting in sub-Saharan Africa. <b>2021</b> , 22, 1312	
139	Determinants of acute care discharge in adults with chronic obstructive pulmonary disease. <b>2021</b> , 1-10	
138	Association of Patient and Primary Care Provider Factors with Outpatient COPD Care Quality <b>2021</b>	O
137	<del>明期間</del> <del>明 1                                   </del>	
136	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Lowand Middle-Income Country Settings <b>2022</b> , 327, 151-160	5
135	Telomere length in chronic obstructive pulmonary disease. <b>2015</b> , 9, 20-26	2
134	Pulmonary hypertension: From an orphan disease to a global epidemic. <b>2020</b> , 2020, e202005	4
133	Effect of chronic obstructive pulmonary disease combined with ventilator-associated pneumonia on patient outcomes: A systematic review and meta-analysis. <b>2020</b> , 20, 1-1	2
132	Sleep-related hypoventilation and hypercapnia in multiple system atrophy detected by polysomnography with transcutaneous carbon dioxide monitoring <b>2022</b> , 1	O

131	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. <b>2022</b> , 23,	1
130	Effects of Home-Based Pulmonary Rehabilitation on Dyspnea, Exercise Capacity, Quality of Life and Impact of the Disease in COPD Patients: A Systematic Review <b>2022</b> , 1-29	O
129	Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio 2022, 9, 103-110	
128	The Effects of an Acceptance and Commitment-Informed Interdisciplinary Rehabilitation Program for Chronic Airway Diseases on Health Status and Psychological Symptoms <b>2021</b> , 12, 818659	O
127	IoT Based Delivery System for demand and supply chain of Oxygen Concentrators. 2022,	O
126	Haplotypes in the , and Genes and Biomarkers of Bone Mineral Metabolism in Older Adults <b>2022</b> , 14,	
125	Gender differences in specific trends of COPD mortality in Croatia. <b>2021</b> , 202, 26-31	1
124	Improved Detection of Chronic Obstructive Pulmonary Disease at Chest CT Using the Mean Curvature of Isophotes <b>2022</b> , 4, e210105	1
123	Telemedicine as a Means to an End, Not an End in Itself <b>2022</b> , 12,	О
122	Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort <b>2022</b> ,	4
121	Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias <b>2021</b> , 2021, 4595019	О
120	Sleep patterns in table chronic obstructive pulmonary disease patients at a tertiary care center: a hospital-based observational study. <b>2022</b> , 10, 32	
119	Quantitative assessment the longitudinal changes of pulmonary vascular counts in chronic obstructive pulmonary disease <b>2022</b> , 23, 29	Ο
118	Characteristics of Obese Patients with Acute Hypercapnia Respiratory Failure Admitted in the Department of Pneumology: An Observational Study of a North African Population <b>2022</b> , 2022, 5398460	
117	Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis <b>2022</b> , 14, 278-294	O
116	Sleep-Related Breathing Complaints in Chronic Obstructive Pulmonary Disease <b>2022</b> , 17, 99-109	Ο
115	Profile of Clinical and Analytical Parameters in Bronchiectasis Patients during the COVID-19 Pandemic: A One-Year Follow-Up Pilot Study <b>2022</b> , 11,	O
114	Stronger correlation of peak oxygen uptake with distance of incremental shuttle walk test than 6-min walk test in patients with COPD: a systematic review and meta-analysis <b>2022</b> , 22, 102	3

113	Diagnostic value of pulmonary ultrasound in acute exacerbation of chronic obstructive pulmonary disease: A pilot study <b>2022</b> ,	O
112	Lung function impairment in relation to cognition and vascular brain lesions: the Rotterdam Study <b>2022</b> , 1	1
111	Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis <b>2022</b> , 2022, 1107673	
110	Pulmonary Function and Psychological Burden Three Months after COVID-19: Proposal of a Comprehensive Multidimensional Assessment Protocol <b>2022</b> , 10,	О
109	The double bronchodilation era: new capabilities in a new drug delivery device. 2022, 128-137	
108	Treatment with JianPiYiFei II granules for patients with moderate to very severe chronic obstructive pulmonary disease: A 52-week randomised, double-blinded, placebo-controlled, multicentre trial <b>2022</b> , 100, 154057	
107	Low QRS Voltage in Limb Leads Indicates Accompanying Precordial Voltage Attenuation Resulting in Underestimation of Left Ventricular Hypertrophy <b>2021</b> , 18,	
106	Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study <b>2022</b> , 8,	1
105	Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team <b>2021</b> , 1-8	
104	Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease <b>2021</b> , 2021, 3800211	1
103	Association between Lung Function and New-Onset Diabetes Mellitus in Healthy Individuals after a 6-Year Follow-up <b>2021</b> ,	1
102	A retrospective correlative profiling of lung functions, microbiological, radiological, periodontal, hematological parameters in noncystic fibrosis bronchiectasis patients of North India. <b>2022</b> , 13, 44	
101	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS) <b>2022</b> , 23, 307	1
100	Impairment of scapular control in individuals with chronic obstructive pulmonary disease (COPD): Systematic review and meta-analysis <b>2022</b> , 1-16	O
99	Effects of SOCS1-overexpressing dendritic cells on Th17- and Treg-related cytokines in COPD mice <b>2022</b> , 22, 145	О
98	Impact of Air Pollution Generated by Brick Kilns on the Pulmonary Health of Workers. <b>2021</b> , 11, 210906	О
97	Risk Factors Analysis and Clinical Decision of COPD Based on Machine Learning. 2022,	
96	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective <b>2022</b> , 39, 2302-2322	O

95	RAGE signaling during tobacco smoke-induced lung inflammation and potential therapeutic utility of SAGEs <b>2022</b> , 22, 160	
94	Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications <b>2022</b> , 1	1
93	ECG of the Month <b>2022</b> , 1-3	
92	Association of Reduced BMI, length of hospital stay, mortality, and malnutrition diagnosis in COPD patients with acute exacerbation: A secondary analysis of a cohort study <b>2022</b> ,	
91	Pulmonary emphysema quantification at low dose chest CT using Deep Learning image reconstruction <b>2022</b> , 152, 110338	
90	Structural and functional alterations of subjects with cement dust exposure: A longitudinal quantitative computed tomography-based study <b>2022</b> , 837, 155812	
89	High-flow nasal cannula improves respiratory impedance evaluated by impulse oscillometry in chronic obstructive pulmonary disease patients: a randomised controlled trial <b>2022</b> , 12, 6981	О
88	Lung cancer screening in clinical practice: identification of high-risk chronic obstructive pulmonary disease patients. <b>2022</b> , 68, 502-506	O
87	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. 1-67	О
86	Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. <b>2022</b> , 22,	1
85	Patientsâland their caregiversâlexperiences with regular, low-dose, sustained-release morphine for chronic breathlessness associated with COPD: a qualitative study. <b>2022</b> , 9, e001210	1
84	Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study. <b>2022</b> , 13,	Ο
83	Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: A scoping review. <b>2022</b> ,	1
82	Is There an Association Between Chronic Obstructive Pulmonary Disease and Chronic Renal Failure?. <b>2022</b> ,	
81	The Six-Minute Stepper Test Is Valid to Evaluate Functional Capacity in Hospitalized Patients With Exacerbated COPD. 13,	1
80	Lung disease burden assessment by oscillometry in a systematically disadvantaged urban population experiencing homelessness or at-risk for homelessness in Ottawa, Canada from a prospective observational study. <b>2022</b> , 22,	Ο
79	Outpatient Pulmonary Rehabilitation in Severe Chronic Obstructive Pulmonary Disease. <b>2022</b> , 52, 197-201	2
78	Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools. <b>2022</b> , 13,	2

77	Impact of Obstructive Sleep Apnea (OSA) in COVID-19 Survivors, Symptoms Changes Between 4-Months and 1 Year After the COVID-19 Infection. 9,	1
76	Development and applicability of a dignity-centred palliative care programme for people with idiopathic pulmonary fibrosis: A qualitative-driven mixed methods study.	
75	Application of artificial intelligence in the diagnosis of pulmonary emphysema. 2022,	
74	Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Causes and Impacts. <b>2022</b> , 56, 93-104	4
73	Pathophysiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap. 2022,	
72	Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. <b>2022</b> , 32, 356-392	3
71	Federal guidelines on diagnosis and treatment of chronic bronchitis. 2022, 32, 448-472	
70	What Are the Benefits of Different Ventilatory Techniques?. <b>2023</b> , 231-240	
69	Epidemiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap. <b>2022</b> , 42, 533-547	
68	Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease. <b>2022</b> , 17, e0273170	
67	Standardization of the assessment process within telerehabilitation in chronic diseases: a scoping meta-review. <b>2022</b> , 22,	
66	Comparative Evaluation of Fine Particle Fraction and T2 Fraction by Using Next Generation Impactor (NGI) and Glass Twin Impinger (GTI) on Formoterol Fumarate and Tiotropium Dry Powder Inhaler (DPI) Marketed Products.	
65	Importancia de los virus en las exacerbaciones de Enfermedad Pulmonar Obstructiva Crâica (EPOC). ¿Podrâ cambiar su comportamiento durante la pandemia de SARS-COV-2 (COVID-19)?. <b>2022</b> , 29, 65-78	
64	Urban environment and physical activity and capacity in patients with chronic obstructive pulmonary disease. <b>2022</b> , 214, 113956	О
63	Breath Analysis as Part of Pulmonary Function Diagnostics. 2022,	O
62	Breathing Pattern Estimation Using Wearable Bioimpedance for Assessing COPD Severity. 2022, 1-10	Ο
61	Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study. <b>2022</b> , 39, 408	O
60	A real-world cost-effectiveness analysis of nebulized budesonide and intravenous methylprednisolone in acute exacerbation of chronic obstructive pulmonary disease. 13,	О

59	Prevalence of Chronic Obstructive Pulmonary Disease in an Urban Area. Changes in COPD Ten Years on. Volume 17, 2431-2441	0
58	Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease. <b>2022</b> , 23,	0
57	Clinical Changes of Respiratory Parameters in Institutionalized Older Adults after a Physiotherapy Program Combining Respiratory and Musculoskeletal Exercises. <b>2022</b> , 10, 1680	0
56	Neisseria species as pathobionts in bronchiectasis. <b>2022</b> , 30, 1311-1327.e8	1
55	Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study. <b>2022</b> , 12,	0
54	Clinical assessment of balance and functional impairments in people with stable chronic obstructive pulmonary disease: A Systematic Review and Meta-Analysis. 00164-2022	О
53	High blood urea nitrogen to creatinine ratio is associated with increased risk of sarcopenia in patients with chronic obstructive pulmonary disease. <b>2022</b> , 169, 111960	О
52	Investigation of ocular microstructural changes according to disease severity in patients with chronic obstructive pulmonary disease. <b>2022</b> ,	O
51	Frailty transitions in older persons with lung function impairment: a population-based study.	О
50	Transcription Factor p300 Regulated miR-451b Weakens the Cigarette Smoke Extract-Induced Cellular Stress by Targeting RhoA/ROCK2 Signaling. <b>2022</b> , 2022, 1-18	О
49	How and when to manage respiratory infections out of hospital. 2022, 31, 220092	О
48	Study of correlation of red cell distribution width with acute exacerbation of chronic obstructive pulmonary disease. <b>2022</b> , 7, 108-115	О
47	The role of brain inflammation and abnormal brain oxygen homeostasis in the development of hepatic encephalopathy.	О
46	Habitual fish oil supplementation and incident chronic obstructive pulmonary disease: Data from a prospective cohort study. <b>2022</b> , 41, 2651-2658	O
45	Effects of scapulothoracic exercises on chest mobility, respiratory muscle strength, and pulmonary function in male COPD patients with forward shoulder posture: a randomized control trial. 11, 1284	О
44	A Telemedicine Approach for Monitoring COPD: A Prospective Feasibility and Acceptability Cohort Study. Volume 17, 2931-2944	o
43	Impact of high-risk of obstructive sleep apnea on chronic cough: data from the Korea National Health and Nutrition Examination Survey. <b>2022</b> , 22,	О
42	Prediction of exercise-induced desaturation in COPD patients without resting hypoxemia: a retrospective study. <b>2022</b> , 22,	O

41	Interpretation of Spirometry: Selection of Predicted Values and Defining Abnormality. 2022, 57, 91-105	1
40	A Study on Microalbuminuria in Patients with Chronic Obstructive Pulmonary Disease at a Tertiary Care Centre in North India. <b>2022</b> , 59, 17-21	0
39	Clinical and functional characteristics of patients with chronic obstructive pulmonary disease and bronchiectasis: results of a 10-year prospective observational study. <b>2022</b> , 25, 54	0
38	Associating the Severity of Emphysema with Coronary Flow Reserve and Left Atrial Conduit Function for the Emphysema Patients with Known or Suspected Coronary Artery Disease. <b>2022</b> ,	0
37	Prediction of Low-intensity Physical Activity in Stable Patients with Chronic Obstructive Pulmonary Disease. <b>2022</b> , 25, 143-149	0
36	Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study. <b>2022</b> , 19, 147997312211407	O
35	Advancing electrochemical biosensors for interleukin-6 detection. <b>2023</b> , 13, 100288	0
34	An open-label, multicentre, observational, post-marketing study to monitor the safety and effectiveness of umeclidinium/vilanterol in Korean patients.	0
33	Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. Volume 17, 2987-3000	0
32	COPD: Providing the right treatment for the right patient at the right time. <b>2022</b> , 107041	О
31	Add-on Chinese medicine for Hospitalized chronic Obstructive Pulmonary disease (CHOP): A cohort study of hospital registry. <b>2022</b> , 154586	0
30	Health literacy in asthma and chronic obstructive pulmonary disease (COPD) care: a narrative review and future directions. <b>2022</b> , 23,	1
29	Therapeutic Approaches for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. <b>2022</b> , 11, 1513	0
28	Diagnostic value of pulmonary ultrasound in acute exacerbation of chronic obstructive pulmonary disease: A pilot study. <b>2022</b> , 159, 509-514	O
27	Pre-operative Physical Performance Is Associated With Early Return to Work in Peri-operative Lung Cancer Patients. <b>2022</b> , 44, 341-351	O
26	Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017. <b>2022</b> ,	0
25	Clinical usefulness of end-tidal CO 2 measured using a portable capnometer in patients with respiratory disease.	O
24	Dysbiosis and leaky gut in hyper-inflated COPD patients: have smoking and exercise training any role?. <b>2023</b> , 100995	O

23	COPD in Africa: risk factors, hospitalisation, readmission and associated outcomesâl systematic review and meta-analysis. thoraxjnl-2022-218675	Ο
22	Occupational therapy for improving occupational performance in COPD patients: A scoping review. 0008417	42@11480
21	The impact of body composition disorders on the quality of life of patients with chronic obstructive pulmonary disease. <b>2022</b> , 22, 56-69	О
20	Development of Inhalable Spray Dried Nitrofurantoin Formulations for the Treatment of Emphysema. <b>2023</b> , 15, 146	O
19	Short- and Long-Term Impact of Prior Chronic Obstructive Pulmonary Disease Exacerbations on Healthcare Resource Utilization and Related Costs: An Observational Study (SHERLOCK). <b>2023</b> , 20, 92-100	О
18	Development of the ESEx index: a tool for predicting risk of recurrent severe COPD exacerbations. <b>2023</b> , 14, 204062232311551	O
17	Early COPD diagnosis and treatment: A case report. <b>2023</b> , 42, 101821	0
16	Exploration of the optimal pulse oximetry-derived oxygen saturation target for critically ill AECOPD patients: a retrospective cohort study.	Ο
15	COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments. <b>2023</b> , 8, 240-254	0
14	Further evidence of a type 2 inflammatory signature in chronic obstructive pulmonary disease or emphysema. <b>2023</b> ,	Ο
13	Fractional Dynamics Foster Deep Learning of COPD Stage Prediction. 2203485	1
12	Sauerstofftherapie und nichtinvasive Beatmung/Ventilation. 2022, 361-381	O
11	Changes in mortality among patients with chronic obstructive pulmonary disease from the 1990s to the 2000s: a pooled analysis of two prospective cohort studies. <b>2023</b> , 13, e065896	O
10	The regulatory feedback of inflammatory signaling and telomere/telomerase complex dysfunction in chronic inflammatory diseases. <b>2023</b> , 174, 112132	Ο
9	Mindâ <b>B</b> ody Issues for Children in Palliative and End-of-Life Care. <b>2023</b> , 377-387	O
8	The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. <b>2023</b> , 28,	O
7	Chronic Obstructive Pulmonary Disease. <b>2013</b> , 405-413.e1	О
6	What Are the Benefits of Different Ventilatory Techniques?. <b>2013</b> , 147-154	Ο

5	Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate. <b>2023</b> , 15, 1966	O
4	The clinical features of pneumonia in patients with chronic obstructive pulmonary disease. <b>2023</b> , 97, 39-54	О
3	Development of a prediction model to identify undiagnosed chronic obstructive pulmonary disease patients in primary care settings in China. <b>2023</b> , 136, 676-682	О
2	Activity Map and Transition Pathways of G Protein-Coupled Receptor Revealed by Machine Learning.	O
1	Prevention of Progression and Remission in Public Health Sectors: Bangladesh Perspectives. <b>2023</b> , 131-150	О